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Abstract 
 
Keratoconus is a condition in which the corneal shape becomes steeper and 
more irregular between adolescence and the mid-thirties. It is a common 
cause of visual impairment with disease progression typically managed with 
rigid contact lens. Traditionally, no intervention has been available to arrest or 
slow disease progression. As a result, keratoconus is the commonest 
indication for corneal transplantation in young people. Over the last decade, 
outcome data has accumulated for new interventions for keratoconus that 
have radically altered the treatment options for these patients and promises to 
avoid the sight loss associated with this condition. These interventions include 
corneal collagen cross-linking (CXL), intracorneal ring implantation and 
photorefractive keratectomy (PRK). The laboratory and clinical work 
presented in this thesis explores these new interventions under two key 
headings: corneal shape stabilisation and visual rehabilitation. 
 
I have developed two novel ex vivo techniques which provide quantitative 
means of measuring riboflavin across the whole cornea in both epithelium-off 
and –on techniques. Using these methods I have concluded that no existing 
commercial transepithelial CXL protocol matches the riboflavin penetration 
achieved following epithelial debridement. I present novel iontophoretic 
protocols that, by increasing riboflavin concentration, soak duration and 
current dosage, matches epithelium-off absorption. 
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I additionally report prospective outcomes of an accelerated version of CXL in 
keratoconus confirming it is a safe and effective iteration of the original 
‘Dresden’ protocol. Finally, I present interim outcomes from a prospective 
study of simultaneous ocular wavefront-guided PRK and CXL showing 
significant improvements in corrected distance visual acuity beyond that 
expected with standard CXL. 
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1 Introduction 
Keratoconus is a condition in which the corneal shape becomes steeper and 
more irregular between adolescence and the mid-thirties. For the age group 
10-44 years, the prevalence of keratoconus in white Europeans has been 
estimated at 1 in 1750, rising to 1 in 450 in South Asians.(Pearson et al. 2000) 
Traditionally no intervention has been available to arrest or slow disease 
progression. As the corneal shape becomes more abnormal, first spectacles, 
then rigid contact lenses become ineffective. Prior to the availability of newer 
surgical interventions, including corneal collagen cross-linking (CXL) and 
intrastromal corneal ring segments, approximately 20% of patients eventually 
required a corneal transplant to correct vision. As a result, keratoconus is the 
commonest indication for corneal transplantation in young people. Although 
corneal transplantation for keratoconus usually achieves good visual 
outcomes, long-term graft survival in keratoconic eyes is poor. The Australian 
Graft Registry data identified only 17% of penetrating grafts functioning at 23 
years, with survival rates falling further with second and third grafts.(Kelly, 
Coster, et al. 2011; Kelly, Williams, et al. 2011)  
 
Over the last decade, outcome data has accumulated for new interventions 
for keratoconus that have radically altered the treatment options for these 
patients and promise to reduce transplantation rates significantly, arrest 
disease progression, and save many patients from long-term reliance on rigid 
contact lens wear. 
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This thesis presents the findings of laboratory and clinical studies of these 
new keratoconus interventions under two key aims: 
 
1. To measure riboflavin absorption through an intact epithelium in an animal 
model. 
2. To determine visual and refractive outcomes for accelerated corneal cross-
linking, intrastromal corneal ring segments and photorefractive keratectomy in 
progressive keratoconus. 
 
In the following chapter, using the current evidence base, I review these new 
treatment options addressing two essential treatment strategies: shape 
stabilisation and visual rehabilitation.   
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2 Systematic review 
2.1 Methodology 
I searched MEDLINE (1950-2015) and the Cochrane Central Register of 
Controlled Trials using the following search terms: keratoconus; corneal 
cross-linking; cross-linkage; intracorneal ring segment; topographic 
photorefractive keratectomy; phakic intraocular lens. For the meta-analysis, 
two investigators (Alex Shortt & I) independently assessed the search results 
for randomised controlled trials (RCTs) of corneal cross-linking in 
keratoconus. The authors of 2 RCTs (O’Brart et al. 2011; Wittig-Silva et al. 
2014) were contacted for clarification of trial methodology and provision of 
additional unpublished data. A risk of bias assessment was performed on 
studies and only studies with a low risk of selection, performance, detection 
and attrition bias were included.  Data extraction was done independently by 
DG and AS. Data synthesis was performed using a meta-analysis software 
package, Review Manager (RevMan, The Nordic Cochrane Centre, The 
Cochrane Collaboration, Copenhagen, 2008). The effect of the intervention 
was expressed as odds ratios and confidence intervals were 
calculated.  The Mantel-Haenszel fixed-effect method of meta-analysis was 
used. 
2.2  Conventional keratoconus management 
Traditional management focused on maintaining useful vision in either 
spectacles until irregular astigmatism necessitated rigid contact lens fitting, 
then corneal transplantation where contact lenses failed (Figure 2.1). 
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2.2.1 Contact lens fitting 
Soft lenses and soft toric lenses can provide good visual rehabilitation in early 
keratoconus; but RGP lenses are generally required to neutralize significant 
corneal surface irregularity. RGP lenses provide good tear exchange, but lens 
stability deteriorates as the corneal profile steepens in more advanced 
keratoconus. Traditional corneal RGP lenses are between 8 and 10 mm in 
diameter. Newer intralimbal RGP lenses (10.5 - 12 mm diameter) can improve 
corneal coverage and centration in some patients,(Ozbek & Cohen 2006) but 
the increased diameter may make application and removal more difficult. 
‘Piggyback’ (soft beneath RGP) lens combinations and hybrid (RGP center 
and a soft skirt) lenses can improve wearing time in patients with poor RGP 
lens tolerance. The SynergEyes™ lens is a relatively new hybrid lens with a 
silicone hydrogel skirt providing greater oxygen permeability than earlier 
 
Figure 2.1 Traditional management pathway 
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hydrogel-based models. Hybrid lenses should ideally fit with apical clearance 
over the central cornea with little or no touch in the RGP portion of the lens.  
 
Where these options fail, RGP scleral (and semi-scleral) lenses, which vault 
clear of the corneal surface, are a solution applicable to almost any corneal 
shape.(Pecego et al. 2012) Scleral lenses can rescue vision in patients with 
late stage disease – particularly where technical obstacles such as a thin 
peripheral cornea limit options for corneal transplantation.     
 
Despite advances in contact lens fitting for keratoconus, contact lens 
dependence may be associated with significant impairment of vision-related 
quality of life that continues to decline over time.(Kymes et al. 2008)  
 
2.2.2 Corneal transplantation 
Without treatments to halt disease progression in keratoconus, up to 21% of 
eyes have required a corneal transplant.(Lass et al. 1990) Using established 
techniques (Markov modelling), the lifetime cost of conventional keratoconus 
treatment has been estimated at US$25,168 per patient, with the likelihood of 
primary and repeat corneal transplantation being the key cost 
determinants.(Rebenitsch et al. 2011) Given the relatively high prevalence of 
keratoconus and the frequency with which corneal transplantation is required, 
this represents a significant health economic burden.  
 
While penetrating keratoplasty (PK) for keratoconus generally achieves good 
visual outcomes, long-term graft survival in keratoconic eyes declines rapidly 
 24 
after the second decade. Primary graft survival rates from the Australian Graft 
Registry are 89% at 10 years, 49% at 20 years and 17% at 23 years.(Kelly, 
Williams, et al. 2011) These rates fall further with repeat grafts. 10 year 
survival rates are 53% for second and 33% for third grafts.(Kelly, Coster, et al. 
2011) Most grafts for keratoconus are performed in relatively young patients. 
In an effort to reduce the rate of repeat transplantation and associated 
complications, many surgeons now use deep anterior lamellar keratoplasty 
(DALK), with preservation of the host endothelium, as the transplantation 
procedure of choice in keratoconus. Accelerated long-term endothelial cell 
loss observed after PK does not occur after DALK.(Reinhart et al. 2011) 
Extrapolation from observed endothelial cell loss rates predicts a median graft 
survival of 49 years for DALK versus 17 years for PK.(Borderie et al. 2012) 
But current DALK techniques are technically challenging. Intraoperative 
complications and conversion to PK are common. A recent UK transplant 
registry comparison of results for PK and DALK in keratoconus showed a high 
early failure rate for DALK.(Jones et al. 2009) This was attributed to the 
learning curve in the surgical transition from PK to DALK for many surgeons in 
the period studied (1999-2005). Where transplantation is successful, irregular 
astigmatism and high postoperative anisometropia commonly prevent 
successful visual rehabilitation in spectacles without recourse to further 
surgical intervention.(Kelly, Williams, et al. 2011)  
Corneal transplantation is an effective but costly intervention in advanced 
keratoconus (stage IV modified Krumeich classification,(Colin & Velou 2003) 
[Table 2.1]), with an estimated incremental cost-utility ratio of between $1,942 
and $3,025 per quality-adjusted life-year.(Roe et al. 2008; Koo et al. 2011) 
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The life impact of repeat intervention, and slow, often incomplete, visual 
rehabilitation after transplantation should not be underestimated.(Yildiz et al. 
2010) Transplantation costs, and evidence for reduced quality of life in contact 
lens wearers,(Kymes et al. 2008) underline the need for a new, more 
proactive approach to keratoconus management.  
 
 
Table 2.1 Modified Krumeich classification of keratoconus  
Stage Characteristics 
I Eccentric corneal steepening 
Induced myopia and/or astigmatism <5D 
Corneal radii ≤48D 
Vogt’s striae, no scars 
 
II Induced myopia and/or astigmatism >5D, <8 D 
Corneal radii ≤53D 
No central scars   
Corneal thickness ≥400µm 
 
III Induced myopia and/or astigmatism >8D, <10D 
Corneal radii >53D 
No central scars 
Corneal thickness 200 - 400µm 
 
IV Refraction not measurable 
Corneal radii >55D 
Central scars, perforation 
Corneal thickness <200µm 
Originally published by (Colin & Velou 2003) 
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2.3 Defining disease progression – monitoring keratoconus 
Defining disease progression and the threshold for surgical intervention in 
keratoconus patients under observation remains a challenge. Assuming no 
diurnal variation in corneal shape, the coefficient of repeatability (CoR) should 
correspond closely to the limits of agreement for successive measures of 
corneal tomography indices,(Fraser & Fogarty 1989) defining a threshold 
beyond which there is a 95% probability that an observed difference reflects 
disease progression rather than measurement inaccuracy. Keratometry 
measurement repeatability in keratoconic eyes (stage II, 3mm zone steep K ≤ 
53 D) has been shown to be significantly poorer than in normal corneas, with 
a 1D CoR for steepest keratometry (Kmax) using Fourier-domain anterior-
segment OCT (Casia SS-1000 Tomey Corp. Japan) and between 1.5 – 2 D 
using a Scheimpflug-based imaging device (Pentacam HR, Oculus GmbH, 
Wetzlar, Germany).(Szalai et al. 2012; Hashemi et al. 2015) This compares 
with CoR values in normal corneas of less than 0.5 D for both imaging 
devices.(Szalai et al. 2012) Based on this, a change in Kmax of +1.5 D versus 
measurement at presentation on Pentacam image comparison maps may be 
a useful contemporary threshold indication for CXL using a widely available 
corneal tomography device. A lower threshold (+1 D versus baseline Kmax) is 
used in contemporary studies (Table 2.2). Changes in other criteria used to 
define disease progression (Table 2.2) may tip the balance in favour of 
intervention where the observed increase in Kmax is less than 1.5 D.  
 
The frequency with which patients should be screened and the optimum 
corneal tomography method also require additional research. More frequent 
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initial monitoring may be valuable in younger patients at high risk of rapid 
progression. Where possible, rigid contact lenses should be left out for a 
minimum of 2 weeks prior to each topography examination to reduce corneal 
warpage. 
 
Table 2.2 Progression criteria used in published clinical trials 
Kmax 1D increase 
Kmax – Kmin 1D increase 
Kmean 0.75D increase 
Pachymetry ≥2% decrease in CCT 
Corneal apex power >1D increase 
MRSE >0.5D 
RCTs vary in how progression is defined. I have listed different definitions above, one or more 
of which has been used in any one trial. D = dioptres; Kmax = steepest keratometry; Kmin = 
flattest keratometry; Kmean = (Kmax+Kmin)/2; CCT=central corneal thickness; corneal apex 
power is measured with cone location and magnitude index (CLMI), MRSE = manifest 
refractive spherical equivalent 
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2.4 Shape stabilisation 
Corneal cross-linking (CXL) is the only treatment proven to halt disease 
progression in keratoconus.(Wittig-Silva et al. 2014; O’Brart et al. 2011) CXL 
is performed by irradiating riboflavin-soaked corneal tissue with an ultraviolet 
A (UVA) light source (370 nm). The riboflavin acts both as a photosensitizer to 
encourage UVA-induced corneal stiffening (cross-linking), and a shield to 
reduce UVA levels at the endothelial level below the cytotoxic threshold. The 
exact mechanisms of CXL-induced corneal shape stabilisation remain 
unclear. The original CXL protocol (Wollensak, Spoerl, et al. 2003a) described 
mechanical removal of the corneal epithelium with repeated application of 
riboflavin 0.1% drops before and during UVA treatment (3 mW/cm2 power for 
30 minutes). The optimum corneal riboflavin soak and UVA irradiation 
required to achieve effective corneal stabilisation is unknown. A number of 
protocol variations emerging including speeding up the treatment (accelerated 
CXL) and delivering riboflavin through an intact epithelium (transepithelial 
CXL), both of which I investigate in this thesis. 
 
2.4.1 Mechanism of cross-linking 
Corneal cross-linking is a natural phenomenon that stiffens and strengthens 
the cornea. This cumulative age-related process is attributable to glycation-
end-products inducing cross-link formation within collagen lamellae, which 
explains why for most patients stability is achieved by their fourth decade, as 
well as the protective effect against the development of keratoconus in young 
diabetics.(Naderan et al. 2014) Instead of glycation, the molecular 
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mechanisms of UVA/riboflavin-induced CXL appear to rely on photoactivated 
riboflavin forming singlet or triplet states. These react with oxygen to produce 
‘reactive oxygen species’ which photo-oxidate stromal proteins (Type II 
mechanism).(Kamaev et al. 2012) Once the oxygen supply is depleted within 
the first few seconds, reactive species of radical ions form which can then 
form covalent cross-links with numerous molecules within the corneal stroma 
(type I mechanism). (Wollensak 2006) Ex vivo measured tissue oxygen 
concentrations suggests that type I photochemical kinetic mechanisms 
predominate.(Kamaev et al. 2012) While the exact nature and location of 
these cross-links remains unclear(Meek & Hayes 2013) they are thought to 
mediate increases in corneal rigidity, elastic modulus and resistance to 
enzymatic degradation.(Wollensak, Spoerl, et al. 2003b; Spoerl, Wollensak, 
Dittert, et al. 2004; Spoerl, Wollensak & Seiler 2004; Kohlhaas et al. 2006; 
Wollensak & Iomdina 2009)  
 
2.4.2 Effect of cross-linking on corneal structure and biomechanics 
Compounding the uncertainty regarding the mechanism of CXL is our 
inadequate understanding of what this treatment does to structures within the 
cornea (i.e. how it stabilises keratoconus). One theory relates to the concept 
of lamella slippage. X-ray scattering has previously revealed that keratoconic 
corneal lamellae lack the orthogonal fibrillar uniformity of normal corneas, 
particularly at the cone.(Meek et al. 2005) Displacement between (and 
probably within) these lamellae is postulated to underlie steepening and 
thinning as tissue is redistributed (as apposed to lost).(Meek et al. 2005; 
Daxer & Fratzl 1997) The sequitur would be that increased cohesion force 
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between corneal lamellae mediated by additional collagen cross-links would 
prevent these sliding movements. Interlamellar cohesion forces have been 
specifically measured by the Dresden group (Wollensak et al. 2011). In this 
study, the investigators prepared 400 µm (porcine) corneal strips which were 
cleaved at 50% depth just at one end of the strip. Once this split had been 
created, the 200 µm anterior and posterior flaps were clamped into a 
microcomputer-controlled biomaterial testing machine. This machine 
measured the cohesive force required to propagate the stromal split as the 
clamps were moved apart. The investigators compared untreated controls 
with standard cross-linked tissue and observed no change in interlamellar 
cohesion force. This finding probably rules out the lamellar slippage 
theory.(Meek & Hayes 2013) 
 
An alternative mechanism relates to enzymatic degradation resistance. 
Enzyme digestion studies have demonstrated that CXL increases the stromal 
resistance to collagenolytic enzymes, (Spoerl, Wollensak & Seiler 2004) as 
well as increasing the temperature threshold for hydrothermal 
shrinkage.(Spoerl, Wollensak, Dittert, et al. 2004) This appeared to 
corroborate transmission electron microscopy findings by the same group of 
an increase in collagen fibrillar diameter (Wollensak et al. 2004), although this 
finding has not been replicated since (by x-ray scattering). (Hayes et al. 2013) 
A consensus, therefore, is lacking as to the direct involvement of collagen 
fibrils themselves in the cross-linking process.  
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A lack of validated clinical devices capable of measuring in vivo mechanical 
properties is a current limitation to further understanding the effects of CXL. 
Different measures of corneal biomechanical properties may not necessarily 
correlate between different tests. For example, the original stress/strain tests 
of excised strips of cornea pulled in a tangential direction do not measure the 
same property as pneumatically deforming the corneal in the sagittal direction 
(e.g. Ocular Response Analyzer (ORA); Reichert, Inc, Buffalo, NY). The 
Corvis ST (Oculus GmbH, Wetzlar, Germany) uses a Scheimpflug camera to 
record a similar air-puff corneal indent, the characteristics of which are 
expected to yield more information of biomechanical behaviour than 
deformation alone. Significant challenges remain, however, in interpreting 
these images due to the contributions of intraocular pressure and corneo-
scleral geometry.(Girard et al. 2015) 
 
More recently, Brillouin microscopy has been used to map corneal 
biomechanics in three dimensions with a high spatial resolution.(Scarcelli et 
al. 2012; Scarcelli et al. 2013) This non-contact technique measures light-
scattering arising from the interaction of incident light with hypersonic acoustic 
waves (phonons) generated within the tissue. Brillouin-scattered light is 
characterized by a frequency shift which is proportional to the longitudinal 
modulus of elasticity of the tissue.(Scarcelli & Yun 2008) Although not 
commercially available, this no-touch, non-deformational optical test has great 
potential as a tool to both monitor the response to CXL, as well as screen 
keratoconus suspects.  
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2.4.3 Standard cross-linking  
Corneal collagen cross-linking (CXL) using the standard, epithelium-off 
protocol originally developed at the University of Dresden (Wollensak, Spoerl, 
et al. 2003a) is effective in arresting disease progression (52% stabilising, 
45% regressing) with 3% of eyes progressing despite treatment.(Hersh et al. 
2011; O’Brart et al. 2011; Wittig-Silva et al. 2014)(Table 2.3, Table 2.4) Long-
term outcomes (mean 52 months follow-up, range 48-60 months) for standard 
CXL have been reported in the Siena Eye Cross Study, a prospective, non-
randomised study of 44 eyes with progressive keratoconus treated with CXL 
and fellow eye controls.(Caporossi et al. 2010) Control eyes, in which disease 
progression was less rapid than treated eyes prior to assignment, were 
observed initially then crossed over to CXL after 2 years. Their data confirmed 
a halt in ectatic progression in all treated eyes, with a mean reduction in Kmax 
of 2 D, while fellow eyes progressed by a mean 1.5 D for 24 months (prior to 
cross-over) before also demonstrating comparable reductions in Kmax after 
CXL. Refraction stabilised at 2 years and spectacle CDVA improved 2 ± 1 
Snellen lines (mean ± SD).(Caporossi et al. 2010) Two year outcome data 
from an uncontrolled prospective study (Vinciguerra et al. 2012) in 40 children 
(mean age 14.2 ± 1.7 years) with mild disease (3 mm zone steep K ≤ 53 D) 
confirmed similar findings with both UDVA and CDVA improving by 2 lines 
(LogMAR) and a reduction in Kmax of 1.27 D. 
Table 2.3 Summary of efficacy outcomes following standard (epithelium-off) corneal cross-linking 
Reference 
Study 
design 
n (latest 
follow-up) 
Mean age (range) 
Latest 
follow-up 
(months) 
Mean UDVA 
change 
(logMAR) 
Mean CDVA 
change 
(logMAR) 
MSE 
change 
(D) 
Cylinder 
change (D) 
K max 
change (D) 
Pachymetry 
change (microns) 
Failure (%) 
(Agrawal 2009)  CS
a
 37 16.9 (12–39) 12 — −Ϭ.Ϭϵ — −ϭ.ϮϬ −Ϯ.ϰϳ — 8.1 
(Arora et al. 2013) CS 30 16 (12–18) 12 −Ϭ.ϭϴb −Ϭ.ϭϮb — — 0.4b −ϲϲ.ϰϲb — 
(asri et al. 2011) CS 64 24.12±7.58 12 0.00 −Ϭ.Ϭϭ — +0.07 −Ϭ.ϰϵ −ϭϭ 9.8 
(Caporossi et al. 2012) CS 44 10–40 48 −Ϭ.ϯϳ −Ϭ.ϭϰ +2.15 −Ϭ.ϱϱ −Ϯ.Ϯϲ +0.6 — 
(Caporossi et al. 2012) CS 77 10–18 36 −Ϭ.ϭϱ −Ϭ.Ϭϵ — — −Ϭ.ϳϮ — — 
(Ghanem et al. 2014) CS 42 22.4 (14–34) 24 −Ϭ.Ϯϰ −Ϭ.ϭϮ 0.39 0.46 −Ϭ.ϵ — — 
(Greenstein et al. 2010) CS 31 32.3 (15–52) 12 — — — — — — 
 
(Greenstein, Shah, et al. 2011) CS 54 No data 12 — — — — — −ϭϮ.ϭ — 
(Greenstein, Fry, Hersh, et al. 
2012) 
CS 64 No data 12 — — — — — — — 
(Greenstein, Fry & Hersh 2012) CS 46 No data 12 — — — — — — — 
(Greenstein, Fry, et al. 2011) CS 66 No data 12 −Ϭ.Ϭϴ −Ϭ.ϭϬ — — −ϭ.ϲϬ — — 
(Grewal et al. 2009) CS 102 25.6(18–31) 12 — −Ϭ.ϬϮ +1.43 −Ϭ.ϭϳ — −ϯ.ϳ — 
(Guber et al. 2013) CS 33 26.36 (13–40) 12 — −Ϭ.Ϭϰ — 0.73 −Ϭ.ϭϲ −ϭϭ.ϯϯ — 
(Hashemi et al. 2013) CS 40 22.45 (16–35) 60 −Ϭ.ϬϮ −Ϭ.ϭϮ 0.41 0.65 −Ϭ.Ϯϰ 2 — 
(Hersh et al. 2011) CS 49 No data 12 −Ϭ.Ϭϱ −Ϭ.ϭϰ +0.85 −Ϭ.Ϭϴ −Ϯ.ϬϬ — — 
(Hoyer et al. 2009) CS 35 27.92 36 — −Ϭ.ϭϰ — −ϭ.ϲϰ −Ϯ.ϳϯ — 8.6 
(Ivarsen & Hjortdal 2013) CS 28 12–38 22 — −Ϭ.Ϭϳ — — 1.1 −Ϭ.ϱϮ — 
(Jordan et al. 2014) CS 38 21.9 12 — — — — — — — 
(Kampik et al. 2011) CS 46 33.5 24 — −Ϭ.Ϭϱ — — −ϭ.Ϯϯ −Ϯϭ.ϲ — 
(Kontadakis et al. 2013) CS 24 25 (20–36) 24 — — — — — — — 
(Kránitz et al. 2012) CS 25 29.92 12 −Ϭ.ϭϯ −Ϭ.Ϭϵ +1.32 −Ϭ.ϰϵ −ϭ.ϲϴ −ϯϭ — 
(Kymionis et al. 2010) CS 55 24.4 (18–36) 12 — — — — — — — 
(Lamy et al. 2013) CS 68 24.4 (18–33) 24 — −Ϭ.ϭϲ — — −Ϭ.ϵϵ — 
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(Legare et al. 2013) CS 39 26.8 (15–56) 15.8 0.18 (12 
months)
c
 
0 (at 24 
months)
c
 
1.55 (at 
24 
months)
c
 
1.30 (at 24 
months)
c
 
— −ϭϱ.ϱϴ ;at Ϯϰ 
months) 
— 
(Magli et al. 2013) CS 23 14.75 (12–18) 12 −Ϭ.Ϭϭ 0.01 — 0.11 −ϭ.ϭϰ −ϭ.ϵϴ — 
(Mastropasqua et al. 2013) RCT 20 23 (16–23) 12 — — — — 
 
37 — 
(Mazzotta et al. 2008) CS 44 No data 36 — — — — — — — 
(Mazzotta et al. 2012) CS 44 No data 12 −Ϭ.ϭϵ −Ϭ.ϭϭ — — −Ϭ.ϯϬ +14.5 — 
(Mencucci et al. 2012) CS 54 26.2 12 — — — — — +1 — 
 (O’Brart et al. 2011) RCT) 24 29.6 (21–42) 18 −Ϭ.Ϭϴ +0.06 +0.82 −Ϭ.ϱ −Ϭ.ϲϮ +3.4 — 
 (O’Brart et al. 2013) CS 30 26.3 (12–40) 53.3 0.03 0.05 0.82 0.28 — 3 
 
(Poli et al. 2013)  CS 45 26 (15–46) 21.7 −Ϭ.Ϯ ;at ϭϮ 
months) 
−Ϭ.Ϯϯ  
(at 36 months) 
— — −Ϭ.ϭϰ  
(at 2 years) 
−Ϭ.Ϯϰ — 
(Raiskup-Wolf et al. 2008) CS 33 30.04 36 — −Ϭ.ϭϱ — −ϭ.ϰϱ −Ϯ.ϱϳ — 33.3 
(Raiskup et al. 2009) CS 163 31.53 12 — 0.05 — — −Ϭ.ϳϱ — — 
(Raiskup & Spoerl 2011) CS 32 27.4 12 — −Ϭ.Ϭϰ — — −Ϭ.ϳ — — 
(Rechichi et al. 2013) CS 28 28.8 (18–41 years) 12 0.25 −Ϭ.Ϭϱ 0.96 0.99 — −ϭϱ — 
(Sloot et al. 2013) CS 53
b
 21.5 (12–49) 12 — −Ϭ.ϭϯb — — −ϭ.ϱb −ϵb 9   
(Spoerl et al. 2011) CS 50 29.4 (16–45) 12 — — — — — — — 
(Toprak & Yildirim 2013) CS 59 28.7 12 — −Ϭ.ϭϯ — — −Ϭ.ϴϰ — — 
(Vinciguerra, Albè, Trazza, Seiler, 
et al. 2009) 
CS 28 24–52 24 −Ϭ.Ϯϰ −Ϭ.ϭϱ +0.81 −Ϭ.ϯϰ −ϭ.ϯϱ −ϴ.ϭ — 
(Vinciguerra, Albè, Trazza, Rosetta, 
et al. 2009) 
CS 28 24–52 12 −Ϭ.ϮϬ −Ϭ.ϭϰ +0.41 −Ϭ.Ϯϲ −ϲ.ϭϲ −ϭϰ.ϵ — 
(Vinciguerra et al. 2010) CS 24 15–36 12 
   
— −Ϭ.ϳϯ +11.0 — 
(Vinciguerra et al. 2012) CS 40 14.2 (9–18) 24 −Ϭ.Ϯϭ −Ϭ.ϭϵ +1.57 −ϭ.ϯϭ −ϭ.Ϯϳ +14.0 — 
(Wittig-Silva et al. 2014) RCT 46 25.6 36 −Ϭ.ϭϱ −Ϭ.Ϭϵ −Ϭ.ϲϭ −Ϭ.ϵϬ −ϭ.Ϭϯ 5.86 
 
CDVA, Corrected Distance Visual Acuity; DALK, deep anterior lamellar SD, standard deviation; RCT, randomised controlled trial; UDVA, uncorrected visual acuity. 
a 
Case series; 
b 
Mean of all eyes in all groups;
 c 
Extrapolated from graphical data. — indicates data not provided in published article. 
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Table 2.4 Summary of safety outcomes following standard (epithelium-off) corneal cross-linking 
Reference 
Eyes at latest 
follow-up (n) 
Latest follow-
up (months) 
Failure to re-
epithelialise (%) 
Stromal 
oedema (%) 
Sterile 
infiltrate (%) 
Haze (%) Scar (%) 
Infection 
(%) 
Loss of 
CDVA (%) 
ECC 
change 
(/mm
2
) 
(Agrawal 2009)  37 12 — — — — — — 
18.9 (7 of 
37 eyes at 
1 year) 
— 
(Arora et al. 2013) 30 12 — 27 (8 of 30 
eyes)
a
 
3 (1 of 30 
eyes)
a
 
3 (1 of 30 
eyes) 
— — — 4 (at 1 
year) 
(asri et al. 2011) 64 12 — 
1.56 (1 of 64 
eyes at 1 
month) 
— 
1.5% (1 of 64 
eyes at 1 
year) 
0.96%(1 of 
104 eyes at 
1 month) 
— 
7.8%(5 of 
64 eyes at 
1 year) 
−ϭϭϬ ;at ϭ 
year) 
(Caporossi et al. 2012) 44 48 — 
70 (31 of 44 
eyes within 6 
weeks) 
— 
9.8% (4 of 44 
eyes within 3 
months) 
— —   
−ϭϵ ;at Ϯ 
years) 
(mean loss 
of 2%per 
year) 
(Caporossi et al. 2012) 152 36 — 55 — 9.80 0 0 — — 
(Ghanem et al. 2014) 42 24 — — 2% (1 of 42 
eyes) 
— — — — — 
(Greenstein et al. 2010) 31 12 — — — — — — — — 
(Greenstein, Shah, et al. 2011) 54 12 — — — — — — — — 
(Greenstein, Fry, Hersh, et al. 
2012) 
64 12 — — — — — — — — 
(Greenstein, Fry & Hersh 2012) 46 12 — — — — — — — — 
(Greenstein, Fry, et al. 2011) 66 12 — — — — — — — — 
(Grewal et al. 2009) 102 12 — — — — — — — — 
(Guber et al. 2013) 33 12 — — — — 6 (2 of 33 
eyes) 
— 6 (2 of 33 
eyes) 
— 
(Hashemi et al. 2013) 40 60 — — — — — — — — 
(Hassan et al. 2013) 38 36 — — — — — — — — 
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Reference 
Eyes at latest 
follow-up (n) 
Latest follow-
up (months) 
Failure to re-
epithelialise (%) 
Stromal 
oedema (%) 
Sterile 
infiltrate (%) 
Haze (%) Scar (%) 
Infection 
(%) 
Loss of 
CDVA (%) 
ECC 
change 
(/mm
2
) 
(Hersh et al. 2011) 49 12 — — — — — — — — 
(Hoyer et al. 2009) 35 36 0 — 
No data but 
seen in few 
eyes 
— — 3% (1 of 
35eyes) 
— — 
(Ivarsen & Hjortdal 2013) 28 22±8 (10–43) — — — — — — 0 — 
(Jordan et al. 2014) 38 12 — — — — — — — — 
(Kampik et al. 2011) 46 24 
0% (46 eyes at 1 
week) 
— — 
100%(46 
eyes within 3 
months) 
— — 
27%(12 of 
46 eyes at 
2 years) 
55 (at 2 
years) 
(Kontadakis et al. 2013) 24 24 — — — — — — — — 
(Kránitz et al. 2012) 25 12 — — — — — — — — 
(Kymionis et al. 2010) 55 12 0 (0 of 55 eyes) — — — — — — — 
(Lamy et al. 2013) 68 24 — — — — — — — — 
(Legare et al. 2013) 39 24 0 — — — — 0 — — 
(Magli et al. 2013) 23 12 0 8 (2 of 23) — — — — — −Ϯϰ ;at ϭ 
year) 
(Mastropasqua et al. 2013) 20 12 — 1.68 — — — — — 
No 
significant 
change- 
(Mazzotta et al. 2008) 44 36 — — — 11.4%(5 out 
of 44 eyes.  
— — — — 
(Mazzotta et al. 2012) 44 12 0 (0 of 44 eyes) — — — — — — 0 (at 12 
months) 
(Mencucci et al. 2012) 54 12 — — — — — — — — 
(O’Brart et al. 2011) 24 18 0% (24 eyes at 1 
week) 
— — 
100%(24 
eyes within 6 
months) 
0% (at 18 
months) 
0% (at 18 
months) 
— — 
(O’Brart et al. 2013) 30 48–72 — — — — — — 17%(5 of 
29 eyes) 
  
(Poli et al. 2013) 45 21.7±6.14 — — — — — — — 
No 
significant 
change 
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Reference 
Eyes at latest 
follow-up (n) 
Latest follow-
up (months) 
Failure to re-
epithelialise (%) 
Stromal 
oedema (%) 
Sterile 
infiltrate (%) 
Haze (%) Scar (%) 
Infection 
(%) 
Loss of 
CDVA (%) 
ECC 
change 
(/mm
2
) 
(Raiskup-Wolf et al. 2008) 33 36 — — — — — — — — 
(Raiskup et al. 2009) 163 12 — — — 
8.6%(14 of 
163 eyes at 1 
year) 
— — — — 
(Raiskup & Spoerl 2011) 32 12 0 0 0 0 0 0 — — 
(Rechichi et al. 2013) 28 12 — — — — — — — −ϭϱ ;at ϭ 
year) 
(Sloot et al. 2013) 53
a
 21.5 (12–49) — — 2% (1 of 53)a — — 2% (1 of 
53)
a
 
— — 
(Spoerl et al. 2011) 50 12 — — — — — — — — 
(Toprak & Yildirim 2013) 59 12 — — — — — — — — 
(Vinciguerra, Albè, Trazza, Seiler, 
et al. 2009) 
28 24 0 — —   — — — 
−ϱϯ ;at ϭ 
year)  
−ϭϯϭ ;at 
2years) 
(Vinciguerra, Albè, Trazza, Rosetta, 
et al. 2009) 
28 12 — — — 
12.7 (4 of 28 
eyes at 1 
year) 
— — — −ϱϯ ;at ϭ 
year) 
(Vinciguerra et al. 2010) 24 12 — — — — — — — −ϮϮ ;at ϭ 
year) 
(Vinciguerra et al. 2012) 40 24 — — — 6.9 (3 of 40 
eyes) 
— — — 
−ϯϮ ;at ϭ 
yearͿ −ϭϮ 
(at 2 years) 
(Wittig-Silva et al. 2014) 50 36 — — 4% (2 of 46 
eyes) 
— — — — 
28 (at 1 
year) 13 (at 
2 years) 
−ϯϱ ;at ϯ 
years) 
CDVA, corrected distance visual acuity; ECC, endothelial cell count. — indicates data not provided in published article. a Mean of all eyes in all groups. 
Further evidence for the efficacy of standard, epithelium-off CXL is found in 3 
randomised-controlled trials (RCTs) with fellow eye controls that have 
published 12-month results.(O’Brart et al. 2011; Hersh et al. 2011; Wittig-Silva 
et al. 2014)(Figure 2.2) Excluding one study (Hersh et al. 2011) in which 
control eyes were crossed over to treatment after just 3 months, we combined 
1 year post-CXL keratometric and acuity outcome data for patients (n = 31) in 
the remaining 2 trials.(Gore et al. 2012) Clinically significant ectatic 
progression (increase in Kmax ≥ 1 D at 12 months) was observed in 32% 
untreated control eyes and 3% eyes treated with CXL (p = 0.01, z-test); 
whereas significant regression (decrease in Kmax ≥ 1 D at 12 months) was 
seen in 45% of CXL treated eyes and 10% untreated control eyes (p = 0.005, 
z-test). (Gore et al. 2012) After conversion of 12-month acuity data to 
LogMAR values, combined data showed a statistically significant 
improvement in CDVA for patients treated with CXL (p = 0.04, z-test).  
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Figure 2.2 Forest plot of CXL meta-analysis 
This Forest plot is a graphical representation of the above meta-
analysis. The right-hand column is a plot of the measure of effect 
(i.e. an odds ratio) for each of the two studies (represented by the 
blue squares), with horizontal black lines representing the 
confidence intervals. The size of the blue squares is proportional to 
the study’s weight in the meta-analysis. The black diamond 
represents the meta-analysed measure of effect of the two studies 
combined. The lateral points of the diamond represent the 
confidence intervals for this estimate. If the confidence interval 
horizontal lines for any individual study (or the points of the diamond 
for the meta-analysed effect) cross the vertical black line, it 
demonstrates that at the given level of confidence the result can not 
be said to differ from no effect. 
This meta-analysis of 12-month results from two placebo controlled 
randomised trials shows disease progression (defined in these trials 
by an increase in maximum keratometry (Kmax) ≥1D) is significantly 
less likely after collagen cross-linking (black diamond does not 
cross the vertical line of no effect). Following recent 
correspondence with Melbourne study authors I have updated the 
above forest plot to include additional patients from that included in 
the original meta-analysis (Gore et al. 2012) 
 
Spontaneous disease regression does not normally occur in keratoconus, and 
apparent disease regression (decrease in Kmax ≥ 1 D) in 10% of control eyes 
in RCTs may simply reflect limitations in measurement accuracy for 
contemporary topographers (Szalai et al. 2012) – a problem compounded by 
corneal warpage in rigid contact lens wearers. These limitations and varying 
inclusion criteria (Table 2.2) in contemporary studies underline the problem of 
defining disease progression and the thresholds for intervention in 
keratoconus. 
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2.4.4 Complications of corneal cross-linking 
Although generally safe, (O’Brart et al. 2011; Hersh et al. 2011; Wittig-Silva et 
al. 2014; Caporossi et al. 2010; Koller et al. 2009) a range of complications is 
seen after standard, epithelium-off CXL. Sterile corneal infiltrates, thought to 
be an immune reaction to bacterial antigen deposition, were observed in 7.6% 
of patients in a prospective series of 117 eyes with 12 month follow-up after 
CXL.(Koller et al. 2009) Culture-proven bacterial keratitis with permanent loss 
of vision has also been reported.(Snibson 2010) Mild stromal haze is common 
after CXL and typically resolves within a year without detriment to visual 
acuity; but mid-stromal scarring was observed in 3% of cases by Koller et al, 
and 3% (95% confidence interval [CI] 1-9%) lost 2 or more lines of Snellen 
CDVA. Although the mechanism of visual loss was not identified, risk factors 
for loss of vision in this study were age > 35 years and pre-operative CDVA > 
20/25. 
 
 Rates of endothelial cell loss similar to background age-related change were 
recorded in the Siena Cross Study (Caporossi et al. 2010) where treated 
corneas had ≥ 400 µm central thickness after epithelial removal, but 
significant cell loss and corneal endothelial failure have been reported in 
thinner corneas, or where corneas thinned intra-operatively following 
application of dextran-containing riboflavin solution.(Gokhale 2011; Kymionis 
et al. 2012; Lange et al. 2012; Sharma et al. 2012) Shielding by riboflavin-
saturation in a 400 µm-thick cornea reduces irradiance at the endothelial level 
to 0.18 mW/cm2, (Spoerl et al. 2007) well below the cytotoxic threshold of 
0.35mW/cm2 previously established in porcine endothelial cell 
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cultures.(Wollensak, Spörl, et al. 2003) Hypotonic riboflavin can be used to 
increase corneal thickness prior to UVA exposure in thinner corneas. This 
technique was originally described in 2009, with no reported complications or 
progression of ectasia at 6 months in a series of 20 eyes with > 320 µm initial 
corneal thickness after epithelial removal.(Hafezi et al. 2009) Similar 
encouraging 1 year results for CXL using hypotonic riboflavin in thinner 
corneas were reported by in a prospective series of 32 eyes.(Raiskup et al. 
2011) 
 
2.4.5 Keratocyte apoptosis and the demarcation line 
An indirect qualitative outcome of CXL is a demarcation line within the stroma 
commonly interpreted as representing the border between treated tissue 
(anterior to the line) and untreated tissue (posterior to the line). This line is 
demarcated at the slit-lamp within the first few months following CXL by 
anterior stromal haze abruptly clearing posteriorly. The line can be 
quantitatively imaged (at a typical depth of 300 – 350 µm following standard 
CXL) by either optical coherence tomography (OCT) or confocal 
microscopy.(Spoerl et al. 2007; Seiler & Hafezi 2006) The latter imaging 
modality has the additional advantage of quantifying UVA-mediated 
keratocyte apoptosis. Using this technique in a prospective study, Jordan et 
al. identified complete absence of keratocyte nuclei in 86% of corneas 1 
month post-CXL (Jordan et al. 2014), with a return to baseline by 12 months. 
The authors described the demarcation between treated and 
untreated corneal stroma appearing as ‘a region where normal keratocytes 
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transitioned into elongated, hyper-reflective, needle-like structures and then 
into large hyper-reflective stromal bands.’ 
 
Keratocyte apoptosis and demarcation line depth have additionally been used 
as a surrogate means of comparing treatment efficacy between different CXL 
protocols. Touboul et al observed, by confocal microscopy, that the 
demarcation line following accelerated CXL (30mW/cm2 for 3 minutes, total 
energy 5.4 J/cm2) lay more superficial, at a mean depth of 100-150 mm. 
(Touboul et al. 2012) Bouheraoua et al systematically investigated this in a 
prospective study of 45 patients with progressive keratoconus equally divided 
(n = 15) into standard CXL, accelerated CXL and iontophoretic transepithelial 
CXL.(Bouheraoua et al. 2014) They observed the demarcation line was visible 
1 month after surgery in 93%, 87.5% and 47.7% of standard, accelerated and 
iontophoresis CXL corneas respectively. The depth of the demarcation line 
similarly differed for the same respective groups: 303 µm, 184 µm and 212 
µm. The investigators additionally documented mean anterior stromal 
keratocyte densities remained significantly lower at 6 months (compared to 
baseline) in the standard and accelerated CXL groups, whereas they had 
returned to preoperative values in the iontophoresis CXL group. While 
tempting to extrapolate these differences to compare treatment efficacy, such 
tissue changes do not supersede the principle outcome measure of CXL 
which is to stabilise the corneal shape.  
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2.4.6 Accelerated cross-linking 
Accelerated treatment protocols for CXL based on shorter UVA exposure 
times and higher irradiances are emerging. The underlying premise is that 
delivering a similar total energy over a shorter period of time will not 
compromise safety or efficacy in comparison with the standard protocol 
(30minutes at 3mW/cm2). Stress–strain measurements on porcine corneal 
strips using a accelerated protocol (9 minutes at 10mW/cm2) demonstrated 
equivalent increases in corneal stiffness in comparison with the standard 
protocol.(Schumacher et al. 2011) In a recent prospective randomized 
trial,(Kanellopoulos 2012a) contralateral eyes of 21 patients with progressive 
keratoconus were randomized to either conventional or accelerated CXL (7 
mW/cm2 for 15 minutes). A halt in ectasia progression was seen in all cases 
at a mean follow-up of 46 months. Both groups responded similarly: CDVA 
improved from 20/60 to 20/40, UDVA from 20/30 to 20/25, mean sphere 
reduced by 2.4D and Kmax reduced from 49.5D to 46.1D. Endothelial cell 
loss was less in the accelerated CXL group (-100 cells/mm2) than in the 
conventional CXL group (-250 cells/mm2).  
 
2.4.7 Transepithelial cross-linking 
Transepithelial CXL, in which riboflavin is delivered through an intact 
epithelium (rather than epithelial debridement), promises to deliver the 
benefits of standard epithelium-off treatments without the painful rehabilitation 
and complications of epithelial removal. Epithelial-toxic agents used include 
benzalkonium chloride (BAC), sodium ethylenediaminetetraacetic acid 
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(EDTA), tetracaine, proparacaine, ethanol and gentamicin. A non-toxic 
reversible synthetic nonselective ion channel-forming peptide, NC-1059, has 
also been shown in a chick corneal model to enhance riboflavin permeability 
across an intact epithelium.(Zhang et al. 2012) In addition to novel 
formulations, iontophoresis is an alternative trans-epithelial methodology in 
which the negatively-charged riboflavin molecules can be driven through an 
intact epithelium across an electrical gradient. (Bikbova & Bikbov 2013; 
Vinciguerra et al. 2014; Buzzonetti et al. 2015) Finally, a hybrid technique has 
been described by Stojanovic et al. using of a riboflavin-soaked polyvinyl 
acetal pledget (Merocel sponge, Medtronic, Inc., Minneapolis, MN) inserted 
into the conjunctival sac (with proparacaine, genatmicin and BAC) to produce 
microabrasions of the superficial epithelial layers with eyelid 
blinking.(Stojanovic et al. 2012)  
 
Results from preliminary clinical case series (Table 2.6, Table 2.7) using non-
iontophoretic transepithelial riboflavin preparations have been equivocal, with 
some showing similar efficacy to epithelium-off CXL,(Filippello et al. 2012; 
Magli et al. 2013) whilst most have demonstrated less pronounced 
effects.(Leccisotti & Islam 2010; Caporossi et al. 2013; Koppen et al. 2012a; 
Soeters et al. 2015; Kocak et al. 2014) The earliest prospective (paired-eye) 
studies in humans documented small, but significant improvements in CDVA 
over fellow untreated eyes at 12 and 18 months respectively, with a trend 
towards 
Table 2.5 Summary of efficacy outcomes of non-iontophoresis transepithelial corneal cross-linking 
Reference Study design 
Eyes at 
latest 
follow-up 
(n) 
Age (years) 
(mean±SD) 
(Range) 
Latest 
follow-
up 
(months) 
UDVA 
change 
(logMAR) 
CDVA 
change 
(logMAR) 
MSE 
change 
(D) 
Cylinder 
change 
(D) 
K max 
change (D) 
Pachymetry 
change 
(microns) 
(Caporossi et 
al. 2013) CS 26 
22 (11–26 
years) 24 0.08 0 0 0 1.55 −32 
(Filippello et 
al. 2012) CS 20 
27 (12–42 
years) 18 −0.23 −0.11 — — −1.17 −4.00 
(Koppen et al. 
2012a) CS 37 
24.02± 7.29 
(12–46 years) 12 — −0.04 +0.21 +0.04 1.33 −8.06 
(Leccisotti & 
Islam 2010) CS 51 
26.9±6.3 (18–
39 years) 12 — −0.04 +0.36   0.51 — 
(Mastropasqua 
et al. 2013) RCT  20 
23±2.5 (16–23 
years) 12 — — — — — 0.51 
(Gupta et al. 
2015) RCT  40 18-30 years 6 — -0.09 -1.3 — -3.25 +15 
(Soeters et al. 
2015) RCT  33 18-48 12 -0.06 -0.14 0.3 +1.5 0.3 0 
(Stojanovic et 
al. 2012) CS 61 
32±10 (15–52 
years) 12 −0.30 −0.12 +0.74 −1.15 −0.57 +9.00 
CDVA, corrected distance visual acuity; CS, case series; K, keratometry; MSE, mean spherical equivalent; RCT, randomised controlled trial; SD, standard 
deviation; UDVA, uncorrected visual acuity. — indicates data not provided in published article. 
 
 
 
 
 46 
Table 2.6 Summary of safety outcomes of non-iontophoresis transepithelial corneal cross-linking 
Lead Author 
Eyes at 
latest 
follow-up 
(n) 
Latest follow-up 
(months) 
Stromal 
oedema  
Sterile 
infiltrate Haze (%) Scar (%) 
Infection 
(%) 
Loss of 
CDVA 
(%) 
ECC change 
(/mm2) 
(Caporossi et 
al. 2013) 26 24 — — — — — — — 
(Filippello et 
al. 2012) 20 18 — — 
0 (0 of 20 
eyes) 
0 (0 of 20 
eyes) 
0 (0 of 20 
eyes) — 
−34 (at 1.5 
years) 
(Koppen et al. 
2012a) 37 12 — — 
0 (0 of 37 
eyes) 
0 (0 of 37 
eyes) 
0 (0 of 37 
eyes) 
0 (0 of 37 
eyes) — 
(Leccisotti & 
Islam 2010) 51 12 — — 4 (2 eyes 51) 
0 (0 of 51 
eyes) 
0 (0 of 51 
eyes) 
0 (0 of 51 
eyes) +27 (at 1 year) 
(Mastropasqua 
et al. 2013) 20 12 0 — — — — — 
No significant 
change 
(Gupta et al. 
2015) 40 6 
0 (0 of 40 
eyes) 
0 (0 of 40 
eyes) 
0 (0 of 40 
eyes) 
0 (0 of 40 
eyes) 
0 (0 of 40 
eyes) 
0 (0 of 40 
eyes) -2 
(Soeters et al. 
2015) 33 12 
0 (0 of 33 
eyes) 
0 (0 of 33 
eyes) 
0 (0 of 33 
eyes) 
0 (0 of 33 
eyes) 
0 (0 of 33 
eyes) 
0 (0 of 33 
eyes) +1 
(Stojanovic et 
al. 2012) 61 12 — — 
0 (0 of 61 
eyes) 
0 (0 of 61 
eyes) 
0 (0 of 61 
eyes) — −130 (at 1 year) 
CDVA, corrected distance visual acuity; ECC, endothelial cell count. — indicates data not provided in published article. 
deterioration in topographic and acuity measures in non-treated control 
eyes.(Leccisotti & Islam 2010; Filippello et al. 2012) Improvements in corneal 
curvature (approximately 2 D mean reduction in Kmax) were similar to those 
seen after epithelium-off CXL. Filippello et al did, however, observe a 
difference in tissue effect by optical coherence tomography with a more 
superficial demarcation line typically visible at around 100 µm depth as 
opposed to 250-300 µm after epithelium-off CXL. (Filippello et al. 2012) 
Statistically significant improvements in CDVA were also observed 
(retrospectively) at 12-months by Stojanovic’s hybrid technique (Stojanovic et 
al. 2012) as well as in an uncontrolled prospective study (Koppen et al. 
2012b) though the authors recorded conflicting keratometric results 
depending on the imaging device used (progression by Scheimpflug, no 
change by Placido disc). The best evidence to date is 12-month results from 
one recently published randomised controlled trial (Soeters et al. 2015) which 
concluded that transepithelial CXL using Ricrolin TE (Sooft Italia S.p.A. 
Montegiorgio, Italy) was not effective at stabilising corneal shape compared 
with epithelium-off treatment. 
 
 For iontophoresis, up to 15 month follow-up data have been published (Table 
2.7, Table 2.8), with reported cessation of disease progression and 
improvements in keratometric and visual parameters.(Bikbova & Bikbov 2013; 
Vinciguerra et al. 2014; Buzzonetti et al. 2015; Bouheraoua et al. 2014) 
However, the relative efficacy of this technique compared to epithelium-off 
CXL remains to be determined especially over longer term follow-up, and 
current randomized prospective studies comparing the two techniques 
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(clinicaltrials.gov.uk NCT02117999, NCT01868620, ISRCT 04451470) have 
yet to be reported. 
 
Table 2.7 Summary of efficacy outcomes of iontophoresis transepithelial corneal cross-linking 
Reference Study design 
Eyes at 
latest 
follow-up 
(n) 
Age (years) 
(mean±SD) 
(Range) 
Latest 
follow-
up 
(months) 
UDVA 
change 
(logMAR) 
CDVA 
change 
(logMAR) 
MSE 
change 
(D) 
Cylinder 
change 
(D) 
K max 
change (D) 
Pachymetry 
change 
(microns) 
(Bikbova & 
Bikbov 2013) CS 22 32.15 ± 9.12 12 -0.13 0.05 0 0 
2.35 
(Kmean) -6 
(Bouheraoua 
et al. 2014) CS 15 
32.4 ± 6.6 
  
6 — −0.06 — — 1.33 +0.4 
(Vinciguerra 
et al. 2014) CS 20 27.7 ± 6 12 — -0.12 +1.11   0.66 -0.55 — 
(Bonnel et al. 
2015) CS 15 
27.75 ± 6.2 
(17–37 years) — — — — — — — 
(Buzzonetti et 
al. 2015) CS 14 
13 ±2.4 (10–18 
years) 15 −0.30 −0.1 +0.70 +0.70 +0.40 -4 
Bonnel et al study reporting depth of demarcation line only with no other results. — indicates data not provided in published article. 
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Table 2.8 Summary of safety outcomes of iontophoresis transepithelial corneal cross-linking 
Lead Author 
Eyes at 
latest 
follow-up 
(n) 
Latest follow-
up (months) 
Stromal 
oedema  
Sterile 
infiltrate 
Haze 
(%) 
Scar 
(%) 
Infection 
(%) 
Loss of CDVA 
(%) 
ECC 
change 
(/mm2) 
(Bikbova & 
Bikbov 2013) 22 12 — — 
0 (0 of 
22 
eyes) 
— — 0 (0 of 22 eyes) +6 
(Bouheraoua et 
al. 2014) 15 6 — — — — — — — 
(Vinciguerra et al. 
2014) 20 12 — — 
0 (0 of 
20 
eyes) 
— 0 (0 of 20 
eyes) 0 (0 of 20 eyes) — 
(Buzzonetti et al. 
2015) 14 15 0 — — — — — -3 
— indicates data not provided in published article.
2.5 Visual rehabilitation 
In the future, early intervention with CXL should greatly reduce the numbers of 
patients dependent on rigid contact lenses and corneal transplantation for 
visual rehabilitation in keratoconus. For the present, many patients are 
already past the point at which they still have good spectacle corrected or 
unaided acuity. Current strategies for contact lens fitting in keratoconus are 
discussed on page 21. Whilst transplantation remains the principal treatment 
for contact lens intolerant patients with stage IV keratoconus, newer 
interventions can be combined for earlier stage disease with the aim of 
restoring good spectacle corrected or unaided vision.  
 
2.5.1 Gross corneal shape adjustment – intracorneal ring segments 
Intrastromal corneal ring segments (ICRS) are effective in flattening the 
corneal shape and improving vision for most recipients with keratoconus 
(Table 2.10, Table 2.11), but the magnitude of effect is highly variable; and 
inclusion of different implantation techniques, different types of ICRS, and 
patients with late stage disease in earlier studies makes the existing evidence 
base for ICRS harder to interpret.(Piñero et al. 2009; Kubaloglu, Cinar, et al. 
2010; Rabinowitz et al. 2006; Kubaloglu, Sari, et al. 2010) Many surgeons 
now use smaller diameter ICRS designs (Table 2.9) and femtosecond laser 
assisted implantation. Earlier case series reporting manual implantation of the 
original Intacs ICRS (designed for simple myopic rather than keratoconus 
correction) are therefore not considered here. Femtosecond laser channel 
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cutting has, by ensuring a consistent cut depth, both facilitated and enhanced 
safety in ICRS implantation.(Coskunseven et al. 2011)  
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Table 2.9 Characteristics of available intracorneal ring segments (ICRS) 
Name Manufacturer Internal 
diameter/mm 
External 
diameter/mm 
Arc length 
/degree 
Profile Thickness/mm 
Intacs Addition Technology Inc. 
Sunnyvale, CA, USA 
6.8 8.1 150 Hexagonal 0.25-0.45  
(0.05 increments) 
Intacs SK Addition Technology Inc. 
Sunnyvale, CA, USA 
6.0 7.3 150 Oval 0.4 & 0.45  
 
Ferrara Mediphacos Ltd,  
Belo Horizonte, Brazil 
4.4 5.6 160 Triangular 0.2-0.35 
KeraRing 
SI5 
Mediphacos Ltd,  
Belo Horizonte, Brazil 
5.0 - 90, 120, 
160 & 210 
Triangular 0.15-0.35 
KeraRing 
SI6 
Mediphacos Ltd,  
Belo Horizonte, Brazil 
5.5, 6.0 - 90, 120, 
150 & 210 
Triangular 0.15-0.35 
MyoRing Dioptex GmbH, 
Linz, Austria 
5-8 - 360 Triangulara 0.2-0.4  
(0.02 increments) 
aConvex anterior and concave posteriorly 
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Table 2.10 Summary of outcomes using Intacs ICRS 
Reference, ring 
design 
No. 
of 
eyes 
Follow-up 
(mths) 
Surgery Mean 
change  
SE (D) 
Mean 
change 
cylinder (D) 
Mean change 
keratometry (D) 
% gaining 
CDVA, mean 
gain 
Complications 
(Rho et al. 
2013),Intacs SK 
25 3 Femtosecond 2.25 0.76 1.91 -, 0.19 LogMAR - 
(Kotb & Hantera 
2013), 
Intacs SK 
37 6 Femtosecond 1.8 - 4.1 55%, 0.06 
LogMAR 
5.4% oedema 
2.7% segment overlap 
(Niknam et al. 2012), 
Intacs SK 
37 6 Mechanical - - 4.48 -, 0.79 LogMAR 2.7% explantation 
(Khan et al. 2011), 
Intacs SK 
31 12 Mechanical 3.73 0.51 6.7 -, 0.15 LogMAR 19.3% extrusion 
6.4% vascularisation 
3.2% infection 
(Haddad et al. 
2012), 
Intacs SK 
66 12 Femtosecond 2.9 0.99 1.97 -, 0.12 LogMAR - 
(Fahd et al. 
2012),Intacs SK 
24 6 Femtosecond 6.50 1.65 5.08 - None 
(Sansanayudh et al. 
2010), Intacs SK 
10 6 Femtosecond 3.0 1.1 6.8 0%, 0.26 
LogMAR 
None 
(Kubaloglu, Sari, 
Cinar, Cingu, et al. 
2010), 
Intacs 
68 12 Mechanical/ 
Femtosecond 
1.87 1.17 3.5 82%, 1.61 
Snellen lines 
4.4% decentration 
5.8% extrusion 
(Shetty et al. 2009), 
Intacs 
12 6 Mechanical 2.98 1.5 3.6 83%, 0.13 
LogMAR 
0.8% vascularisation 
25% deposits 
(Ertan & Kamburoğlu 
2008), Intacs 
306 10 Femtosecond 3.0 0.2 2.7 72%, 0.20 
LogMAR 
0.9% extrusion 
(Shetty et al. 2008), 
Intacs 
14 12 Mechanical 5.0 1.8 3.9 69%, 0.17 
LogMAR 
- 
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(Zare et al. 2007), 
Intacs 
30 6 Mechanical 3.6 0.7 2.1 73%, 0.12 
LogMAR 
13% exposure, 3.3% 
keratitis 
(Colin & Malet 
2007), Intacs 
100 24 Mechanical 3.13 1.31 3.3 68%, -  4% explantation 
2% extrusion 
(Kymionis et al. 
2007), Intacs 
17 67 Mechanical 2.52 - 1.57 59%, - 71% vascularisation 
(Alio et al. 2006), 
Intacs 
13 48 Mechanical 1.4 2.0 3.3  15% vascularisation 
30% deposits 
(Ertan & Kamburoğlu 
2008), Intacs 
118 12 Femtosecond 3.8 1.7 3.9 74%, 1.6 
Snellen lines 
9% deposits 
(Colin 2006), Intacs 57 12 Mechanical 1.5 2.8 3.7 62%, - 12% explanted 
(Kanellopoulos et al. 
2006), Intacs 
20 12 Mechanical 3.4 2.5 2.9 - 5% perforated 
30% exposure 
(Alió et al. 2005, p.2), 
Intacs 
26 12 Mechanical 3.2, 1 ring 
1.9, 2 
rings 
2.4, 1 ring 
2.3, 2 rings 
4.6, 1 ring 
5.2 2 rings 
82%, 0.22 
LogMAR  1ring 
87%, 0.24 
LogMAR 2 rings 
None 
(Hellstedt et al. 
2005), Intacs 
50 6 Mechanical 2.78 0 
 
4.2 77%, 0.21 
LogMAR 
8% unsuccessful 
(Levinger & Pokroy 
2005), Intacs 
58 12 Mechanical 2.84 1.37 3.44 12%, - 10% additional 
segment implantation 
(Boxer Wachler et al. 
2003), Intacs 
74 20 Mechanical 2.4 - - 45%, 0.17 
LogMAR 
1.3% extrusion 
(Siganos et al. 
2003), Intacs 
33 11 Mechanical 1.3 - 3.2 76%, 0.17 
LogMAR 
3% vascularisation 
(Colin et al. 2001), 
Intacs 
10 12 Mechanical  2.7 4.6 - None 
(Colin et al. 2000), 
Intacs 
10 6 Mechanical 2.1 1.5 4.8 - 8% explanted 
SE (spherical equivalent), CDVA (corrected distance visual acuity), D diopter, mths months, dash (-) indicates not reported 
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Flattening of central curvature with ICRS implantation increases with smaller 
ring diameter and greater segment thickness. The penalty for using a smaller 
diameter ring is a greater potential for dysphotopsia. The triangular profile 
used in Ferrara and KeraRing ICRS is designed to reduce forward light 
scatter by total internal reflection of incident light, but further clinical studies 
are required to quantify dysphotopsia associated with ICRS implantation.  
 
In a series with 12-month postoperative results of 50 consecutive 
femtosecond laser KeraRing ICRS cases reported from Turkey,(Coskunseven 
et al. 2008) approximately two-thirds of patients gained spectacle CDVA 
compared with pre-implantation levels (1 - 4 Snellen lines). Only 2 patients 
lost 2 lines of spectacle CDVA, and neither wanted the implants removed 
because of gains in UCVA.  Overall improvement in mean keratometry was 
approximately 3D (50.6 ± 4 D pre ICRS; 47.6 ± 4.5 D post-ICRS) with larger 
gains for cases with a steeper initial shape (stage III, 3mm zone steep K > 53 
D) in which thicker ICRS were implanted. Asymmetric ICRS implantation 
(asymmetric arc length and thickness in superior and inferior ICRS) or single 
ring implantation can be used in patients with reduced spectacle CDVA 
associated with high pre-operative coma (cone decentration). Results in a 
smaller series of 21 cases of femtosecond laser KeraRing ICRS implantation 
reported similar significant gains in overall higher order aberration levels for 
patients with high starting levels of coma (> 3 µm).(Shabayek & Alio 2007) A 
retrospective series of 173 femtosecond laser cut eyes comparing
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Intacs SK and KeraRing SI6 (both with a 6mm diameter optical zone) 
observed comparable improvements in vision and keratometry, with no 
statistically significant differences between the two ICRS models.(Haddad et 
al. 2012) 
 
Femtosecond ICRS implantation has a good safety profile. A recent 
multicenter retrospective review of 850 eyes with femtosecond KeraRing 
ICRS implantation using an Intralaser femtosecond laser for ring channel 
creation reported a 5.7% overall complication rate.(Coskunseven et al. 2011) 
Intraoperative complications did not result in failure to complete ICRS 
implantation. Incomplete ring channel formation was the commonest 
complication (2.7%). In these cases, ring channels can be completed 
manually allowing ICRS implantation to proceed. Endothelial perforation was 
evident in 0.6% cases. In this circumstance, channel creation 90µm superficial 
to the initial attempted depth can be completed 1 month after surgery. The 
target depth for femtosecond KeraRing implantation is 80% of corneal 
thickness at the location of the ring channel (5mm diameter). Ultrasound 
pachymetry was used in this study. Availability of more accurate regional 
pachymetry methods, OCT tomography in particular, may eliminate the risk of 
perforation.  Postoperative complications occurred in 1.6% of cases. Within-
channel migration of ring segments was noted in 7 eyes and treated 
successfully with repositioning and a sutured vertical incision closure. 4 cases 
of stromal thinning over the ICRS and 2 cases of corneal melting required 
implant removal. As with endothelial perforation, melting was attributed to 
inaccurate regional pachymetry and superficial channel creation in relatively 
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thin corneas. Infection (an infiltrate at the entry site) was seen in one case in 
this series and treated without ICRS explantation.  Problems for this study are 
lack of acuity, refractive and keratometric outcome data. The authors also do 
not state the follow-up period studied or whether these were consecutive 
cases. Nonetheless, data from this and smaller prospective series indicate 
that sight-threatening complications are rare.(Coskunseven et al. 2011; 
Shabayek & Alio 2007)  
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Table 2.11 Summary outcomes using Keraring or Ferrara ICRS 
Author, year, ring 
design 
No. 
of 
eyes 
Follow
-up 
(mths) 
Surgery Mean 
change  
SE (D) 
Mean 
change 
cylinder (D) 
Mean change 
keratometry 
(D) 
% gaining CDVA, 
mean gain 
Complications 
(Torquetti et al. 
2014),Ferrara 
36 120 Mechanical - - 2.99 67%, 0.16 LogMAR _ 
(Alfonso et al. 
2013), Keraring 
41 6 Femtosecond - - 1.62 49%, 0.06 LogMAR None 
(Tunc et al. 
2013), Keraring 
30 12 Mechanical 5.16 - 4.95 93%, 0.34 LogMAR None 
(Alfonso et al. 
2012), Keraring 
56 6 Femtosecond - - - 60%, 0.1 LogMAR None 
(Haddad et al. 
2012), Keraring 
107 12 Femtosecond 2.65 1.93 1.44 -, 0.08 LogMAR - 
(Gharaibeh et al. 
2012), Ferrara  
55 6 Mechanical 0.06 1.05 5.75 87%, 0.21 1.8% extrusion 
3.6% infection 
(Coimbra et al. 
2012), Keraring 
35 3 Femtosecond 2.58 3.92 3.07 82%, 0.15 LogMAR None 
(Ameerh et al. 
2012), Ferrara  
79 6 Mechanical 3.36 1.32 4.59 -, 0.14 LogMAR - 
(Ferrara et al. 
2011), Ferrara  
1073 23 Mechanical 
I 160° arc 
II 210° arc 
I 1.72 
II 4.58 
- I 3.46 
II 3.82 
I 80%, - 
II 69%, - 
3.8% complication 
rate 
(Kubaloglu et al. 
2011), Keraring 
96 6-18 Mechanical 3.62 - 5.01 91%, 0.42 LogMAR 58% deposits 
1% extrusion 
(Hamdi 2011),  
Ferrara  
100 6 Mechanical 1.08 2.28 3.05 64%, -  13% complication 
rate 
(Alfonso et al. 
2011), Keraring 
219 6 Femtosecond - - - 57%, 0.11 LogMAR None 
(Kubaloglu, Sari, 
Cinar, Koytak, et 
al. 2010), 
Keraring 
100 12 Femtosecond 2.83 1.33 2.76 85%, 3 Snellen lines 4% decentration 
1% extrusion 
1% perforation 
(Pesando et al. 
2010), Ferrara  
130 37 Mechanical 5.51 - 3.59 98%, 0.19 LogMAR 3% explantation 
0.76% perforation 
 60 
(Torquetti et al. 
2009),Ferrara  
35 60 Mechanical - - 5.98 74%, 0.21 LogMAR - 
(Kwitko & Severo 
2004),Ferrara  
51 13 Mechanical 1.53 1.66 5.59  20% extrusion 
2% infection 
SE (spherical equivalent), CDVA (corrected distance visual acuity) dash (-) indicates not reported 
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2.5.2 Combined ICRS and CXL 
ICRS implantation can be combined with CXL,(Coskunseven et al. 2009; 
Saelens et al. 2011; El-Raggal 2011; Chan et al. 2007; Ertan et al. 2009) but 
the treatment sequence is important: ICRS appears more effective in 
improving corneal shape before the cornea is stiffened with CXL. 
Coskunseven et al, in an RCT comparing CXL first and ICRS later (group 1) 
with ICRS first and later CXL (group 2), showed significantly greater 
improvements (mean 7 months follow-up) in spectacle CDVA (3 line gain 
[group 1]; 2 line gain [group 2], p < 0.01) and manifest astigmatism (2.48D 
mean absolute cylinder reduction [group 1]; 1.76  D reduction [group 2], p < 
0.05) where ICRS was performed first.(Coskunseven et al. 2009) 
Simultaneous CXL and ICRS may be equally effective. El-Raggal showed a 
trend towards greater improvement at 12 months in mean K values where 
simultaneous ICRS and CXL was performed versus CXL 6 months after ICRS 
(50.2 ± 3.8 D to 44.9 ± 2.9 D simultaneous treatment; 50.4 ± 3.8 D to 47.3 
±3.5D delayed CXL, p = 0.046), although there were no differences in UDVA, 
CDVA or refractive error.(El-Raggal 2011) But this study was underpowered 
(n = 8 each arm). More evidence is required to determine the optimum interval 
between ICRS and CXL in combined treatment; but the practical advantages 
to combining ICRS with transepithelial treatment in particular are clear. An 
interesting variation here has been described by Selans et al who augmented 
stromal riboflavin penetration by injection into the ring channels prior to 
transepithelial CXL. (Saelens et al. 2011)
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Table 2.12 Summary outcomes for combined ICRS and CXL 
Reference, ring 
design 
No. 
of 
eyes 
Follow-
up 
(mths) 
Surgery Mean 
change  
SE (D) 
Mean 
change 
cylinder (D) 
Mean change 
keratometry 
(D) 
% gaining CDVA, 
mean gain 
Complications 
(El-Raggal 2011), 
Keraring 
16 12 Femtosecond -2.52 0.86 3.88 - 100% haze (CXL) 
(Coskunseven et 
al. 2009), Keraring 
Group 1* 
Group 2 
48 
 
NR 
NR 
 
 
13 
13 
 
 
Femtosecond 
Femtosecond 
 
 
-4.15 
-4.24 
 
 
1.76 
2.48 
 
 
 
 
4.26 
3.98 
 
 
-, 1.5 lines 
LogMAR 
-, 3 lines LogMAR 
 
 
- 
- 
(Saelens et al. 
2011), Ferrara 
7 12 Mechanical -3.5 - 2.84 -, 0.26 (decimal) Explantation n=1 
(Chan et al. 2007), 
Intacs 
12 3 Mechanical - 1.25 1.13 -, 1 line 
(unspecified) 
None 
(Ertan et al. 2009), 
Intacs 
25 5 Femtosecond - 0.63 2.44 -, - - 
* Group 1: CXL then ICRS; group 2: ICRS, then CXL. NR, not recorded (numbers in each group). ICRS, intrastromal corneal ring segments; CXL, corneal 
cross-linking; D, diopter, dash (-) indicates not reported 
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2.5.3 ICRS implantation protocols 
Inclusion criteria in Coskunseven’s recent prospective series of femtosecond 
KeraRing ICRS implantation include a minimum central corneal thickness of 
350 µm and 450 µm at the incision site.(Coskunseven et al. 2008) No upper 
limit for keratometry values was specified. Neovascularisation has not been 
reported after femtosecond KeraRing ICRS implantation and 5 mm diameter 
ICRS are within the block of tissue normally removed in any subsequent 
transplantation procedure. Where corneal thickness is adequate and there is 
no central scar, it is probably reasonable to consider ICRS implantation with 
CXL in patients with advanced stage III disease since there should be no 
increased risk of failure in any subsequent corneal transplant. But a stratified 
analysis of patients with contact lens fitting problems associated with steep 
keratometry is required to determine whether ICRS is a viable alternative to 
corneal transplantation for this group or whether there is an upper limit to the 
Kmax for ICRS. For the present, limits for ICRS implantation are probably 
best defined by Coskunseven’s pachymetric inclusion criteria 
above.(Coskunseven et al. 2008)  
 
2.5.4 Thermal keratoplasty 
Thermal keratoplasty has been proposed  as a possible alternative to ICRS 
for gross corneal shape correction in advanced keratoconus. The underlying 
principle is that above heat causes corneal collagen fibers to undergo a 
degree of shrinkage and reformation, resulting in a change in corneal 
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curvature. Conductive keratoplasty (CK) was the original method of 
thermokeratoplasty, involving a thin probe penetrating to 90% corneal depth 
delivering radiofrequency energy to the stroma. The resistance to current flow 
within the stroma generates the required heat and tissue effect. CK was 
previously described as a treatment for simple hyperopia in which mid-
peripheral stromal shrinkage caused central corneal steeping.(McDonald et al. 
2002) As a treatment in pathological corneas, Kato et al treated 21 advanced 
keratoconic eyes using pre-operative topography to guide CK spot application 
(with intraoperative keratometric monitoring). Although large initial shape 
improvements were obtained, almost complete regression was seen within 3 
months: mean keratometry values were 55 ± 8 D at baseline, 45 ± 9 D at 1 
week, 50 ± 7 D at 1 month and 54 ± 7 D at 3 months.(Kato et al. 2010)  
 
A non-contact method of thermokeratoplasty was reported more recently by 
Celik et al using a radiofrequency-generating device held just above the eye 
to deliver of a ring of microwave energy to the stroma.(Celik et al. 2015) In 
this study, 24 eyes with progressive keratoconus were treated with microwave 
thermokeratoplasty following by immediate accelerated CXL (30 mW/cm2 
irradiation for 3 minutes; total dose of 5.4 J/cm2). Although the desired 
reduction in keratometry was produced without significant side-effects, there 
was early and complete regression of the thermokeratoplasty effect by 12-
months post-operatively. 
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2.5.5 Fine corneal shape adjustment – photorefractive keratectomy 
Combination with CXL may allow safe application of surface excimer laser 
ablation techniques to fine tune corneal shape in keratoconus. To date, 
topography guided photorefractive keratectomy (PRK) has been studied in 
combined therapy (Table 2.13).  But wavefront ablation would be a viable 
alternative in cases with good aberrometry data.  
 
For simultaneous combined treatment, in which CXL is applied immediately 
after PRK, the aim is to improve CDVA by reducing irregular astigmatism 
rather than to correct spherocylindrical error fully. Reasons for this are the 
requirement for a 400µm residual stromal bed after ablation to allow safe 
CXL, and the danger of hypermetropic overcorrection if spherical equivalent 
reductions induced by CXL are not anticipated. Simultaneous combined 
treatment has clear advantages for patient comfort (the epithelium is only 
removed once), but takes no account of improvements in corneal regularity 
and spectacle CDVA that might normally be produced by CXL alone. 
 
In a large comparative case series with minimum 2 year postoperative follow-
up, Kanellopoulos (Kanellopoulos 2009) compared outcomes of 198 eyes 
treated with topography guided PRK followed immediately by CXL 
(simultaneous combined treatment) with an earlier series of 127 eyes treated 
with topography guided PRK a minimum of 6 months after CXL (sequential 
combined treatment). Simultaneous combined treatment produced greater 
improvement across a range of measures: LogMAR CDVA improved from 
0.39 ± 0.3 D to 0.11 ± 0.2 D, with a reduction in spherical equivalent of -3.2 ± 
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1.4 D and mean keratometry of -3.5 ± 1.3 D. This compares with the 
sequential group’s CDVA improvement from 0.41 ± 0.3 D to 0.16 ± 0.2 D, 
spherical equivalent reduction of -2.5 ± 1.2 D and mean keratometry reduction 
of -2.75 ± 1.3 D. Haze scores were also significantly better for simultaneous 
combined treatment. 20 second intraoperative applications of mitomycin C 
were used throughout, and the maximum ablation depth was limited to 50 µm. 
The essential problem for this comparison is that the time interval between 
CXL and PRK for sequential treatment was not specified, and may have been 
considerably shorter than the 2 year period in which refractive results typically 
continue to improve after CXL alone.(Caporossi et al. 2010) Further study is 
required to quantify any gain in spectacle CDVA over CXL alone for 
simultaneous combined CXL and PRK, and to determine whether increased 
haze scores for sequential combined treatment observed by Kanellopoulos, 
are still evident where PRK is performed later in the post CXL wound healing 
cycle, a minimum of 2 years after treatment.  
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Table 2.13 Summary outcomes for combined photorefractive keratectomy and CXL 
Author  Study 
Design  
No. of eyes Surgical Procedures  Follow-up % eyes gain ≥ 
1 line CDVA 
Mean gain  
CDVA 
(LogMAR) 
Remarks 
(Shetty et al. 
2015) 
CS 29 Simultaneous topography-
guided PRK followed by CXL  
12 months 45% 0.21 No complications 
(Sherif et al. 
2015) 
CS 20 Simultaneous topography-
guided PRK followed by CXL  
12 months 75% 0.19 30% haze at 3 months 
(Fadlallah et al. 
2014) 
CS 140 Simultaneous  non-
topography-guided PRK 
followed by CXL 
24 months N/A (Aiming to correct UDVA) 
 
_ 
(Alessio et al. 
2014) 
CS 17 Simultaneous topography-
guided PRK followed by CXL  
48 months Confocal 
outcomes only 
_ _ 
(Sakla et al. 
2014) 
CS 31 Simultaneous topography-
guided PRK followed by CXL  
12 months 100% 0.22 No complications 
(Mukherjee et 
al. 2013) 
CS 22 Simultaneous transepithelail 
(manifest-guided) PTK 
followed by CXL 
12 months 95% 0.11 No complications 
(Kymionis et al. 
2009) 
CS  14 Simultaneous topography-
guided PRK followed by CXL  
Range: 3 -16 
months 
44 % (Snellen) 0.10 No complications 
(Kanellopoulos 
2009) 
CS  127 
sequential 
198 
simultaneous 
Sequential (> 6 months after 
CXL) and simultaneous 
topography-guided PRK 
followed by CXL  
 Range: 24 - 
68 months 
Sequential: 0.25 
Simult.: 0.28 
_ Significant haze in 19 eyes 
(17 of sequential and 2 of 
simultaneous group) 
(Kanellopoulos 
& Binder 2011) 
CS  32 Simultaneous topography-
guided partial transepithelial 
PRK and CXL  
27 months  _ _ 2 of 32 eyes had corneal 
progression, corneal haze 
grade 2 in 2 of 32 eyes 
(Tuwairqi & 
Sinjab 2012) 
CS  22 Simultaneous topography-
guided PRK and CXL  
12 months N/A (Aiming to 
correct UDVA) 
-0.01 No complications 
(Lin et al. 2012) CS  217 (only 72 Simultaneous topography- 12 months 64% _ 2 eyes had sufficient haze, 
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completed 12 
months f/u) 
guided PRK and CXL  1 eye had herpetic keratitis, 
2 eyes had PKP, 2 eyes 
had re-treatment 
(Kymionis et al. 
2012) 
Nonrand
omized, 
clinical 
trial  
17 (PRK and 
CXL), 17 
(CXL) 
Transepithelial topography-
guided PRK and CXL/CXL  
24 months 42.1% 0.11 No ocular adverse events 
(Kapasi et al. 
2012) 
Prospecti
ve, 
compara
tive  
   34 t-PTK (group 1) and mechanical 
epithelial debridement (group 
2) during CXL  
1 months - 0.03 
(decimal) 
 No complications 
(Kanellopoulos 
& Asimellis 
2014) 
CS  175 Simultaneous topography-
guided PRK and CXL  
36 months Epithelial remodelling 
outcomes only 
No complications 
PTK, phototherapeutic keratectomy; PRK, photorefractive keratectomy; t, transepithelial; CXL, corneal cross-linking 
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2.5.6 Refractive correction – phakic intraocular lens implantation 
For patients with a stable corneal shape and regular astigmatism underlying  
good CDVA, phakic intraocular lens (pIOL) implantation can be used to 
complete functional visual rehabilitation. A number of recent papers have 
reported effective refractive correction using pIOLs in keratoconus, (post-
operative spherical equivalent range -0.08 ± 0.4 to +0.1 ± 0.4; 64-67% within 
0.5 D and 84-100% within 1 D of target refraction)(Izquierdo et al. 2011; 
Alfonso et al. 2008; Kamiya et al. 2011; Sedaghat et al. 2011; Alfonso et al. 
2010; Kato et al. 2011) and for post-keratoplasty ametropia.(Alfonso et al. 
2009) Of the pIOLs available,(Kohnen et al. 2010) the Visian ICL (Staar 
Surgical, Monrovia, CA) offers the longest safety track record for an injectable 
pIOL and is available in a wide range of powers (including toric correction up 
to 6 D). Pesando et al reported retrospective 10-year follow-up data in 59 ICL-
implanted hypermetropic eyes, showing a mean endothelial cell loss of 4.7%, 
mostly occurring within the first few weeks of implantation and remaining 
almost unchanged thereafter.(Pesando et al. 2007) Edelhauser et al reported 
prospective, multicenter, 4-year follow-up data on 526 eyes with a 2%-3% cell 
loss rate over the first 3 years, followed by a cell increase of 0.1% between 
years 3 and 4, suggesting that endothelial remodeling and stability may have 
been achieved.(Edelhauser et al. 2004) 
 
Combined ICRS and pIOL implantation has been described,(Moshirfar et al. 
2011; Cakir & Utine 2010; El-Raggal & Abdel Fattah 2007) but refractive 
correction with pIOLs is highly predictable,(Huang et al. 2009) whereas the 
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refractive effect of ICRS implantation is highly variable.(Piñero et al. 2009; 
Kubaloglu, Cinar, Sari, Koytak, et al. 2010; Rabinowitz et al. 2006; Kubaloglu, 
Sari, Cinar, Cingu, et al. 2010; Coskunseven et al. 2009; Saelens et al. 2011; 
El-Raggal 2011; Chan et al. 2007; Ertan et al. 2009) Gross shape correction 
with ICRS implantation followed by CXL (with fine shape correction with PRK 
if necessary) should, therefore, precede pIOL implantation as a logical 
pathway to visual rehabilitation in grade II-III keratoconus.
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3 Shape stabilisation - quantifying epithelium-off 
riboflavin absorption  
3.1 Introduction 
Corneal collagen cross-linking (CXL) is performed by irradiating riboflavin-
soaked corneal tissue with an ultraviolet A (UVA) light source (370 nm). The 
riboflavin acts both as a photosensitiser to encourage UVA-induced corneal 
stiffening (cross-linking), and a shield to reduce UVA levels at the endothelial 
level below the cytotoxic threshold.  The original Dresden protocol described 
removal of the corneal epithelium with application of riboflavin 0.1% drops 
every 2 minutes for 30 minutes prior to, and during, UVA treatment (3 
mW/cm2 power for further 30 minutes, total energy dose 5.4 
J/cm2).(Wollensak, Spoerl, et al. 2003a) 
 
3.2 Two-photon fluorescence microscopy 
The optimum riboflavin soak duration and concentration in the cornea 
required to achieve effective collagen cross-linking is unknown. Originally, slit-
lamp biomicroscopy was used in patients to check for riboflavin fluorescence 
in the aqueous as a surrogate marker of complete corneal stromal 
penetration. Confocal (i.e. single-photon) and two-photon fluorescence (TPF) 
microscopy have both been used to quantify the concentration and 3-
dimensional distribution of riboflavin in feline, chick embryo and porcine 
corneas.(Cui et al. 2011; Zhang et al. 2012; Kampik et al. 2010; Søndergaard 
et al. 2010) Single-photon fluorescence microscopy describes the principle of 
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a single photon of light exciting a fluorophore from one state (usually the 
ground state) to a higher energy state. An example of single-photon 
fluorescence microscopy is shining blue light onto a fluorescein stained 
cornea to emit green light (Figure 3.1). The same energy can be delivered by 
the absorption of two photons of light, each of double the wavelength and half 
the energy (energy is inversely proportional to wavelength). The probability of 
the near-simultaneous absorption of two photons is very low. Therefore a 
high flux of excitation photons is typically required, usually from 
a femtosecond laser. 
 
 
Figure 3.1 Fluorescence microscopy 
Left: Photograph of single-photon fluorescence microscopy with 
blue light (490 nm) causing excitation of fluorescein with the 
subsequent emission of light with a longer wavelength (green, 520 
nm) and, therefore, lower energy. Right: Two-photons of light (violet 
arrows) each with double the wavelength (490 x 2 = 980 nm), and 
therefore each with half the energy, can deliver the same total 
energy as a single photon of blue light. This process is called two-
photon fluorescence 
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Advantages for TPF include reduced bleaching and phototoxicity outside the 
focal point (Figure 3.2), making it easier to obtain quantitative, 3D 
measurements, and reduced attenuation of the excitation light in the target 
medium due to its longer wavelength.  
 
 
Figure 3.2 Excitation inside and outside the focal point 
Localization of excitation by two-photon excitation within a cuvette 
filled with fluorescein solution. (a) Single-photon excitation of 
fluorescein by focused 488-nm light. Note the bright intensity of 
fluorescence at the top of the cuvette as soon as the light enters the 
fluorescent solution, outside of the focal plane (i.e. not where the 
fluorescence is intended) (b) Two-photon excitation using focused 
femtosecond pulses of 960-nm light. Note that fluorescence 
excitation is now restricted to a small localized area at the focal 
plane (black arrow) (Reprinted by permission from Macmillan 
Publishers Ltd: Zipfel et al. Nature Biotechnology 21, 1369-1377, 
copyright (2003)) 
 
  
Near-absence of TPF signal attenuation has been demonstrated within a 
microfluidic system imaging at depths up to 37 μm.(Schafer et al. 2007) In 
tissue, however, a number of additional factors, principally scattering and 
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aberration, may cause TPF signal loss with increasing scan depth.(Cui et al. 
2011; Zhang et al. 2012; Kampik et al. 2010) While acknowledging this 
problem, Cui et al. made no correction for signal attenuation with increasing 
scan depth in their application of TPF imaging to the measurement of 
riboflavin concentration in (feline) corneas.(Cui et al. 2011) 
 
In this chapter I present work investigating the use of TPF microscopy in an 
ex vivo whole globe animal model to measure riboflavin concentration at 
different depths within the cornea. 
 
 
3.3 Materials and methods 
Ethical approval for corneal two-photon fluorescent microscopy studies in an 
ex vivo model was granted by University College London Institute of 
Ophthalmology (ref. 10/H0106/57-2012ETR27). 
 
3.3.1 Riboflavin spectrophotometry 
The fluorescence absorption and emission spectra of 0.1% w/v riboflavin 5’-
monophosphate (1.45 mg/ml) in saline and hydroxypropyl methylcellulose 
(HPMC)  (VibeX Rapid, Avedro, Mass. USA) were measured by 
spectrophotometery (UV-3101PV UV-VIS-NIR; Shimadzu, Kyoto, Japan).  
Riboflavin exhibited a bimodal absorption spectrum with a lower peak at 374 
nm, and a higher peak at 445 nm (Figure 3.3). The maximum emission 
wavelength was 524 nm. 
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Figure 3.3 Riboflavin absorption and emission spectra 
The absorption and fluorescence emission spectra of dextran-free 
0.1% riboflavin 50-monophosphate in saline and HPMC (Avedro, 
Inc.). Absorption peaks are seen at 374 nm and 445 nm; a 
fluorescence emission peak is seen at 524 nm when excited at 445 
nm. 
 
 
3.3.2 Two-photon microscope set-up  
A Ti:Sapphire laser (Chameleon Vision II, Coherent, CA, USA) equipped with 
a prism based Group Velocity Dispersion (GVD) compensation unit was used 
as the excitation laser source. The laser has a tuning range from ~680 nm up 
to 1080 nm, operating with a 140 femtosecond pulse duration and 80 MHz 
pulse repetition rate. The excitation laser beam was guided to a Leica 
DM6000CS upright microscope via an Electro-Optical-Modulator (EOM) to 
control laser output and coupled into the Leica SP8 Spectral Scan-head 
(Leica Microsystems, GmBH) where it passes through two galvoscanners, 
allowing scanning in the x-y plane, before being focused into the sample by a 
Leica 25X /0.95 NA water immersion objective (coverslip corrected) that 
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facilitated a working depth of up to 2 mm. Theoretical (full-width half-
maximum) resolutions were calculated at 0.34 μm laterally and 1.4 μm axially. 
Employing the two-photon fluorescence principle, I used excitation light of 
wavelength 890 nm to correspond with the highest absorption wavelength of 
riboflavin (i.e. 445 x 2 = 890 nm, Figure 3.3). The emitted fluorescence 
passed through an 800 nm short pass dichroic filter (Chroma Technology 
Corp., Vermont, USA), which was then spectrally separated by a Leica 
Acousto-Optic-Beam Splitter (AOBS®) before passing to the Leica HyD® 
detectors.  
 
3.3.3 Sample preparation 
Freshly enucleated porcine eyes (First Link Ltd., Wolverhampton, UK), stored 
within a sealed bottle of phosphate buffered saline (0.85% NaCl, 0.01M 
NaPhos, pH 7.2-7.4), were transported on ice to arrive within 24 hours of 
death. Rabbit globes, more closely matching human corneal epithelial 
thickness were additionally used to confirm findings in epithelium-on 
experiments. Each globe was secured within a custom-made perspex cylinder 
to ensure stability on the microscope stage (Figure 3.4A). A custom reservoir 
chamber for riboflavin (a coverslip glued onto two rubber O-rings) was placed 
coverslip down and filled with ~400 µl of riboflavin solution. The epithelium 
was either left intact or debrided using a hockey stick scraper (e.janach srl, 
Como, Italy), the cornea of the intact globe was apposed to the O-ring and 
immersed in riboflavin and a timer was started (time = 0 minutes). Relying on 
surface tension to keep the O-ring/coverslip and cornea apposed, the 
assembly was then inverted, creating a bubble-free, sealed lake of riboflavin 
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over the cornea and beneath the coverslip ready for imaging (Figure 3.4B). 
The assembly was then positioned within a custom-built recessed stage to 
house the cylinder-supported globes beneath the objective. The first TPF z-
stack was started at time = 2.5 minutes. 
 
 
Figure 3.4 Sample and stage set-up 
Intact globe set-up on microscope stage. (A) Perspex cylinder used 
to secure whole globe on the microscope stage with a sealed, air 
bubble free reservoir of riboflavin on top of the cornea (B). 
 
 
 
3.3.4 Imaging protocol and concentration calibration 
All TPF experiments were performed with the room lights at a minimum. The 
microscope stage and objective were enclosed in opaque Perspex casing to 
reduce incident light being detected. TPF excitation light of 890 nm 
wavelength was chosen to correspond with the highest riboflavin absorption 
peak (445 nm) as determined by spectrophotometry. The average laser 
output power at 890 nm was 33 mW at the objective with minimal fluctuation 
in average power being observed during the course of any given day’s 
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experiment. Emitted riboflavin fluorescence was collected between 525 nm 
and 650 nm, to avoid overlap with the absorption spectrum of riboflavin. I 
confirmed the absence of any reabsorption of this emitted light by 
demonstrating no change in measured TPF signals with excitation depth in 
homogeneous riboflavin solutions within a well slide (Figure 3.5).  
 
 
Figure 3.5 Confirming absence of reabsorption of emitted light 
TPF signal calibration for riboflavin in solution. (A) Well slide setup 
beneath a coverslip-corrected objective. (B) Serial riboflavin 
dilutions from 0.1% to 0.0125% (wt/vol) produced constant TPF 
signals with-depth through the drop sample. 
 
 
Serial z-stacks at 10 µm intervals were started within the pre-corneal riboflavin 
reservoir at approximately 30 µm above the corneal surface to provide a 
reference TPF signal level for this 0.1% w/v solution. This level provided a 
signal-to-concentration calibration for each eye. Z-stacks were acquired 
through the depth of the cornea (scan rate: 600 Hz, 512 x 512 pixels, image 
size: 445 µm x 445 µm, line average: 2, pinhole wide open). An iterative 
approach to developing this protocol was used, balancing the need for 
sufficient axial resolution with 10 µm stacks and a fast total acquisition time 
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(approximately 130 seconds) to limit the possibility to riboflavin migration 
during each whole corneal scan. Each run was repeated every 2.5 minutes, 
up to 20 minutes, and then every 5 minutes, up to 60 minutes.  
 
3.3.5 Confirming TPF signal attenuation  
To demonstrate that TPF signal attenuation must be occurring when imaging 
en face, I excised corneal strips from riboflavin-soaked intact globes. A cross-
sectional (sagittal) surface of each strip was placed face-down onto a 
microscope slide and a coverslip was placed on top. A single TPF image 
(using a 10x 0.30 NA objective) was acquired of a plane approximately 50 µm 
below the coverslip. Excised corneo-scleral buttons were also imaged from 
both directions, draped over a scleral contact lens to avoid stromal folds. A 
coverslip was then placed directly on top, applanating a central area of the 
cornea without coupling fluid, and z-stacks of TPF images were acquired. No 
immersion fluid was used for either excised tissue experiment to minimise the 
migration of riboflavin within the cornea prior to imaging. The time taken to 
excise and mount the tissue prior to imaging was under 2 minutes. Results 
from both these experiments were compared with z-stacks acquired in intact 
globes.  
 
3.3.6 TPF signal correction  
The average raw TPF signal data for each image in a z-stack were exported 
in .CSV format (Excel for Mac, 2011; Microsoft Corp) and plotted against 
corneal depth for measurements with corneas soaked for increasing times. A 
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uniform concentration of riboflavin was judged to have been achieved when 
the posterior corneal TPF signal stopped increasing (typically after ~50 
minutes). The z-stack data for this condition was then used to provide the 
attenuation reference for this eye (i.e. each eye provided its own internal 
reference).  A detailed example using this methodology to correct the 
attenuation at earlier time points is shown in Figure 3.6. 
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Figure 3.6 Signal attenuation correction example 
Example methodology of correcting TPF signal attenuation when imaging 
epithelial debrided intact globes. (A) Spatially (x-y) averaged raw TPF data 
for 5- and 50-minute soak durations in the same eye plotted against corneal 
depth (z). After 50 minutes the TPF signal recorded at the back of the 
cornea (blue arrow) plateaued, with no further increases observed at 55 or 
60 minutes (plots not shown). This indicated the tissue was completely and 
uniformly soaked, with attenuation of the signal preventing a flat signal plot. 
This 50-minute plot was used to model the signal attenuation. (B) Enlarged 
box insert from (A) delineating the changes in signal slope at the beginning 
of the z-stack: 1 to 2 is within the precorneal riboflavin reservoir; 2 to 3 is 
part- cornea, part-reservoir; 3 onwards, the whole of the image is within the 
cornea. (C) All TPF signal readings at 5 minutes were then divided by the 
reading for the corresponding depth in the 50-minute plot (uniformly 
saturated), giving a uniform corrected TPF signal level throughout the 
cornea for the 50-minute plot and a corrected slope for the earlier time 
point. (D) The y-axis of the plot was converted to riboflavin concentration by 
normalizing to the TPF signal level within the reservoir of 0.1% riboflavin 
solution. The x-axis of the plot was shifted so that a depth of 0lm 
corresponded with the start of the cornea. 
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3.4 Results 
3.4.1 Proof of TPF signal attenuation 
In epithelial debrided controls (i.e. no riboflavin) negligible fluorescence was 
detected. Cross-sectional TPF images (Figure 3.7) taken of excised corneal 
strips demonstrated near-uniform signals after 40 minutes’ soak time. After 60 
minutes’ soak time to ensure uniform saturation, the TPF signal was seen to 
diminish with depth in the cornea in an excised corneo-scleral button (Figure 
3.8). Although the relative amplitude of the TPF signal was reduced compared 
with the intact globe image prior to excision, reversing the tissue (i.e. 
endothelial side up) did not reverse the slope of the TPF signal loss, 
confirming that the decrease in TPF signal when imaging through the z-axis is 
due to signal attenuation rather than a depth-dependent drop in riboflavin 
concentration. 
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Figure 3.7 Cross-sectional TPF images 
TPF images of cross-section of excised corneal strips (epithelium-
off) showing increasingly uniform TPF signal with longer soak times. 
In the Leica imaging software the saturation spectrum increases 
from green (zero fluorescence) to black to orange to red]. At 5 
minutes, low levels of fluorescence are detected as indicated by the 
dim red colour. Compare this with scans performed after more 
prolonged soak duration in which the signal increases (brighter red), 
as well as the signal remaining more uniform in the posterior 
cornea. Plots of TPF signal variation across the sectioned corneal 
specimens, produced using Java-based imaging software (ImageJ, 
1.47v, http:// imagej.nih.gov.ij; provided in the public domain by the 
National Institutes of Health, Bethesda, MD, USA); are shown below 
each strip.  
 
These images confirm that the signal drop observed with increasing 
depth in uniformly soaked corneal specimens on z-stack imaging 
was attributable to signal attenuation rather than any variation in 
riboflavin concentration with depth. Excising strips of cornea was 
inevitably complicated by aqueous loss which is likely to wash and 
dilute some of the riboflavin from the tissue. In addition significant 
distortion of the tissue was observed when laid face-up on a slide 
(the images presented have been rescaled to the thicknesses 
observed on z-stack imaging prior to excision). This method is not 
suitable for quantifying TPF signals. 
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Figure 3.8 Confirming signal attenuation from both tissue sides 
The aim of this figure is to show that the same signal attenuation 
with depth is produced whether imaging epithelium to endothelium, 
or upside down (endothelium to epithelium). 
The blue plot shows the TPF signal achieved imaging coronally 
through a fully soaked epithelial-debrided whole globe. The signal is 
seen to decrease with increasing depth through the stroma. 
The corneoscleral button was then excised from this globe and 
draped over a scleral contact lens (endothelium down) to maintain 
relative corneal curvature (with a coverslip on top) before repeating 
the TPF z-stack. The same decrease in signal (red plot) is 
produced, although at a lower signal amplitude, attributable to 
increased light scatter when the corneal tissue architecture is 
distorted, despite trying to minimize this with a contact lens support. 
The button was then re-laid endothelium facing up (green plot). 
Note that the slope does not reverse when the same corneal 
specimen is reimaged endothelium face-up. This is further evidence 
that the drop in TPF signal level with increasing tissue depth on z-
stack images of a uniformly soaked specimen is attributable to 
signal attenuation rather than any variation in riboflavin 
concentration. The further small drop in signal amplitude when the 
same specimen is reverse mounted (difference between red and 
green plots) is attributed to the same tissue distortion effects, also 
causing bunching of the tissue such that the thickness appeared to 
increase as compared to imaging the globe intact.  
Note that the Y-axis TPF uses an arbitrary unit (a.u.) meaning that 
this particular plot should not be compared for absolute signal 
amplitude with other plots. 
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3.4.2 Time and dose-dependent corrected corneal riboflavin 
concentrations (epithelium-off) 
In epithelial-debrided samples, after correcting for this signal attenuation, I 
observed that TPF signals increased with longer riboflavin soak duration, with 
the mean (± SD) maximum tissue concentration recorded at 0.094 (±0.001) % 
w/v [1.36 mg/ml] (Figure 3.9, Figure 3.10). Uniform riboflavin absorption 
across the entire corneal depth was achieved after a minimum 50 minutes 
(range 50–55 minutes). Following a 30 minute soak, as used in the standard 
epithelium-off CXL protocol, a mean stromal concentration of 0.086 (±0.001)% 
w/v [1.25 mg/ml] was achieved at a depth of 300 µm. Half this concentration 
(0.043 [±0.014]% w/v, 0.62 mg/ml) was observed within the first 5 minutes. 
Without correcting for attenuation, the concentration after 30 minutes at 300 
µm was calculated at 0.06%. 
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Figure 3.9 Riboflavin concentration with depth (epithelium-off) 
Mean riboflavin concentrations, corrected for TPF signal 
attenuation, in epithelial debrided samples, presented over a 500 
µm depth corresponding to the approximate thickness of a human 
cornea after epithelial removal (n = 4, standard deviation error 
bars). The shaded box highlights the demarcation zone between 
250 and 350 lm commonly seen after epithelium-off corneal cross-
linking in human corneas. 
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Figure 3.10 Depth-specific changes in riboflavin concentration with 
time 
Mean changes in corneal riboflavin concentration in epithelial-
debrided samples, corrected for TPF signal attenuation, at different 
depths (n = 4, alternate plot standard deviation error bars). 
 
3.4.3 TPF signal attenuation through an intact epithelium 
Replicating the above protocol through an intact epithelium I observed 
significant, and variable TPF signal attenuation from the epithelium itself. 
Figure 3.11 shows TPF signals achieved when imaging through a reservoir of 
riboflavin above the globe, mimicking my original set-up. TPF signals within 
the cornea can be seen to rise with increasing time, along with a drop in 
signal within the reservoir as the dye moves from the reservoir into the 
cornea. However, the peak tissue signal even after soaking for 2 hours was 
approximately one-tenth of that in the reservoir. Removing the epithelium from 
the same globe and immediately reimaging the underling stroma yielded an 
almost 4-fold increase in TPF signal (Figure 3.11, epithelium-off plot). This 
epithelial-masking effect was observed in all imaged eyes. There was no 
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consistent ratio between the signal achieved before or after epithelial removal, 
nor within the same eye when imaging through varying epithelial thickness at 
different locations on the test corneas.  
 
Figure 3.11 TPF signal attenuation through an intact epithelium 
Two-photon fluorescence (TPF) signal of ParaCel riboflavin solution 
(Avedro Inc., Waltham, MA, USA) imaged through an intact rabbit 
epithelium. Insert magnifies the transepithelial signals at the back of 
the cornea revealing a peak at 60 minutes (chevron), before 
dropping by 120 minutes. Rising TPF signal within the anterior 
chamber (arrow) confirms the presence of a third compartment for 
riboflavin. AC, anterior chamber. NB. Absolute TPF signal varies 
depending on laser power and detector gain settings, explaining the 
differences between Y-axis scale above compared with figures 2.6 
& 2.8). 
 
Figure 3.11 above also shows that the signal within the epithelium itself was 
consistently near-zero. This can also be seen graphically looking at an 
individual stack (Figure 3.12 below) passing obliquely through this layer.  
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Figure 3.12 Single stack 
TPF image 
(transepithelial) 
Stack oriented obliquely 
passing from the 
hyperfluorescent pre-
corneal reservoir (orange, 
high signal), through the 
cellular epithelium (green, 
no signal) to the 
hypofluorescent anterior 
stroma (black, low signal). 
[In the Leica imaging 
software the saturation 
spectrum runs from green 
(zero fluorescence) to 
black to orange to red]. 
This image shows that the 
TPF signal within the epithelium itself was near-zero. passing obliquely 
through this layer. This apparent epithelial hypofluorescence proved to be 
false – the methodology I describe in chapter 3 imaging sagittal corneal 
sections confirms that the concentration of riboflavin within the epithelium at 
least equals that that within the underling stroma.  
 
I was additionally unable achieve a steady signal at the back of the cornea. In 
Figure 3.11 above (insert), the posterior corneal signal can be see to peak at 
approximately 60 minutes, before dropping at 120 minutes. Soaking for these 
extended durations resulted in an approximate 10% drop in reservoir signal, 
as well as riboflavin moving intraocularly, with a rising TPF signal detected 
within the anterior chamber, confirming the presence of a third compartment 
for riboflavin. Despite soaking for more than 3 hours I was unable to equalise 
the riboflavin concentration within the cornea to that of the reservoir. 
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3.5 Discussion 
I have shown that riboflavin TPF signal is attenuated with increasing depth in 
corneal tissue and demonstrated a correction method designed to increase 
measurement accuracy for epithelium-off ex vivo comparisons of riboflavin 
absorption for different soak protocols.  
 
There are a number of potential causes of increased TPF signal attenuation 
with depth, including absorption and scattering of both excitation and emission 
radiation and aberration of the excitation beam focus. Fluorescence photons 
emitted at wavelengths corresponding to the overlap between the absorption 
and emission spectra (Figure 3.3) can be reabsorbed.  This ‘inner-filter’ effect 
is more pronounced the higher the concentration of fluorescence photons in 
the sample. As such, when fluorescence microscopy is used to determine 
fluorophore concentration, fluorescence intensity will only be proportional to 
the concentration at less concentrated solutions. I initially observed this effect 
at the highest (0.1%) riboflavin concentration, with an increasingly attenuated 
signal when imaging through calibration drops on a well slide. By shifting the 
microscope detector range beyond the riboflavin absorption spectrum (>525 
nm), I minimized this phenomenon, obtaining near-flat TPF signals with 
increasing depth through the drop (Figure 3.5B).  
 
Previous studies using TPF microscopy to quantify corneal riboflavin 
absorption ignore the inner-filter effect. Cui et al measured both fluorescein 
and riboflavin absorption in feline corneas, and while the effects of 
reabsorption of the fluorescence emitted from fluorescein were mitigated by a 
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bandpass filter of appropriate wavelength, no such detection filter was used 
for the riboflavin measurements.(Cui et al. 2011) By way of a signal 
attenuation correction factor, Kampik et al. used the intensity loss in collagen 
fiber second-harmonic generation (SHG) signals taken simultaneously during 
the same z-scan.(Kampik et al. 2010) However, the SHG detector wavelength 
channel used (420-460 nm), and to a lesser extent that used for riboflavin 
(505-555 nm), overlap with the absorption spectrum of riboflavin (300-525 nm, 
Figure 3.3). This would be expected to cause significant re-absorption of the 
emitting SHG light, compromising its use as a reference to correct TPF signal 
attenuation.  
 
My calibration method is based on 2 assumptions: firstly, that the 
concentration within the riboflavin reservoir above the cornea remains 
constant throughout the entire soak; and secondly, that in a fully soaked 
cornea the riboflavin concentration within the cornea equals that of the 
reservoir. For epithelium-on samples, the utility of this two-compartment 
model was fatally undermined by the failure to achieve a fully soaked cornea. 
Even when imaging epithelium-off, neither of these two assumptions may be 
strictly correct. Figure 3.6B reveals that the TPF signal within the reservoir 
does decrease with time, albeit by only a few per cent. With a finite (small) 
volume, the reservoir is potentially susceptible to photobleaching. I 
investigated this by repeating the above z-stack protocol through the same 
custom chamber reservoir of riboflavin placed on a slide (i.e. no cornea). Over 
50 minutes I observed near-identical TPF signal plots over a depth of 
1200 µm, with no evidence of photobleaching. I have additionally investigated 
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the possibility of photobleaching within the corneal tissue, by performing a 
final z-stack at the end of the full 60 minute protocol in a new adjacent axial 
location (i.e. un-irradiated tissue). I observed near identical TPF signal plots 
over a depth of 800 μm, with no evidence of photobleaching. As graphically 
demonstrated in Figure 3.2, fluorescence excitation restricted to the focal 
plane is a key advantage of multi-photon microscopy, explaining the lack of 
photobleaching demonstrated. An alternative explanation could be that the 
reduction in TPF signal with time is due to loss of fluorescent riboflavin 
molecules as they diffuse into the cornea. However, as illustrated in Figure 
3.6B, this decrease over 50 minutes was small, with a mean of 2.5 (±1.1)% for 
all imaged eyes. For future work, this small effect could be reduced by 
increasing the volume of the reservoir. The assumption that the concentration 
in a fully soaked cornea is the same as that in the reservoir also appears to be 
not quite correct. I consistently observed a step-like decrease in TPF signal as 
the imaged plane transitioned from the fluid-filled reservoir into the cornea 
(Figure 3.6B), measured to be 6.1 (± 1.6)% after 50 minutes soak. This small 
loss of signal may result from optical aberrations encountered as the laser 
light crosses the curved surface of the cornea or it may reflect a true 
difference in concentration between the reservoir and the fully soaked cornea.  
 
The percentage transmission of light of wavelengths between 600 nm and 
1000 nm has been previously measured in early post-mortem eyes between 
95% and 98%.(Beems & Van Best 1990) Scattering of light may still occur in 
an otherwise healthy optical system, becoming more prevalent in disease (for 
example cataract, corneal oedema or corneal scarring). Oedema is likely to 
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be particularly relevant in the porcine corneas used in this current study 
which, although optically clear to the naked eye, were regularly over 800 µm 
in central corneal thickness (pre-riboflavin soak), compared with published in 
vivo measurements of 666 ± 68 µm.(Hatami-Marbini et al. 2013) This is 
presumed to be due to early endothelial failure within the first 24 hours after 
harvest and is a limitation of this animal model. I did not attempt to deturgesce 
the porcine corneas with a dextran solution (as is used clinically prior to 
transplantation) due to the infrared absorption properties of dextran (see 
below paragraph for further discussion of dextran). 
 
There is a lack of consensus regarding the exact nature and location of CXL-
induced collagen cross-links.(Hayes et al. 2013; Wollensak et al. 2004) Two-
photon microscopy of corneal collagen has been used in an in vivo rabbit 
model to quantify corneal collagen cross-links after treatment.(Krüger et al. 
2011) In this study, the investigators identified a well-demarcated change in 
both autofluorescence and SHG signal down to a depth of 250 µm. This 
correlates well with a demarcation line visible by optical coherence 
tomography (OCT) in human patients, typically around 250 – 300 µm after 
epithelium-off CXL.(Seiler & Hafezi 2006; Doors et al. 2009) At this depth 
(300µm), following a standard 30 minute soak, I measured a mean stromal 
concentration of 0.086%. It is, however, not possible to make any absolute 
correlation between the concentrations reported in this study (using an 
HPMC-based riboflavin preparation) and demarcation line tissue changes 
observed in vivo on OCT (using a dextran-based riboflavin preparation). I 
attempted to apply this methodology to determine concentration depth profiles 
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using 0.1% riboflavin in 20% dextran (500 kDa) as used in the original CXL 
study,(Wollensak, Spoerl, et al. 2003a) in both well-slide and soaked corneas, 
but was unable to achieve any consistent TPF signals. Dextran has previously 
been shown to strongly absorb near-infrared light (Xu et al. 2003) and 
absorption of the TPF excitation beam may have been raising the temperature 
of dextran and affecting its optical properties. This is likely to have been the 
cause of variations in the TPF signal levels I measured. TPF microscopy may 
therefore not be suitable to investigate corneal riboflavin absorption for 
dextran-based preparations, although these are increasingly being replaced 
by HPMC-based preparations.   
 
Replicating this whole-globe imaging technique through an intact epithelium 
was not successful. Besides the variable signal-attenuating effect of the 
epithelium itself, the principle problem I could not resolve was the failure to 
achieve a full stromal riboflavin soak through the epithelium, thereby breaking 
a principle assumption of my calibration method, that in a fully soaked cornea 
the riboflavin concentration within the cornea equals that of the reservoir. I 
was also unable to achieve a steady state signal at the back of the cornea 
which I interprete as being due to riboflavin migration from the stroma into the 
anterior chamber over such extended soak durations. Lastly, I was unable to 
explain the apparent epithelial hypofluorescence which proved to be false – 
the methodology I describe in chapter 3 imaging sagittal corneal sections 
confirms that the concentration of riboflavin within the epithelium at least 
equals that that within the underling stroma.  
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In conclusion, this work describes a method for accurately measuring stromal 
riboflavin absorption in an ex vivo epithelium-off whole-globe animal model. I 
present evidence that TPF microscopy of corneas is affected by significant 
signal attenuation when imaging at depth. To account for this, I have 
presented a new time-lapse measurement approach carried out during the 
riboflavin soak in which each cornea acts as its own internal reference. I 
additionally conclude that while suitable for epithelium-off imaging, this whole-
globe technique is unsuitable when imaging through an intact corneal 
epithelium. In the next chapter I describe an alternative method to resolve this 
issue by imaging cross-sections of corneal tissue. 
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4 Shape stabilisation – quantifying transepithelial 
riboflavin absorption  
4.1 Introduction 
Riboflavin is a key ingredient in the UV-driven photochemical CXL 
process.(McCall et al. 2010) Whilst riboflavin is hydrophilic with a molecular 
weight of 340 Dalton (Da), the corneal epithelium is lipophilic and has a 
reduced permeability to molecules larger than 180 Da.(Huang et al. 1989; 
Spoerl et al. 1998) Thus standard CXL requires debridement of the central 
epithelium to facilitate stromal riboflavin absorption and achieve adequate 
efficacy.(Spoerl et al. 1998) Epithelial debridement, however, is associated 
with post-operative pain, delayed visual recovery and increases the risks of 
infection, corneal melt and scarring.(Koller et al. 2009) As a result, CXL is 
normally reserved for patients with documented disease progression. 
 
Transepithelial (epithelium-on) CXL aims to avoid the pain, delayed recovery 
and complications of epithelial removal inherent in epithelium-off CXL. A 
number of formulations of riboflavin designed to facilitate absorption across an 
intact corneal epithelium are currently available.(Filippello et al. 2012; Magli et 
al. 2013; Leccisotti & Islam 2010; Caporossi et al. 2013; Koppen et al. 2012b; 
Soeters et al. 2015; Kocak et al. 2014) Most contain toxic agents to increase 
epithelial permeability, including benzalkonium chloride (BAC), high 
concentration sodium chloride, sodium ethylenediaminetetraacetic acid 
(EDTA) or trometamol.(Filippello et al. 2012; Magli et al. 2013) A non-toxic 
reversible synthetic nonselective ion channel-forming peptide, NC-1059, has 
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also been shown in a chick corneal model to enhance riboflavin permeability 
across an intact epithelium.(Zhang et al. 2012) Despite these permeability 
enhancers, results in clinical studies with current commercial transepithelial 
riboflavin preparations have been equivocal: some studies report similar 
efficacy to epithelium-off CXL, but most report inferior results.(Leccisotti & 
Islam 2010; Caporossi et al. 2013; Koppen et al. 2012b; Soeters et al. 2015; 
Kocak et al. 2014) Iontophoresis, in which an electrical gradient is used to 
drive negatively-charged riboflavin molecules across the intact epithelium, 
may further enhance riboflavin absorption in transepithelial CXL.  
 
Previous studies to quantify riboflavin penetration through an intact epithelium 
have used high-performance liquid chromatography (HPLC)(Baiocchi et al. 
2009; Ostacolo et al. 2013; Cassagne et al. 2014) and fluorescence 
microscopy.(Zhang et al. 2012; Gore et al. 2014; Cui et al. 2011; Kampik et al. 
2010; Søndergaard et al. 2010) HPLC, in which the sample is dissolved in a 
solvent for analysis, can accurately quantify the concentration of riboflavin in a 
whole block of tissue, but is unable to provide information about the 
concentration at different depths within the corneal stroma (unless lamella 
sections are prepared and separately dissolved).(Mastropasqua et al. 2014) 
Fluorescence microscopy, both single-photon excitation (i.e. confocal) and 
multi-photon excitation(Gore et al. 2014; Zhang et al. 2012; Cui et al. 2011; 
Kampik et al. 2010; Søndergaard et al. 2010) has the added advantage of 
quantifying concentration at depth within the cornea; both excitation 
techniques, however, suffer from signal attenuation with increasing scan 
depth, principally attributable to scattering and aberration.(Gore et al. 2014; 
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Cui et al. 2011; Kampik et al. 2010) In chapter 2 I described a novel time-
lapse measurement approach to correct for two-photon fluorescence (TPF) 
signal attenuation;(Gore et al. 2014) although applicable to epithelium-off 
absorption, this method has not proven suitable when imaging through an 
intact epithelium.(Gore et al. 2015) 
 
 
In this chapter I describe an alternative method for quantifying riboflavin 
penetration in an epithelium-on ex vivo animal model and compare the 
efficacy of different transepithelial protocols with standard epithelium-off 
absorption. 
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4.2 Materials and methods 
Ethical approval for corneal two-photon fluorescent microscopy studies in an 
ex vivo model was granted by University College London Institute of 
Ophthalmology (ref. 10/H0106/57-2012ETR27). 
 
4.2.1 Sample preparation 
Adult pigmented rabbit heads transported on ice in a phosphate buffered 
saline (PBS) bath were received within 5 hours post-mortem (First Link Ltd., 
Wolverhampton, UK). Intact globes were enucleated and examined under a 
low-magnification light microscope to rule out obvious epithelial trauma or 
scars. The globes were warmed to room temperature in balanced salt solution 
before different commercially-available riboflavin solutions (Table 4.1) were 
applied to the corneas of intact globes according to the manufacturers’ 
protocols (Protocols tested, section 4.2.3).  
 
4.2.2 NC-1059 solution preparation 
NC-1059 is a synthetic non-selective ion channel-forming peptide. A 200 µM 
NC-1059 peptide solution (amino acid sequence KKKK-
AARVGLGITTVLVTTIGLGVRAA; LifeTein LLC, New Jersey, USA) was 
prepared by dissolving it in either 0.25 % or 0.1 % w/v riboflavin 5’-
monophosphate solution (Ricrolin +, Table 4.1) 
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Figure 4.1 Mass spectrometry report of NC-1059 peptide 
Analysis and report provided by manufacturer, LifeTein LLC, 
Hillsborough, New Jersey, USA 
 
 
Figure 4.2 High performance liquid chromatography (HPLC report 
for NC-1059 peptide 
Purity 95.95%. Analysis and report provided by manufacturer,  
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Table 4.1 Commercially prepared riboflavin solutions 
Formulation Manufacturer Composition 
Vibex Rapid Avedro, Inc., MA, USA 0.1% wt/vol riboflavin 5’-monophosphate, saline, HPMC 
Ribocross TE 
 
IROS Srl, Napoli, Italy 0.125% wt/vol riboflavin 5’-monophosphate,     
D-alpha-tocopheryl poly(ethylene glycol) 1000 succinate 
Medio-Cross TE  
 
Peschke Meditrade GmbH, Germany 0.25% wt/vol riboflavin 5’-monophosphate, HPMC, benzalkonium 
chloride 0.01% 
Ricrolin + 0.1% 
 
Sooft Italia S.p.A. Montegiorgio, Italy 0.1% wt/vol riboflavin 5’-monophosphate, sodium edetate, 
trometamol, sodium dihydrogen phosphate dihydrate, sodium 
phosphate dibasic dehydrate 
Ricrolin + 0.25% 
 
Sooft Italia S.p.A. Montegiorgio, Italy 0.25% wt/vol riboflavin 5’-monophosphate, sodium edetate, 
trometamol, sodium dihydrogen phosphate dihydrate, sodium 
phosphate dibasic dehydrate 
ParaCel  
 
Avedro, Inc., MA, USA 0.25% wt/vol riboflavin 5’-monophosphate, HPMC, sodium edetate, 
trometamol, benzalkonium chloride, saline 
VibeX Xtra  Avedro, Inc., MA, USA 0.25% wt/vol riboflavin 5’-monophosphate, saline  
All the above solutions (except Vibex Rapid) are designed for transepithelial use. HPMC, hydroxypropyl methylcellulose 
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4.2.3 Protocols tested 
Positive controls were prepared using a 9 mm vacuum well secured to 
epithelial-debrided corneas of whole globes filled with 0.1 % w/v riboflavin in 
HPMC and saline (Vibex Rapid) for 30 minutes (n = 5). Unsoaked globes (i.e. 
no riboflavin) served as negative controls (n = 5). 
 
4.2.3.1 Non-iontophoresis protocols 
1. Medio-Cross TE 
A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of Medio-Cross TE solution for 30 minutes. Riboflavin was not rinsed from 
the cornea (n = 5). 
 
2. Ribocross TE  
A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of Ribocross TE solution for 30 minutes. Riboflavin was not rinsed from the 
cornea (n = 5). 
 
3. ParaCel and VibeX Xtra   
ParaCel drops were applied at a rate of 1 drop every 90 seconds for 4 
minutes. The cornea was then rinsed with VibeX Xtra completely coating the 
cornea. Additional VibeX Xtra was applied at a rate of 1 drop every 90 
seconds for 6 minutes (total riboflavin soak time 10 minutes). Riboflavin was 
not rinsed from the cornea (n = 5). 
 
4. 200 µM NC-1059 peptide in 0.1 % w/v Ricrolin + 
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A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of 200 µM NC-1059 peptide in 0.1 % w/v Ricrolin + solution for 30 minutes. 
Riboflavin was rinsed from the cornea with PBS for 1 minute (n = 3). 
 
5. 200 µM NC-1059 peptide in 0.25 % w/v Ricrolin + 
A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of 200 µM NC-1059 peptide in 0.1 % w/v Ricrolin + solution for 30 minutes. 
Riboflavin was rinsed from the cornea with PBS for 1 minute (n = 3). 
 
4.2.3.2 Iontophoresis protocol 
The iontophoresis system comprised 2 electrodes: a negatively-charged metal 
grid housed within the corneal applicator and a positively-charged 20G needle 
inserted through the sclera into the vitreous (Figure 4.3A). The corneal 
applicator was vacuum-attached to the cornea. The reservoir was filled with 
differing riboflavin formulations to above the level of the metal grid before 
beginning the iontophoresis treatment. Protocols varied either by 
iontophoresis dosage, soak time or riboflavin formulation (n = 4, Table 4.2). 
After the iontophoretic procedure, the applicator was removed and the 
corneas were rinsed with PBS to both remove any riboflavin on the corneal 
surface and to try to reduce riboflavin concentration within the epithelium.  
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Table 4.2 iontophoresis protocols 
Protoco Solution Curre Soak I Current Soak Rinse 
Negative 
control 
None None - - - - 
Positive 
Control 
Vibex Rapid None 30 min - - - 
A MedioCross TE 1mA  
5 min 
 
5 min 
 
0.5 mA  
5  min 
5 min 
 
5 min * 
B MedioCross TE 1mA  
5 min 
 
15 min 
 
- - 1 min 
C Ricrolin+ 0.25% 1mA  
5 min 
5 min 
 
0.5 mA  
5 min 
5 min 
 
5 min * 
 
D Ricrolin+ 0.25% 1mA  
10 min 
 
- - - 
5 min 
 
E MedioCross TE 1mA  
5 min 
 
- - - 
1 min 
 
F Ricrolin + 0.1% 1mA  
5 min 
 
- - - 
1 min 
 
G Vibex Rapid 1mA  
5 min 
 
- - - 1 min 
H Vibex Rapid 1mA  
5 min 
5 min 
 
0.5 mA  
5 min 
5 min 
 
5 min 
 
Min, minute;  * St. Thomas’/Cardiff Iontophoresis protocol (unpublished) 
 
 
Figure 4.3 Sample preparation and image acquisition 
(A) Iontophoresis schematic showing a riboflavin-filled corneal well 
housing a negative electrode with the return electrode connected to a 
needle passed into the vitreous cavity. The riboflavin solution acts as an 
electrical contact between the electrode and the eye. The generator 
self-checks the continuity and a warning signal sounded in case of 
current disruption. (B) Slide mounted 35µm tissue sections were 
covered in immersion oil with a coverslip placed on top and coupled to 
the microscope objective with distilled water.  
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4.2.4 Section preparation 
At the end of the riboflavin soak, the globes were immediately immersed in 
liquid nitrogen for 5 minutes and stored overnight at -25 degrees Celsius. A 
broad incision across the posterior globe was made just before immersion to 
prevent the cornea from splitting open on freezing. For each globe, three 
35 µm corneal cross-sections were cut on a cryostat 1 mm apart (Figure 4.5). 
With the frozen section on the blade platform (maintained at -21°C), a knife 
was used to cut the cornea free and the remaining tissue was brushed away. 
The cornea itself was meticulously brushed to ensure no ice remained 
attached that might allow riboflavin to leak out once thawed (transparent 
images of processed sections during the development of the methodology 
confirmed the epithelium itself was not removed by this brushing; see Figure 
4.4 below). Colour photographs were taken of the sagittally-exposed globe 
and free corneal section. 
 
 
Figure 4.4 Epithelial detail in corneal section 
Transparent image confirming epithelial integrity in processed rabbit 
corneal section. Columnar basal epithelial and flatter superficial 
structures visible  
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The corneal section was then mounted on a slide and covered with 
fluorescence-free immersion oil (Immersol 518 F, Carl Zeiss Ltd.) to prevent 
any leakage of riboflavin out of the tissue. No dye leakage was observed over 
several minutes during protocol development using immersion oil. This 
compared with prompt dye leakage when either water-based optimal cutting 
temperature (OCT) compound or water itself was used as an immersion 
medium. A coverslip was placed on top prior to imaging under the microscope 
objective (Figure 4.3B). The time taken from the tissue thawing onto the slide 
to image acquisition on the microscope was approximately 1 minute, and I 
refer to this earliest imaging time point as t = 0 minutes. To investigate 
riboflavin migration within the thawed slide-mounted tissue, serial images 
were captured every minute for selected samples. For all other 
measurements, data was acquired as soon as possible following tissue 
thawing, i.e. after approximately 1 minute. 
 
4.2.5 Two-photon microscope set-up and imaging protocol 
The two-photon microscope set-up is based on that described in chapter 2. A 
Ti:Sapphire laser, operating at a wavelength of 890 nm with a 140 
femtosecond pulse duration and 80 MHz pulse repetition rate,  was used as 
the excitation laser source. The excitation laser beam was guided to a Leica 
DM6000CS upright microscope where it passes through two galvoscanners, 
allowing scanning in the x-y plane, before being focused into the sample by a 
Leica 10 X /0.3 NA water immersion objective. Theoretical (full-width half-
maximum) axial and lateral resolutions were calculated at 16 µm and 1.1 µm 
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respectively. TPF excitation light of 890 nm wavelength was chosen to 
correspond with the highest riboflavin absorption peak (445 nm) as 
determined by spectrophotometry. Emitted riboflavin fluorescence was 
collected between 525 nm and 650 nm to avoid overlap with the absorption 
spectrum of riboflavin. 553 µm x 553 µm (512 x 512 pixel) images were 
captured at a scan rate of 600Hz (line average 16) with the pinhole wide 
open. 
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Figure 4.5 Tissue sectioning 
Section preparation. (A) Globe adhered onto specimen stage (with 
optimal cutting temperature (OCT) compound) and secured within 
cryostat chuck. Yellow cornea visible with white crystalline lens 
marked with ’96.’ Note disrupted posterior segment from relieving 
incision made prior to immersion in liquid nitrogen to prevent 
anterior globe splitting (white arrow). (B) 35 µm whole-globe section 
laid on blade platform. (C) Lens and aqueous brushed away leaving 
sclero-corneal shell (arrow-head) and iris (arrows). (D) Blade used 
to cut cornea out before meticulously brushing away attached ice on 
the back. Note slight corneal crimp from suction well (*). The 
surface riboflavin film - measured by Wollensak et al.(Wollensak et 
al. 2010) at up to 300 µm in cellulose-containing formulations - was 
also brushed away (Ribocross TE film was particularly adherent to 
the epithelium and was still present on imaging (Figure 4.9) despite 
attempts to remove it). 
 
4.2.6 Image analysis 
Grey scale images (Figure 4.6A) were exported and analysed using Java-
based imaging software (ImageJ, 1.48v, http:// imagej.nih.gov.ij; provided in 
the public domain by the National Institutes of Health, Bethesda, MD, USA). 
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For each image, three separate rectangular regions of interest each 40 pixels 
wide in the x-direction were manually selected.  The intensity profiles along 
the z-direction for each region of interest were then exported to a .txt file 
(Excel for Mac, 2011; Microsoft Corp, Redmond, WA, USA) (Figure 4.6B). 
The epithelial/stromal junction was then identified in each trace by the abrupt 
change in signal and confirmed with reference to the corresponding image 
region of interest. This information was then used to align all three plots along 
the z-axis and a mean intensity plot was then generated representing the 
average TPF signal for that image as a function of depth (z). TPF signals 
were converted to riboflavin concentration by normalizing to the TPF signal 
achieved in a well-slide reservoir of 0.1 % riboflavin solution during the same 
experimental session. Mean (SD) concentrations were calculated from 5 
globes tested for each protocol. Unpaired Student t-tests were used to 
compare riboflavin concentrations achieved at a depth of 300 µm. A p value 
less than 0.05 was considered significant. Analyses were performed in Excel 
for Mac, 2011; Microsoft Corp, Redmond, WA, USA).  
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Figure 4.6 Image analysis 
(A) Grey scale two-photon fluorescence image were exported and  
analysed in ImageJ. For each image, three regions of interest (blue 
rectangles) each 40 pixels wide in the x-direction, were manually 
selected. The intensity profiles along the z-direction for each region 
of interest were then exported to a .txt file. The epithelial/stromal 
junction was then identified in each trace by the abrupt change in 
signal and confirmed with reference to the corresponding image 
region of interest. This information was then used to align all three 
plots along the z-axis and a mean intensity plot (B) was then 
generated representing the average TPF signal for that image as a 
function of depth (z). The edges of the images were not analysed to 
avoid areas of vignetting (grey scale image formatted to increase 
brightness and clarity 
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4.3 Results 
4.3.1 Riboflavin migration within thawed tissue 
Serial images were captured at time = 0, 1 and 2 minutes (t = 0 being the first 
scan approximately 1 minute after the tissue had thawed on the slide). Figure 
4.7 confirms fluorophore migration within the sample, redistributing posteriorly 
with time including from the epithelium into the underlying stroma. Measured 
at the beginning of the stroma, this drop in signal is approximately 7 % within 
the first minute. Therefore, all subsequent data was acquired as soon as 
possible following thawing, i.e. after approximately 1 minute. 
 
4.3.2 Depth-specific corneal riboflavin absorption for commercially 
available protocols 
No fluorescence was detected by TPF microscopy in the negative (untreated) 
controls. The maximum riboflavin concentration in positive controls 
(epithelium-off) was 0.09 % (± 0.01). Maximum stromal riboflavin 
concentrations for MedioCross TE, Ricrolin +, Paracel/Xtra and Ribocross TE 
were: 0.054 % (± 0.01), 0.031 % (0.003), 0.021 % (± 0.001) and 0.015 % (± 
0.004) respectively. Depth-specific riboflavin concentrations are displayed in 
Figure 4.9 and Figure 4.10. Stromal absorption of riboflavin by iontophoresis 
was not homogenous, with areas of relative hypo- and hyper fluorescence 
within each section. In all samples, the epithelial concentration was higher 
than that in the underlying stroma. A film of higher signal riboflavin adherent to 
the epithelium was detected in samples treated with Ribocross TE.  
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Figure 4.7 Riboflavin migration within thawed tissue 
Fluorophore migration within the corneal section investigated with 
serial images of the same tissue location at time = 1, 2 and 3 
minutes (A-C). Dark circles are air bubbles within the oil overlying 
the tissue. All images have been formatted to increase brightness 
by the same amount to improve view. (D) Corresponding TPF signal 
across samples. Note the loss of the epithelial peak as riboflavin 
moves into the stroma. 
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Figure 4.8 Colour photographs of corneas soaked with 
commercially-available protocols 
Colour photographic globe and section examples from each group 
tested allowing macroscopic comparative view of riboflavin 
penetration through the cornea into the anterior chamber. Upper 
row: Sagittal sections of treated globes mounted on a cryostat 
during section preparation. Lower row: 35 μm corneal sections 
prepared and laid on white paper for photographic contrast (visible 
shadows indicate section lifting off paper). (A) negative control; (B) 
positive control (epithelium-off) 0.1% riboflavin 30 minutes; (C) 
Ribocross TE 0.125% 30 minutes; (D) MedioCross TE 0.25% 30 
minutes; (E) ParaCel 0.25% 4 minutes, VibeX Xtra 0.25% 6 
minutes; (F) Ricrolin + 0.1% 1 mA 5 minutes iontophoresis. 
 
 
 At a depth of 300 µm (within the demarcation zone commonly seen after 
corneal cross-linking), the stromal concentration in epithelium-off positive 
controls was 0.075 % (± 0.006), while at the same depth MedioCross TE  
and Ricrolin + achieved 0.018 % (± 0.006) and 0.016 % (0.002) respectively 
(Figure 4.10). None of the remaining transepithelial protocols achieved 
concentrations above 0.005% at this same 300 µm depth. 
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Figure 4.9 TPF images for commercially-available protocols 
Two-photon fluorescence images of tissue sections (grey scale). (A) 
negative control (B) positive control (epithelium-off) 0.1% riboflavin 
30 minutes; (C) Ribocross TE 0.125% 30 minutes; (D) MedioCross 
TE 0.25% 30 minutes; (E) ParaCel 0.25% 4 minutes, VibeX Xtra 
0.25% 6 minutes; (F) Ricrolin + 0.1% 1 mA 5 minutes iontophoresis. 
e, epithelium; DM Descemet’s membrane; †, Ribocross TE 
‘riboflavin film’ on top of epithelium. All images have been formatted 
to increase brightness by the same amount to improve view. DM 
scroll artifact visible in some preparations. 
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Figure 4.10 Depth-specific riboflavin concentrations for 
commercially-available protocols 
Mean concentrations (standard deviation error bars) of riboflavin 
achieved using different transepithelial protocols, compared with 
epithelium-off absorption. Shaded area denotes epithelium. 
 
4.3.3 Depth-specific corneal riboflavin absorption for NC-1059 peptide 
The maximum riboflavin concentration in positive controls (epithelium-off; 0.1 
% w/v riboflavin, Vibex Rapid) was 0.09 % (± 0.01). The maximum stromal 
riboflavin concentration for 200 µM NC-1059 peptide solution in 0.25 % w/v 
Ricrolin + was 0.043 (± 0.01) % w/v riboflavin. The maximum stromal 
riboflavin concentration for 200 µM NC-1059 peptide solution in 0.1 % w/v 
Ricrolin + was 0.015 (± 0.003) % w/v riboflavin. Macroscopic globe sections 
(Figure 4.11), TPF images (Figure 4.12) and depth-specific riboflavin 
concentrations (Figure 4.13) are displayed below.  
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Figure 4.11 Colour 
photographs of 
corneas soaked 
with NC-1059 
peptide and 
riboflavin  
Macroscopic view of 
riboflavin absorption 
through the cornea 
into the anterior 
chamber. Upper row: 
Sagittal sections of 
globes mounted on a 
cryostat during 
section preparation. 
Lower row: 35 μm 
corneal sections laid 
on paper 
 
 
 
 
 
 
 
Figure 4.12 TPF images for NC-
1059 peptide  
Two-photon fluorescence images of 
tissue sections (grey scale). The 
right-hand image (0.1% Ricrolin +) 
shows very low levels of 
fluorescence, but is not zero (just 
over 0.01% w/v). The corresponding 
colour photograph in Figure 4.11 is 
not intended to be quantitative due 
to differences in background lighting 
and contrast (note colour of 
background paper also differs) 
e, epithelium. Note Descemet’s 
membrane scroll processing artifact. 
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Figure 4.13 Depth-specific riboflavin concentrations for NC-1059 
assisted riboflavin absorption 
Mean concentrations (standard deviation error bars) comparing 
epithelium off controls (0.1% w/v riboflavin) with 200 µM NC-1059 
peptide dissolved in two concentrations of Ricrolin +.  Shaded area 
denotes epithelium. Note the near-uniform concentration with depth 
which is presumed a result of the long soak duration (30 minutes) 
allowing the riboflavin to near-evenly distribute across the stroma. 
 
4.3.4 Depth-specific corneal riboflavin absorption for modified 
iontophoresis protocols 
Higher concentrations were achieved with longer iontophoretic dosage and 
longer solution contact (diffusion) time with the cornea (Figure 4.14, Figure 
4.15, Figure 4.16; Table 4.3). The best protocol (A), utilizing 0.25 % w/v 
riboflavin with BAC and two separate iontophoretic treatments followed by 
soak periods of 5 minutes to allow diffusion of riboflavin from the sub-epithelial 
tissues deeper into the stroma (the ‘St. Thomas’/Cardiff Iontophoresis 
protocol’, total time 20 minutes), was not significantly different with respect to 
stromal riboflavin concentrations compared with epithelium-off controls (0.089 
[± 0.006] % w/v vs. 0.083 [± 0.013] % w/v at a depth of 300 µm, p = 0.8, Table 
4.3). The best performing protocol (C) not containing BAC but with 0.25 % w/v 
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riboflavin and the same iontophoresis treatments and soak times as protocol 
A, achieved a mean stromal concentration of 0.056 (± 0.011) % w/v at 
300 µm. 
 
 
Near-uniform stromal riboflavin absorption with depth was observed in longer-
duration protocols (A-C), as compared with shorter treatments in which the 
concentration fell by up to 40 % within the anterior 300 µm (protocols D-F). 
Riboflavin solutions containing saline (protocols G, H), resulted in minimal 
stromal absorption (maximum 0.01 %). Of note, corneal thickness was 
observed to increase by approximately 60 µm following these saline-based 
iontophoretic applications (Figure 4.15 & Figure 4.16).  
Figure 4.14 Macroscopic absorption images for modified 
iontophoresis protocols 
Color photographic globe and section examples from each group 
tested allowing macroscopic comparative view of riboflavin 
absorption through the cornea into the anterior chamber. Upper 
row: Sagittal sections of treated globes mounted on a cryostat 
during section preparation. Lower row: 35 μm corneal sections 
prepared and laid on white paper for photographic contrast (visible 
shadows indicate section lifting off paper). A-H protocols as per 
Table 4.2. 
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Table 4.3 Iontophoresis corneal riboflavin concentrations 
Protocol* Riboflavin concentration ± SD % w/v P value1 
 Epithelium Peak stroma 300 µm*  
Control - 0.095 ± 0.002 0.089 ± 0.006 - 
A 0.069 ± 0.008 0.086 ± 0.012 0.083 ± 0.013 0.74 
B 0.046 ± 0.013 0.059 ± 0.011 0.058 ± 0.01 0.007 
C 0.051 ± 0.012 0.06 ± 0.009 0.056 ± 0.011 0.001 
D 0.049 ± 0.005 0.053 ± 0.007 0.038 ± 0.004 < 0.001 
E 0.041 ± 0.003 0.041 ± 0.002 0.025 ± 0.004 < 0.001 
F 0.031 ± 0.006 0.027 ± 0.002 0.017 ± 0.002 < 0.001 
G 0.008 0.011 0.009 < 0.001 
H 0.008 0.01 0.008 < 0.001 
* See Table 4.2, page 105 for protocol details. 1Unpaired Student t-test 
comparing 300µm riboflavin concentration vs. control. 300µm depth chosen to 
correlate with demarcation zone commonly seen after corneal cross-linking. 
 
 
The concentration of riboflavin within the epithelium was equivalent to or 
higher than that in the immediate underlying stroma. Extended rinsing of the 
surface effectively washed away any pre-corneal riboflavin film but did not 
selectively reduce the fluorophore load within the epithelium itself. A 5 minute 
corneal rinse after protocols A and B (MedioCross TE) resulted in a wash-out 
effect of both the epithelium and anterior stroma up to an approximate depth 
of 200 µm.  
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Figure 4.15 Two-photon fluorescence images of tissue sections  
A-H protocols as per Table 4.2. e, epithelium; DM, Descemet’s membrane. All images have been 
formatted to increase brightness by the same amount to improve view. DM scroll artifact visible in 
some preparations. Apparent epithelial damage with BAC-containing protocol A should not be inferred 
as a treatment effect - this TPF methodology was not designed to qualify epithelial structural changes 
and a processing-induced artefact cannot ruled out. 
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Figure 4.16 Depth-specific riboflavin concentrations for iontophoresis protocols 
Mean concentrations (standard deviation error bars) of riboflavin achieved using different transepithelial 
protocols, compared with epithelium-off absorption. Shaded area denotes epithelium. A-H protocols as per Table 
4.2. Note the increased concentrations achieved at 300um with protocols A and C compared to B and D due to 
the second iontophoresis/soak cycle.  
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4.4 Discussion 
These results reveal that, compared with epithelium-off CXL, absorption of 
riboflavin into the corneal stroma is significantly reduced in all non-
iontophoretic transepithelial CXL protocols. I also demonstrate that stromal 
riboflavin absorption in iontophoretic transepithelial CXL can match that 
achieved ‘epithelium-off,’ by increasing solution formulation, soak time and 
iontophoretic dosage 
 
4.4.1 Methodological advantages 
Since most tissue cross-linking is thought to take place in the anterior 
cornea,(Lombardo, Pucci, et al. 2014) determining the availability of key 
photochemical ingredients (riboflavin, UV light, oxygen) at specific depths may 
add useful additional information. The method I describe above provides 
these depth-specific measurements of riboflavin, with the microscope 
objective and image size determining the resolution available. An additional 
advantage of this technique, as compared to whole-tissue analysis (high-
performance liquid chromatography, HPLC;(Baiocchi et al. 2009; Ostacolo et 
al. 2013; Cassagne et al. 2014) spectrophotometry(Samaras et al. 2009; 
Hayes et al. 2008; Alhamad et al. 2012)) is the ability to quantify riboflavin 
concentration within the epithelium which, as my results demonstrate, often 
exceeds that in the underlying stroma.(Gore et al. 2015) In clinical practice, 
the consequences of loading the corneal epithelium with riboflavin in 
transepithelial CXL could include epithelial toxicity and UV light shielding. The 
normal epithelium filters out an average 20% of UVA light radiation passing 
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through the cornea.(Lombardo, Pucci, et al. 2014) This UV light attenuation is 
increased by riboflavin absorption within the epithelium in transepithelial CXL, 
and stromal concentrations of riboflavin are reduced. Enhanced UV 
absorption with free radical generation within the epithelium could result in 
‘arc eye’ type epithelial toxicity. Epithelial defects are commonly observed on 
day 1 after transepithelial CXL using MedioCross TE,(Taneri et al. 2014) and 
punctate epitheliopathy is evident in all cases (personal communication, David 
O’Brart, February 2015). 
 
The inability to measure concentration at specific depths in the epithelium and 
stroma is a significant limitation of HPLC. Furthermore, unless this riboflavin-
rich epithelium is specifically removed prior to dissolving the sample, the 
concentration result will be inappropriately increased. This may have 
contributed to the observations described by Ostacolo et al.(Ostacolo et al. 
2013) in which Ribocross TE was tested using modified Franz-type diffusion 
cells with freshly excised porcine corneas (both with and without epithelium). 
After 40 minutes, riboflavin accumulation through an intact epithelium (0.394 ± 
0.02 nmol/mg) matched that achieved epithelium-off (0.396 ± 0.03 nmol/mg). 
This contrasts with my results in which Ribocross TE performed poorly 
compared to other protocols tested. As demonstrated in Figure 4.15 and 3.16, 
I observed TFP signals within the epithelium to be higher than in the 
underlying stroma in all tested protocols. Furthermore, the pre-corneal film of 
riboflavin solution exhibited even higher fluorescence signal. Dissolving a full-
thickness specimen, including a riboflavin-loaded epithelium and pre-corneal 
film, will lead to overestimation of corneal stromal riboflavin concentrations by 
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HPLC. This may explain why Ostacolo et al.(Ostacolo et al. 2013) recorded 
only a 4-fold reduction in stromal concentration when their control riboflavin 
solution (i.e. no vitamin E) was applied to an intact epithelium, compared with 
epithelium-off application (0.098 ± 0.04 nmol/mg epithelium-on; 0.396 ± 0.03 
nmol/mg epithelium-off). Cassagne et al.(Cassagne et al. 2014) also used 
HPLC in an in vivo rabbit eye study of iontophoresis, testing both the 
dissolved cornea and aqueous sample. Again, the investigators did not 
remove the epithelium prior to analysis. This may, in part, explain the 
discrepancy in their results in which the relative difference in riboflavin 
concentration between treated tissue and controls was much less in the 
cornea, than in aqueous samples (which would not be affected by epithelial 
contamination). 
 
4.4.2 Iontophoresis 
Riboflavin is water soluble and negatively charged at physiological pH, and 
laboratory studies suggest that iontophoresis can be applied effectively to 
enhance riboflavin absorption in transepithelial CXL. Several groups have 
reported similar increases in corneal biomechanics(Cassagne et al. 2014; 
Lombardo, Serrao, et al. 2014; Touboul et al. 2014) in animal models as 
compared with epithelium-off CXL. Preliminary clinical studies have also been 
encouraging, with reported cessation of disease progression with up to 15 
month follow-up and improvements in keratometric and visual 
parameters.(Bikbova & Bikbov 2013; Vinciguerra et al. 2014; Buzzonetti et al. 
2015) However, the relative efficacy of this technique compared to epithelium-
off CXL remains to be determined especially over longer term follow-up, and 
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current randomized prospective studies comparing the two techniques 
(clinicaltrials.gov.uk NCT02117999, NCT01868620, ISRCT 04451470) have 
yet to be reported. 
 
Existing recommended protocols for iontophoresis in transepithelial CXL 
typically utilize riboflavin solutions of 0.1 % w/v and currents of 0.5 – 1 mA 
with application times of 5 to 10 minutes. Improved riboflavin absorption can 
be obtained by modifying these parameters. Stromal riboflavin concentrations 
using protocol A here were similar to epithelium-off controls (p = 0.8) (figure 4, 
table 3). This protocol utilized a solution of 0.25 % w/v riboflavin with BAC and 
the ‘St. Thomas’/Cardiff Iontophoresis protocol’. This protocol, designed by 
David O’Brart, was derived in collaborative pilot experimentation at St 
Thomas’ Hospital and Cardiff University using spectrophotometry, and 
comprises two cycles of iontophoresis each followed by a 5 minute soak 
period to allow time for riboflavin to diffuse more posteriorly. The use of the 
cationic surfactant BAC has been shown with percutaneous iontophoresis to 
have a synergistic effect on the transport of anions.(Lombardo, Serrao, et al. 
2014) I similarly observed this synergistic effect with higher stromal 
concentrations achieved with protocol A (0.25 % w/v riboflavin, BAC) 
compared to protocol C (0.25 % w/v riboflavin, no BAC) (figure 4, table 3).  
 
 The ideal transepithelial protocol would load the stroma with riboflavin, while 
leaving the epithelium relatively clear. To this end, in this study I rinsed the 
surface of the globe after iontophoresis in a bid to wash out some of the 
riboflavin from within the epithelium. Figures 3 and 4 and table 3 show that 
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this approach did not work since there was no significant difference in 
fluorescence between the epithelium and the subjacent stroma. Extended 
rinsing (5 minutes) of the ocular surface in protocols A and B (MedioCross 
TE) also reduced corneal stromal concentrations of riboflavin up to an 
approximate depth of 200 µm. Stromal riboflavin elution was less evident with 
non-BAC containing solutions (protocols C and D), where the epithelial tight 
junctions were still probably largely intact. Although iontophoresis is not 
commercially promoted to be used with BAC-containing solutions, this stromal 
wash-out effect with prolonged rinsing of the ocular surface may compromise 
tissue cross-linking within the anterior cornea. 
 
It is important to note that iontophoresis is ineffective with riboflavin 
formulations containing saline (Protocols G and H) that produced minimal 
riboflavin absorption and some stromal swelling.  
 
4.4.3 NC-1059 peptide 
NC-1059 peptide has been previously shown in cultured corneal epithelial cell 
monolayers to reversibly modulate the barrier function of intercellular tight 
junctions to enhance drug permeation.(Martin et al. 2009) Tight junctions 
within normal corneal epithelium represent a formidable barrier to the passage 
of molecules and ions. Most drug absorption, therefore, relies on transcellular 
passage, favouring lipophilic molecules. Riboflavin is a large (340 Da) 
hydrophilic molecule, underlying it poor penetration (Huang et al. 1989; Spoerl 
et al. 1998) NC-1059 overcomes this by forming non-selective ion channels 
that increase paracellular transport.(Martin et al. 2009) Zhang and colleagues, 
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using confocal fluorescence microscopy, reported significantly enhanced 
riboflavin diffusion across intact corneal epithelium in chick embryos.(Zhang et 
al. 2012) However, as discussed in chapter 2 and section 4.1, page 97 
above), this method suffers from significant signal attenuation with increasing 
stromal scan depth in ex vivo tissue, even more so when imaging though the 
epithelium. This signal attenuation is clearly visible in their results in which all 
images, including epithelium-off controls, exhibit decreasing fluorescence with 
depth. Furthermore, the investigators have misinterpreted the lack of 
fluorescence within the epithelium itself as indicative of no riboflavin being 
within this layer. Our method described above imaging sagittal sections 
proves that it is not possible to load the stroma with riboflavin without similarly 
loading the epithelium. 
 
4.4.4 Methodological limitations 
There are a number of limitations to the method described above. Firstly, 
results in ex-vivo rabbit corneas, although a better anatomical match to 
human corneal epithelial thickness than porcine eyes, may be affected by 
post-mortem changes in epithelial layer integrity. Measures taken to minimize 
this compromise included a short postmortem interval, immersion in chilled 
PBS immediately postmortem, and warming to physiological temperature prior 
to preparation of corneas for experimentation. I observed no obvious stromal 
swelling (indicative of endothelial pump failure) in negative controls, and mean 
corneal thicknesses to those published for rabbit corneas in vivo (400 
µm).(Riau et al. 2012) Despite this, some epithelial degradation and enhanced 
permeability is likely, and my results may overestimate stromal riboflavin 
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absorption in clinical transepithelial CXL. Secondly, migration of riboflavin 
within the snap frozen tissue will have started as soon as the section thawed 
on the slide. Even with the cryostat next to the microscope, there was still a 
delay of up to a minute before image acquisition. This would tend to result in 
an underestimation of stromal riboflavin concentrations. Finally, imaging 
through two media of different refractive indices (oil and water either side of 
the coverslip) may have increased optical aberrations as the laser light 
passes through. I chose oil to ensure no (water soluble) riboflavin leaked out 
of the tissue. When I tried to embed excised corneas in optimal cutting 
temperature (OCT) compound I observed very prompt dye leakage once 
thawed on the slide (data not shown). This may have impacted the study of 
Cassagne et al.(Cassagne et al. 2014). For lack of an appropriate oil-
immersion objective, I placed a coverslip on top and used a water-immersion 
objective. Any induced aberrations may have resulted in a small absolute loss 
of signal; but since this same method was employed for all imaged samples, 
no relative drop between samples should be present.  
 
4.4.5 Clinical relevance 
Notwithstanding the above laboratory studies, results from preliminary clinical 
case series using non-iontophoretic transepithelial riboflavin preparations 
have been equivocal, with some showing similar efficacy to epithelium-off 
CXL,(Filippello et al. 2012; Magli et al. 2013) whilst most have demonstrated 
less pronounced effects.(Leccisotti & Islam 2010; Caporossi et al. 2013; 
Koppen et al. 2012a; Soeters et al. 2015; Kocak et al. 2014) 12-month results 
from one recently published randomised controlled trial (Soeters et al. 2015) 
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concluded that transepithelial CXL using Ricrolin TE (Sooft Italia S.p.A. 
Montegiorgio, Italy) was not effective at stabilising corneal shape compared 
with epithelium-off treatment. For iontophoresis, up to 15 month follow-up data 
have been published, with reported cessation of disease progression and 
improvements in keratometric and visual parameters.(Bikbova & Bikbov 2013; 
Vinciguerra et al. 2014; Buzzonetti et al. 2015) The longer-term relative 
efficacy of all these transepithelial techniques compared to epithelium-off CXL 
remains unknown. 
 
4.4.6 Conclusion 
The methodology described above provides a quantitative means of 
measuring riboflavin across the whole cornea in an ex vivo model. 
I present evidence that the corneal epithelium represents a significant barrier 
to riboflavin absorption into the stroma. Existing commercial transepithelial 
CXL protocols load the corneal epithelium with riboflavin and achieve 
relatively low riboflavin concentrations in the anterior corneal stroma when 
compared to epithelium-off CXL. I also demonstrate that transepithelial 
riboflavin absorption can be improved using modified iontophoresis protocols, 
increasing soak time, riboflavin concentration in the soak preparation and 
current dosage. Although a key rate-limiting step, the absolute stromal 
concentration of riboflavin required for effective CXL is not known.  
The St. Thomas’/Cardiff Iontophoresis protocol achieves more than 50% 
greater stromal absorption compared to the standard iontophoresis protocol, 
as well as far higher concentrations than with non-iontophoresis 
transepithelial protocols. Although less than that achieved with the ‘gold 
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standard’ epithelium-off, its considerable stromal riboflavin absorption, without 
relying on epithelial-toxic additives, may represent the best transepithelial 
technique to date. Clinical trials will determine whether this level of stromal 
riboflavin absorption produces effective CXL.  
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5 Shape stabilisation - Accelerated CXL results for 
progressive keratoconus   
5.1 Introduction 
Randomised controlled studies confirming CXL works exist only for the 
original ‘Dresden’ epithelial-off protocol. (O’Brart et al. 2011; Wittig-Silva et al. 
2014) This protocol (Wollensak, Spoerl, et al. 2003a) takes over 1 hour, 
including manual debridement of the corneal epithelium with 30 minutes 
application of riboflavin drops prior to UVA exposure of irradiance (power) 3 
mW/cm2 for a further 30 minutes (total energy 5.4 J/cm2). Speeding up the 
procedure is attractive to both patient and practitioner, assuming treatment 
efficacy is not undermined. The absence of evidence has not hindered the 
growing popularity of alternative CXL protocols. 
 
Accelerated protocols are emerging in which the same total UVA energy dose 
is delivered as a shorter, higher-power burst. The premise of shorter UVA 
delivery is that the same total energy can be delivered in a fraction of the time 
by increasing the power (energy = power x time).  To date, low levels of 
evidence are available on accelerated CXL protocols, with evaluation of 
results complicated by variations in total energy, irradiance and/or treatment 
time. (Kanellopoulos 2012a; Celik et al. 2012; Kanellopoulos 2012b; Cınar et 
al. 2013; Gatzioufas et al. 2013; Tomita et al. 2014; Cinar et al. 2013; Sherif 
2014) Notwithstanding this heterogeneity, keratometric and visual outcomes 
following accelerated CXL appear to demonstrate effective disease 
stabilisation.  
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In 2012, Moorfields Eye Hospital began treating patients with progressive 
keratoconus using an accelerated protocol. In this chapter, I present the 
outcomes of this treatment.  
 
5.2 Methods 
5.2.1 Ethics and data handling 
This study design was reviewed by the Research Governance Committee and 
approved as an audit project by the Clinical Audit Working Group at 
Moorfields Eye Hospital NHS Foundation Trust. Patients were identified from 
a prospective electronic database of all patients aged above 15 years of age 
attending the Early Keratoconus Clinic. The database contains keratometric 
and refractive data entered prospectively in clinic and at the time of surgery. I 
extracted data from a consecutive series beginning with the first accelerated 
treatment in September 2012 through to April 2013. Eyes with 12-months’ 
keratometric follow-up data were included in this study. 
 
5.2.2 Outcomes measures 
The primary outcome measure was the failure rate of CXL treatment, defined 
by an increase in maximum anterior keratometry (Kmax) on corneal 
tomography of >1.5 D at 12 months. Secondary outcome measures included 
anterior keratometry of the steep (K2 front) and flat (K1 front) axes in the 
central 3mm zone, posterior keratometry of the steep axis (K2 back), 
uncorrected distance visual acuity (UCVA), spectacle-corrected distance 
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visual acuity (CDVA), subjective refraction, corneal thickness at the thinnest 
point and endothelial cell density. Visual acuities were initially measured in 
Snellen, before the using LogMAR charts in the clinic from September 2013.  
 
5.2.3 Monitoring for disease progression 
Serial corneal tomography (Pentacam HR, Oculus GmbH, Germany) and 
subjective refractions were used to confirm pre-operative keratoconus 
progression. Progression was defined by one or more of the following: >1.5 D 
increase in Kmax or anterior K2 (K2 front); >0.5 D increase in posterior K2 (K2 
back); >1 D increase in refractive astigmatism; >1 line loss of CDVA or >13 
µm decrease in pachymetry. These criteria were based on published (Szalai 
et al. 2012) limits of agreement for repeated measurement using the 
Pentacam in patients with keratoconus, where changes >1.5 D have a >95% 
probability of not being simply attributable to measurement error. Exclusion 
criteria included pregnancy or breastfeeding, active ocular surface disease or 
a minimum stromal thickness less than 375 µm. 
 
5.2.4 Specular microscopy 
Corneal endothelial cell densities were measured using the Topcon SP-2000P 
noncontact specular microscopy and analyzed with IMAGEnet 2000 
computerized analysis system (v2.5x; Topcon, Tokyo, Japan). If a clear image 
could not be acquired centrally, the patient was asked to look just to side of 
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the fixation light. Only whole cells with a continuous border (manually refined) 
on a frame with 75 or more cells, were accepted for planimetric analysis.  
 
5.2.5 Surgical procedure 
Following topical instillation of proxymetacaine 0.5%, tetracaine 1% and 
povidone-iodine 5%, the eyelashes were taped and a lid speculum inserted. 
The corneal epithelium was manually debrided to approximately 9mm. 
Dextran-free riboflavin 5’-monophosphate in saline and hydroxypropyl 
methylcellulose (VibeX Rapid, Avedro, Mass. USA) was applied every 2 
minutes for either 20 minutes (if minimum pachymetry ≥ 400 µm) or 10 
minutes (if minimum pachymetry < 400 µm). Continuous UVA exposure 
(KXL®, Avedro, Mass. USA) at 30 mW/cm2 for 4 minutes was then applied 
(total energy 7.2 mJ/cm2). 
 
At the end of the procedure, preservative-free dexamethasone 0.1% and 
chloramphenicol 0.5% were instilled and a bandage contact lens applied. 
Post-operatively, patients were prescribed a tapered course of preservative-
free topical dexamethasone 0.1%, moxifloxacin and hyaluronic acid 0.1% for 
1 week, along with topical diclofenac 0.1%, cyclopentolate 1% twice a day 
and 50 mg oral diclofenac three times a day for 3 days. Patients were 
additionally provided with 3 minims of proxymetacaine 0.5% for use in the 
early post-operative period. The bandage contact lens was removed at 1 
week after which all therapy was discontinued except topical hyaluronic acid 
0.1% and fluorometholone 0.1% four times a day for 1 month.  
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5.2.6 Statistical analysis 
For purposes of statistical analysis, I have converted Snellen visual acuities to 
logMAR equivalents (−log decimal acuity). I present data as means ± 
standard deviation. I use Paired Student t-tests to compare baseline and 12-
month post-operative data, accepting a p value ≤ 0.05 as significant. Analyses 
were performed in Excel for Mac (2011, Microsoft Corp.). 
 
5.3 Results 
70 eyes were treated between September 2012 and April 2013. 55 eyes 
(79%) had complete 12-month keratometric follow-up data (45 patients, 29 
male, 16 female; mean age 27 ± 7 years). All eyes had documented ectasia 
progression over at least a 6-month period prior to CXL, with a mean Kmax of 
59.7 ± 6.8 D. Forty-five eyes had stage I-III disease (Modified Krumeich 
classification), with the remaining 10 eyes stage IV (K2 > 55 D).  
 
 
At 12-months, the treatment failure rate was 12.7 %, with an increase in Kmax 
of > 1.5 D observed in 7 of 55 eyes. Despite some 12-month keratometric 
comparisons being statistically significant, we observed no clinically relevant 
changes in overall mean corneal shape or thickness. Excluding those eyes 
considered treatment failures, the mean reduction in Kmax was 1.07 ± 1.94 D 
(p < 0.001). Specular microscopy in 10 eyes showed a 3% reduction in 
endothelial cell density (p = 0.033).  Mean UDVA and CDVA remained 
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unchanged, with only one (1.8%) eye losing more than 1 line of CDVA. No 
infective complications occurred. One (1.8%) eye developed a small 
peripheral sterile infiltrate that quickly responded to further topical steroids. 
Full baseline and post-operative data are presented in Table 5.1, Table 5.2 
and Figure 5.1. 
 
 
Table 5.1 Visual function data pre- and post-CXL 
Parameter Baseline 6-months 12-months P value1 
 (n=55) (n=38) (n=32)  
UDVA (LogMAR) 0.80 ± 0.41 0.87 ± 0.41 0.76 ± 0.42  0.037* 
CDVA (LogMAR) 0.19 ± 0.20 0.20 ± 0.29 0.19 ± 0.25 0.382 
Sphere (D) -0.49 ± 4.40 -0.32 ± 3.79 0.57 ± 3.87 0.275 
Cylinder (D) -4.91 ± 2.27 -5.24 ± 3.15 -5.38 ± 3.71 0.708 
SEq (D) -3.03 ± 4.58 -3.00 ± 3.60 -2.12 ± 3.35 0.479 
UDVA uncorrected distance visual acuity; CDVA corrected distance visual acuity; D 
diopter; SEq spherical equivalent. 1Paired T-test of baseline compared with 12-months; 
*statistically significant. Note that CDVA is spectacle-corrected acuity, not contact lens 
acuity). 
 
 
 
 
Table 5.2 Keratometric data pre- and post-CXL 
Parameter Baseline 6-months 12-months P value1 
 (n=55) (n=23) (n=55)  
Kmax (D) 59.7 ± 6.8 59.1 ± 6.2 59.1 ± 6.2  0.036* 
K2 front (D) 51.5 ± 5.2 51.0 ± 4.5 51.6 ± 5.0 0.606 
K1 front (D) 47.3 ± 4.3 47.6 ± 4.5 47.9 ± 4.5  0.001* 
K2 back (D) -7.9 ± 0.9 -7.8 ± 0.8 -7.9 ± 0.9 0.383 
Pachymetry2 (µm) 440 ± 39 431 ± 43 433 ± 34  0.008* 
ECD (mm2) (n=10) 3059 ± 276 - 2964 ± 257 0.058 
ECV (%) (n=10) 35.9 ± 5.3 - 33.9 ± 4.8 0.359 
D diopter; ECD endothelial cell density; ECV endothelial coefficient of variation. 1Paired T-
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test of baseline compared with 12-months; 2Pachymetry at the thinnest location; 
*statistically significant 
 
 
 
Figure 5.1 Mean keratometry changes compared with baseline 
 (95% CI error bars) 
 
 
 
5.4 Discussion 
Overall, these data suggest that accelerated CXL irradiating at 30mW/cm2 for 
4 minutes (total energy dose 7.2 J/cm2) is an effective and safe intervention 
for progressive keratoconus. 
 
A limitation of this study is the lack a quality of life (QoL) assessment of the 
impact of this treatment on ocular and/or general health (e.g. 25-item National 
Eye Institute Vision Function Questionnaire (NEI-VFQ 25). Such 
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questionnaires may have provided valuable insight into whether the patients 
themselves felt the treatment had helped them, irrespective of the specific 
visual and refractive outcomes. Unfortunately, this study was approved, and 
undertaken, as an audit and we were therefore unable to deviate from 
standard clinical care. Introducing health questionnaires before and after 
treatment would have required separate research study approval with formal 
study recruitment and consent by all patients.  
 
The benchmark comparator for all accelerated CXL protocols is the original 
‘Dresden’ protocol. Two randomised-controlled trials (RCT) with at least 12-
month results support it use in progressive keratoconus with, on average, 
maximum keratometry flattening by 1D and CDVA improving by 1 line. 
(O’Brart et al. 2011; Wittig-Silva et al. 2014) One eye in the Melbourne study 
demonstrated continued progression (i.e. treatment failure) at 3 years. (Wittig-
Silva et al. 2014) By contrast, limited clinical data are available on accelerated 
CXL protocols. A prospective, paired-eye randomized trial of conventional vs. 
accelerated CXL (continuous 7 mW/cm2 for 15 minutes, total energy 6.3 
J/cm2) in 21 patients reported similar results in halting ectasia progression in 
each group.(Kanellopoulos 2012a) For conventional and accelerated groups 
respectively, mean steepest keratometry (Kmax) reduced from 49.5 to 46.1 D 
and 48.7 to 45.8 D, while mean sphere was reduced by 2.5D and 2.1D and 
mean cylinder reduced by 2.9D and 2.5D. Problems with this study include 
the paired-eye design (for an asymmetrical disease), the lack of 
randomisation details, variable follow-up rate (18 to 56 months) and the lack 
of statistical analysis of results between the two groups. Furthermore, it is not 
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possible to compare this study with other published series because laser 
phototherapeutic keratectomy (PRK) was used to remove the epithelium. 
Rather than an effect of CXL, the large degree of flattening seen in both 
groups (> 3 D) is likely to be a result of apical stromal ablation, attributable to 
the masking effect of the corneal epithelium that tends to be thinnest over the 
cone.(Kymionis et al. 2012) Using a slightly higher irradiance (continuous 9 
mW/cm2 for 10min, total energy 5.4 J/cm2), Cinar et al reported 6-month 
results in 13 progressive keratoconus eyes compared with 13 conventionally 
treated eyes. (Cinar et al. 2013)They reported statistically significant 
reductions in mean Kmax of 1.14 ± 2.08 D (accelerated) and 0.94 ± 1.86 D 
(conventional), although there were no overall differences in visual or 
refractive outcomes between the two groups. Neither of these two studies of 
accelerated CXL comment on any individual treatment failures. 
 
Lack of consensus on what defines disease progression both before and after 
treatment complicates comparisons between CXL techniques based on the 
current literature. Assuming no diurnal variation in corneal shape, the 
coefficient of repeatability (CoR) should correspond closely to the limits of 
agreement for successive measures of corneal tomography indices, defining a 
threshold beyond which there is a 95% probability that an observed difference 
reflects disease progression rather than measurement inaccuracy. Pentacam 
measurement repeatability in stage II keratoconic eyes has been shown to be 
worse than in normal corneas, with a CoR for Kmax between 1.5 – 2.00 
D.(Szalai et al. 2012; Hashemi et al. 2015) We based our definition of 
progression, and treatment failure, on this CoR value; lower thresholds (+1 D) 
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have been used in alternative studies.(O’Brart et al. 2011; Wollensak, Spoerl, 
et al. 2003a) Changes in this, and other criteria used to evaluate stability, may 
alter the intervention and failure rates where the observed increase in Kmax is 
less than +1.5 D.  
 
Further complicating a comparison of published outcomes are the numerous 
permutations of accelerated protocols in which total energy, irradiance and/or 
treatment time can be changed. Pulsing the light is a more recent protocol 
variable, intended to allow a trace amount of ambient oxygen to diffuse into 
the cornea during the ‘off’ phase. Corneal tissue absorbs radiant energy 
during the CXL process. This can be delivered as either a ‘slow-cook’ (i.e. 
Dresden protocol, 3 mW/cm2 for 30 minutes) or a ‘short burst’ (30 mW/cm2 for 
3 minutes), with the same total radiant energy dose (5.4 J/cm2; energy = 
irradiance x time). This reciprocity is defined in the Bunsen-Roscoe law, which 
states that the induced photochemical reaction depends on the total radiant 
energy dose regardless of the irradiation time. However, this law appears to 
break down at very high irradiances, with no observed increase in Young’s 
modulus in ex vivo pig corneas treated above 50mW/cm2 (treatment time less 
than 2 minutes).(Wernli et al. 2013) Below this cut-off, the same authors 
observed comparable increases in stiffness between the two treatment 
protocols. An alternative technique (scanning acoustic microscopy) has been 
used to demonstrate similar increases in corneal stiffness in ex vivo human 
corneas treated at 9mW/cm2 for 10 minutes (same total energy, 5.4 J/cm2). 
(Beshtawi et al. 2013)  
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UV delivery devices differ as well, although this variable has, to date, not 
received the attention it warrants. The UV-X CXL device (IROC, Zurich, 
Switzerland), as used in the Melbourne RCT(Wittig-Silva et al. 2014) 
comprises an array of 7 overlapping diodes with a resultant non-homogenous 
beam profile of varying intensity across the treatment zone (Figure 5.2). The 
Gaussian beam profile of this device, working at a nominal irradiance of 5.4 
J/cm2 results in zones of central hot-spots of higher surface irradiance (up to 
8.4 J/cm2) and peripherally low irradiance zones (3.7 J/cm2).(Marshall et al. 
2013)  The disparity in treatment efficacy reported in the literature may, in 
part, be a function of the beam profile of the treatment device used, with ‘over-
treatment’ hot-spots over a central cone causing more flattening that areas 
exposed to less UV irradiance. The homogenous beam profile of the KXL 
device, as used in the series of patients I report in this chapter, may be 
expected to produce a more isotropic treatment effect with less flattening.  
 
Besides ex vivo functional comparisons, apparent tissue changes in patients 
following conventional and accelerated CXL protocols have been investigated. 
A demarcation line, typically visible at approximately 300 µm following the 
Dresden protocol, is thought to represent the border between treated tissue 
(anterior to the line) and untreated tissue (posterior to the line). Touboul et al 
observed, by confocal microscopy, that the demarcation line following 
accelerated CXL (30mW/cm2 for 3 minutes, total energy 5.4 J/cm2) lies more 
superficial, at a mean depth of 100-150 mm. (Touboul et al. 2012) However, 
Kymionis et al. saw no such difference by OCT comparing Dresden and an 
alternative protocol (9mW/cm2 for 14 minutes, total energy 7.56 J/cm2), with 
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mean demarcation line depths of 337 and 322 µm respectively. (Kymionis et 
al. 2014) These conflicting findings may reflect the differences in irradiance, 
time and total energy exposure employed in these two studies. For the time 
being, the evidence-base lacks longer-term studies of corneal shape and 
vision using these protocols to prove whether a more superficial treatment, as 
suggested with 30mW/cm2 for 3 minutes, is any less effective. 
 
 
 
 
Figure 5.2 Ultraviolet light beam profile 
(A) Measured beam profile of KXL device (Avedro, Inc, MA, USA) 
demonstrating uniform energy distribution with application of 
nominal 5.4 J/cm2 dose, providing a consistent energy profile 
through a range of focus of more than 1cm from the image plane. 
(B) Beam profile of a multi-LED CXL device (UV-X, IROC, Zurich, 
Switzerland) used in early studies demonstrating uneven energy 
distribution and central hot spot of approximately 8.4 J/cm2 with 
application of nominal 5.4 J/cm2. (Images reprinted with permission 
by Avedro, Inc.) 
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The safety profile of high-irradiance UV exposure has yet to be established. 
Transient signs of endothelial stress (cell density, polymegathism and 
pleomorphism) have been documented by Cingü et al. in 36 keratoconic eyes 
within the first month after high-irradiance CXL (18 mW/cm2 for 5 minutes) 
before returning to normal after 6 months. (Cingü et al. 2013) Kanellopoulos 
reported a drop in the endothelial cell count in both accelerated (7 mW/cm2 for 
15 minutes) and conventional CXL groups (-100 vs. -250 cells respectively) at 
a mean follow-up of 46 months.(Kanellopoulos 2012a) Although I only have 
data in 10 of 55 treated eyes, a mean reduction in cell density of 95/mm2 (3%) 
does not suggest any significant increased risk associated with the 
accelerated protocol.  
 
In summary, I present up to 2 year outcomes following accelerated CXL for 
progressive keratoconus. Practical reasons exist to support a reduction in the 
total treatment time for CXL, and the data presented in this study add to the 
growing published literature on these new accelerated protocol iterations. 
While the debate continues on the relative merits, (MacGregor et al. 2014; 
Tsatsos et al. 2014) it is not possible at present, with an incomplete evidence 
base, to conclude whether UVA delivery times can be reduced without 
compromising the efficacy of the treatment.   
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6 Visual rehabilitation - Gross shape correction: 
Femtosecond laser-assisted intrastromal corneal 
ring segment implantation in progressive 
keratoconus. 
6.1 Introduction 
Intrastromal corneal ring segments (ICRS) were originally developed for the 
correction of myopia, although gained limited popularity compared with 
excimer laser. They act as a spacer between corneal lamellae thereby 
shortening central arc length, the degree of shortening being proportional to 
the thickness of the implant. As an implantable means to remodel the corneal 
profile, interest in these devises has shifted away from the treatment of simple 
ammetropia to ectatic diseases, notably keratoconus.  
 
Available ICRS differ principally in their cross-sectional profile, diameter, 
thickness and segment length. The original Intacs segments (Addition 
technologies, USA) had a hexagonal profile, available in two diameters, with a 
newer design (Intacs SK) available in two different thicknesses and an oval 
profile. Ferrara ICRS (Mediphacos, Brazil), with a triangular profile designed 
to reduce glare associated with other profiles, are available in small diameters 
(6 mm and 5 mm) and a range of thicknesses (150 – 350 µm). Similar in 
design, material and thickness to Ferrara, the same company subsequently 
marketed KeraRings, with the smallest internal diameter (4.4 mm). KeraRings 
are additionally available in different arc lengths (90, 120, 160 and 210 
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degrees), to potentially achieve better astigmatic control. Superiority amongst 
these rings has yet to be convincingly demonstrated, for either quality of 
vision (e.g. glare) or visual, refractive and topographical parameters.  
 
In this chapter, I report 18-month results of femtosecond laser-assisted 
intrastromal corneal ring segment (KeraRing) implantation in keratoconus. 
 
 
6.2 Methods 
6.2.1 Study design 
Retrospective consecutive case series. 
 
6.2.2 Inclusion criteria 
The medical records were reviewed for all keratoconic patients receiving 
KeraRing implantation by 3 surgeons at Moorfields Eye Hospital between 
2010 and 2013 inclusive. All patients met all 4 of the following inclusion 
criteria before surgery: 
1. Contact lens intolerance  
2. Corrected distance visual acuity (CDVA) ≤ 6/9  
3. Corneal thickness at the 6 mm channel site ≥ 450 µm. 
4. Controlled ocular surface inflammation 
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6.2.3 Surgical procedure 
 
Surgical plans based on Scheimpflug tomography and subjective refraction 
were obtained from the manufacturer (Mediphacos Ltd,   Belo Horizonte, 
Brazil). Following topical instillation of proxymetacaine 0.5%, tetracaine 1% 
and povidone-iodine 5%, a 360-degree femtosecond laser channel of internal 
diameter 5mm and external diameter 5.9mm was created at a depth between 
350 – 400 µm as dictated in the surgical plan (see example in Figure 6.1 
below). Into this channel, either 1 or 2 ring segments were implanted. No 
sutures were used. At the end of the procedure, preservative-free 
dexamethasone 0.1% and chloramphenicol 0.5% were instilled.   
 
 
Figure 6.1 Example KeraRing surgical plan 
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6.2.4 Post-operative care 
Post-operatively, patients were prescribed preservative-free topical 
dexamethasone 0.1% and chloramphenicol 0.5% four times a day for 1 week.  
Serial tomography and subjective refractions were performed to monitor for 
post-implantation ectasia progression. The first topography scan after 3 
months post-surgery was used as an updated baseline with which to compare 
for ectasia progression. 
 
6.2.5 Outcome measures 
The main outcome measure was CDVA. Secondary outcomes measures 
included UDVA, manifest refraction, corneal coma, contact lens tolerance and 
complications. Snellen visual acuity was converted to LogMAR equivalent for 
statistical analysis. Mean ± standard deviation are presented. 
 
6.3 Results 
KeraRings were implanted in 26 eyes of 26 patients (mean age 33 ± 7 years) 
and followed-up for a mean 18 ± 6 months. Spectacle-CDVA improved 
(Figure 6.2; Figure 6.3) from 0.32 ± 0.21 LogMAR equivalent pre-operatively 
to 0.18 ± 0.20 post-operatively (p < 0.001), with a mean improvement of 1.5 ± 
1.52 LogMAR equivalent lines of acuity (Figure 6.3). Refractive astigmatism 
reduced significantly by a mean 3.38 ± 2.49 D (p < 0.001), with a trend 
towards a greater post-operative response with higher pre-existing levels 
(Figure 6.4). 
Table 6.1 summarises the changes in outcome measures. 
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Table 6.1 Refractive and keratometric parameters (n = 26) 
Parameter Pre-operative Post-operative P value* 
CDVA (LogMAR) 0.32 ± 0.21 0.18 ± 0.20 < 0.001 
UDVA (LogMAR)† 1.25 ± 0.29 0.66 ± 0.44 < 0.001 
Sphere  -0.53 ± 4.06 -0.35 ± 2.84 0.79 
Cylinder -7.44 ± 2.67 -4.07 ± 2.10 < 0.001 
Kmax 59.60 ± 4.96 58.59 ± 5.35 0.24 
K2 front 52.38 ± 3.56 50.42 ± 3.64 0.001 
K1 front 48.13 ± 4.14 46.92 ± 3.32 0.051 
Mean ± SD; UDVA uncorrected distance visual acuity; CDVA corrected distance 
visual acuity; * Paired student T-test; † n = 15 due to undocumented UDVA 
 
 
No intra--operative complications occurred. One eye lost 1 line of vision 
following KeraRing implantation. Pre-operatively, all eyes were intolerant of 
rigid gas permeable (RGP) contact lenses. Post-operatively, vision correction 
was tolerated in RGP lenses (n = 14, 54%), toric soft contact lenses (n = 6, 
23%) and spectacles (n = 5, 19%). The remaining eye developed post-
implantation central striae; despite achieving 6/9 CDVA, the patient elected to 
 
Figure 6.2 Cumulative corrected distance visual acuity (n = 26) 
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undergo deep anterior lamellar keratoplasty. Corneal collagen cross-linking 
was performed on 4 (15 %) of 26 eyes for progressive keratoconus post-
implantation. 
 
 
Figure 6.3 Change in CDVA (equivalent LogMAR lines), n = 26 
 
 
 
Figure 6.4 Change in manifest astigmatism 
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Figure 6.5 Example pre- and post-ICRS implantation 
(A) Sagittal curvature pre-implantation; (B) sagittal curvature post-implantation; (C) Induced difference (A-B) showing flatting 
over cone, with corresponding steepening superiorly; (D) surgical plan; (E) colour photograph of ICRS in situ. Note axial 
misalignment compared with plan. Pre-op: -1.00/-4.25x60 6/60. Post-op: 6.00/-2.00x130 6/9 
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6.4 Discussion 
This small retrospective series presents data showing significant gains in 
spectacle-corrected vision can be achieved with femtosecond laser-assisted 
intrastromal corneal ring implantation in keratoconus. Through improvements 
in CDVA and/or contact lens tolerance, keratoplasty may be avoided in these 
patients. I have previously detailed comparable outcomes from the literature 
on page 51 which I will not be duplicate here. 
 
However, anecdotal scepticism amongst some surgeons of the benefits of 
ICRS in keratoconic eyes is due, in part, to the poor predictability of outcome 
in any given eye. Underlying this is the lack of validated nomograms for 
deciding optimal ICRS implantation (thickness, diameter, arc length/s etc.). 
The earliest studies described standardized implantation in all eyes 
regardless of shape (Kymionis et al. 2007), while more recent nomograms 
based on regression analysis of empirical data for different ring designs 
purport to improve predictability. Nomograms for each of the principle ICRS 
designs have been used to improve predictability based on preoperative 
spherical equivalent (Ertan & Colin 2007; Zare et al. 2007; Kanellopoulos et 
al. 2006), cone location and morphology, (Torquetti & Berbel 2009) and 
preoperative CDVA. (Vega-Estrada et al. 2013) To date there have been no 
direct comparisons between these various nomograms. Furthermore, data 
predicting which patients are least likely to do well are lacking; for example, 
establishing an evidence-based upper keratometry limit for successful ICRS 
use is not possible at present, with Kmax inclusion criteria in series to date 
ranging from ≤ 55 D to < 70 D. Although implantation need not adversely 
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compromise future lamellar graft options, (Fontana et al. 2009) avoiding ICRS 
in eyes with a predicted poor outcome in favour of more definitive visual 
rehabilitation through transplantation would be preferable. 
 
Very little long-term data is available for ICRS, and any effect of ICRS 
implantation on disease progression remains uncertain. CXL was performed 
on 4 (15 %) of 26 eyes in the above series for progressive keratoconus post-
implantation. Progression has similarly been observed up to 3 years post-
Intacs insertion, indicating that disease stabilization was not achieved by 
ICRS alone.(Alio et al. 2006)    
 
In conclusion, with increasing availability of femtosecond laser technology, 
OCT regional pachymetry, and intraoperative guidance systems to help 
reduce axial misplacement intraoperatively (Figure 6.5), ICRS implantation 
should become safer and more predictable. Several important gaps in the 
evidence base for this intervention exist. As a step towards visual 
rehabilitation (and away from corneal transplantation), there are already 
strong arguments for ICRS implantation for gross corneal shape correction in 
keratoconus patients with reduced CDVA – particularly if they are contact lens 
intolerant. Finer adjustments to correct surface irregularity (as detailed in 
chapter 6) can then be considered.  
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7 Visual rehabilitation - Fine shape correction:  A 
prospective study of simultaneous transepithelial 
photorefractive keratectomy and corneal collagen 
cross-linking for keratoconus  
 
7.1 Introduction 
Irregular astigmatism (irregular corneal shape leading to irregular focus) is a 
common cause of failure to achieve an adequate spectacle correction for 
most patients with corneal disease, including keratoconus. For those affected, 
rigid gas permeable contact lenses are the simplest means of visual 
rehabilitation. Not all patients tolerate rigid contact lens wear, and those that 
do may experience discomfort and have a restricted wearing time. 
Traditionally, where contact lenses fail, a corneal transplant is required to 
restore vision. 
 
Keratoconus, in which the corneal shape becomes progressively steeper and 
more irregular in the 2nd to 4th decades of life, is a common cause of irregular 
astigmatism.(Gore et al. 2012) Disease progression in keratoconus can be 
stabilised with CXL, and although corneal shape can improve, I have shown in 
chapter 4 that significant irregular astigmatism may remain. For this reason, 
most patients already dependent on RGP lenses will continue to be so 
following CXL treatment. 
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Excimer laser treatment designed to regularise the corneal shape may offer 
these patients improvements in vision without the need for rigid contact 
lenses. Transepithelial photorefractive keratectomy (transPRK) has previously 
been used to reduce irregular astigmatism post keratoplasty.(Allan & Hassan 
2013) In this study the authors based their treatment on corneal topography, 
creating a corresponding pattern of tissue removal from the corneal surface 
designed to produce a smoother, more regular focusing shape.  
 
Simultaneous transPRK with CXL in progressive keratoconus is an exciting 
new development. Performing both treatments simultaneously may offer 
advantages over sequential treatments: faster visual improvement, only one 
painful procedure and reduced risk of delayed disease progression. Promising 
results report improvements in spherical equivalent, uncorrected distance 
visual acuity (UDVA) and corrected distance visual acuity (CDVA), with 
stabilisation of corneal shape up to 12 months. (Kymionis et al. 2009; 
Kanellopoulos 2009) 
 
In this chapter, I present 6-month interim outcomes from a prospective study 
of simultaneous ocular wavefront-guided transPRK and CXL. 
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7.2 Methodology 
The primary objective of the study was to investigate the visual benefits in 
patients with progressive keratoconus treated with combined CXL and ocular 
wavefront-guided transPRK. 
7.2.1.1 Design  
Prospective interventional series.  
7.2.1.2 Primary outcome 
LogMAR CDVA at 12 months 
7.2.1.3 Secondary outcomes 
LogMAR UCVA  
Manifest refraction 
Pentacam indices 
Rate of infective keratitis 
7.2.1.4 Subject selection 
Inclusion criteria 
 Patients with progressive stage I - III keratoconus  
 CDVA < 0.00 logMAR  
Exclusion criteria 
 Patients under the age of 18 years 
 Active ocular surface disease 
 Minimum corneal thickness <390 µm (leaving 325 µm residual stromal 
thickness after transPTK) 
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7.2.1.5 Study interventions 
TransPRK programming  
Three consistent scotopic ocular wavefront scans (Ocular Wavefront 
Analyzer, SCHWIND eye-tech-solutions GmbH, Germany) were acquired 
within 0.5 D spherical equivalent refraction of each other. Corneal topography 
(Schwind Sirius) was also recorded to allow a comparison of planned 
wavefront and topography-guided treatments. Patients were required to 
remove gas permeable contact lenses for 2 weeks and soft contact lenses for 
1 week prior to scanning. Pharmacological pupil dilation with tropicamide 1% 
was used where pupil diameter was less than 5.5 mm. The scan with the 
lowest sphere and highest coma was exported for treatment programming. Iris 
scans were taken for static cyclotorsion control during the treatment. Ablation 
depth was minimised during treatment programming by removing all sphero-
cylindrical constraints. I aimed to preserve a minimum corneal stromal 
thickness prior to CXL of 325 µm. To ensure effective CXL was not 
compromised by a smaller diameter zone of epithelial removal, epithelial 
transPTK and stromal PRK was delivered separately where the programmed 
laser ablation zone for transPRK was predicted to be less than 8mm in 
diameter.  
 
TransPRK/CXL surgery 
Treatments were performed by either by myself or Bruce Allan. Following 
topical instillation of proxymetacaine 0.5%, tetracaine 1% and povidone-iodine 
5%, a lid speculum inserted. After the laser treatment was complete, dextran-
free 0.1 % w/v riboflavin 5’-monophosphate solution in saline and 
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hydroxypropyl methylcellulose (VibeX Rapid, Avedro, MA, USA) was applied 
every 2 minutes for a total of 10 minutes before UVA exposure (KXL®, 
Avedro, MA, USA) at 30 mW/cm2 for 4 minutes (pulsed every 1.5 seconds) 
was then applied (total energy 7.2 mJ/cm2). Mitomycin C was not used. 
 
At the end of the procedure, preservative-free dexamethasone 0.1% and 
chloramphenicol 0.5% were instilled and a bandage contact lens applied. 
Post-operatively, patients were prescribed a tapered course of preservative-
free topical dexamethasone 0.1%, moxifloxacin and hyaluronic acid 0.1% for 
1 week, along with topical diclofenac 0.1%, cyclopentolate 1% twice a day 
and 50 mg oral diclofenac 3 times a day for 3 days. Patients were additionally 
provided with 3 minims of proxymetacaine 0.5% for use in the early post-
operative period. The bandage contact lens was removed at 1 week after 
which all therapy was discontinued except topical hyaluronic acid 0.1% and 
fluorometholone 0.1% 4 times a day for 1 month.  
 
 
 
 
 
 
  
  
161 
7.4 Results 
At the time of writing, 52 eyes of 55 recruited patients have been treated. 
Twenty-nine (53%) eyes have at least 3-month follow-up data; 13 (24%) eyes 
have 6-month follow-up data. Data on those patients who have reached at 
least 3-month follow-up is presented here. 
 
7.4.1 Surgical parameters 
All surgery was uncomplicated. Mean ± SD transPRK ablation diameter was 
8.25 ± 0.56 mm, with a mean optical zone of 7.02 ± 0.56 mm. Mean stromal 
ablation depths based on ocular wavefront-guided treatments were 
significantly shallower than projected treatments based on surface topography 
alone (p < 0.001, Table 7.1). At the thinnest part of the cornea (cone apex), 
the mean saving for ocular-wavefront guided treatments was 15 ± 10 µm. 
 
Table 7.1 Stromal ablation depths 
Parameter OWF (µm) Topography (µm) P value 
Cone Apex 33 ± 12 48 ± 11 < 0.001 
Corneal center 19 ± 11 33 ± 7 < 0.001 
Maximum ablation 34 ± 12 52 ± 10 < 0.001 
Mean ± SD; OWF, ocular wavefront; µm, micrometer 
 
7.4.2 Functional and Keratometric outcomes 
At 3-months, neither UDVA nor CDVA had significantly improved, despite 
clear topographical shape regularisation.  This was attributed to stromal haze 
underling the 7 (24%) of 29 eyes that lost more than 1 line of LogMAR acuity 
at 3-months. For the 13 eyes with 6-month follow-up, no eye has lost vision, 
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with a mean improvement of 1.5 lines of LogMAR acuity. Refractive, visual 
and keratometric outcomes are summarised in Table 7.2 and Figure 7.3 
 
Table 7.2 Visual and keratometric outcomes  
Parameter Baseline 3 months 6 months P value† 
 (n = 29) (n = 29) (n = 13)  
CDVA 0.30 ± 0.23 0.24 ± 0.23 0.15 ± 0.18 0.019 
UDVA 0.75 ± 0.41 0.62 ± 0.37 0.45 ± 0.34 0.003 
Sphere 0.95 ± 2.90 -1.42 ± 2.04 -1.06 ± 2.66 0.095 
Cylinder -5.59 ± 3.34 -3.81 ± 2.96 -3.02 ± 3.00 < 0.001 
Kmax 58.94 ± 4.65 53.97 ± 4.51 52.68 ± 4.60 < 0.001 
K2 front 50.91 ± 3.31 49.84 ± 3.43 49.11 ± 3.23 0.739 
K1 front 47.13 ± 2.84 46.07 ± 2.76 45.45 ± 2.07 0.010 
Pachymetry*      447 ± 71        415 ± 42        420 ± 50 0.739 
Mean ± SD; † Baseline vs. 6-months; *minimum pachymetry; UDVA uncorrected distance 
visual acuity; CDVA corrected distance visual acuity; ECC endothelial cell count 
 
7.4.3 Functional and keratometric outcomes 
One patient was temporarily lost to follow-up following surgery, presenting to 
his local eye unit some weeks later with the bandage contact lens still in situ 
and microbial keratitis. A central corneal scar was present at 3-months with a 
4-line loss of CDVA. One other eye developed a small peripheral sterile 
infiltrate which readily responded to further topical steroids. No post-operative 
ectasia has occurred to date. 
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Figure 7.1 Mean visual acuities post-transPRK/CXL 
Data plotted only for eyes with 6 month follow-up (n = 13) 
 
 
 
Figure 7.2 Mean refractive changes post-transPRK/CXL 
Data plotted only for eyes with 6 month follow-up (n = 13) 
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Figure 7.3 Example topography pre- and post-transPRK/CXL 
Upper row: Pre-op; lower row: 3-months post-op 
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7.5 Discussion 
While clearly too early to pass judgement on longer-term viability, these 
interim data demonstrate promising early results for a combined transPRK 
and CXL approach to both improving visual acuity and achieving stabilisation 
in progressive keratoconus. 
 
The principle criticism of photoablative corneal surgery in keratoconus is the 
risk of further destabilising an inherently ‘weak’ cornea. While the underlying 
mechanisms of keratectasia post-excimer laser refractive surgery are poorly 
understood, keratoconus has traditionally been considered an absolute 
contraindication for any photoablative procedure. CXL is considered to 
‘strengthen’ the cornea, but tissue changes following treatment are not well 
defined, principally due to the lack of validated in vivo measures of relevant 
corneal biomechanic properties.(Meek & Hayes 2013) In ex vivo studies, CXL 
has been shown to significantly increases corneal rigidity with a 450% 
increase of Young’s modulus in human corneas at 6% strain.(Wollensak, 
Spoerl, et al. 2003b)  
 
This potential protective effect of CXL has driven the argument against 
excimer laser surgery in keratoconus full circle, with a number of investigators 
specifically advocating its use in keratoconics. (Kymionis et al. 2009; 
Kanellopoulos 2009; Labiris et al. 2012; Kymionis et al. 2012; Mukherjee et al. 
2013)(Table 2.13) The most basic embodiment of transPRK involves removal 
of the corneal epithelium (transphototherapeutic keratectomy, transPTK). 
Using a standard 7.0 mm wide, 50 µm deep ablation, Kymionis et al yielded 
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significant visual gains as compared to mechanical debridement. (Kymionis et 
al. 2012) This ablation takes advantage of the varying epithelial thickness 
that, to an extent, masks underlying stromal surface irregularity (i.e. irons out 
the peaks and troughs) as well as being thinnest over the cone. 
 
TransPRK is a step up from transPTK. Where transPRK is applied 
immediately before CXL (i.e. simultaneous combined treatment), the aim is to 
improve CDVA by reducing irregular astigmatism rather than to fully correct 
spherocylindrical errors. This is in order to maintain a sufficient residual 
stromal bed after ablation to allow safe CXL, as well as reduce the risk of 
hypermetropic overcorrection if spherical equivalent reductions induced by 
CXL are not anticipated. TransPRK treatments can be based on manifest 
refraction (Mukherjee et al. 2013) or be guided by topography or whole eye 
wavefront data. With advanced disease, all of these approaches are likely to 
become less accurate, with indeterminate subjective spherocylindrical 
endpoints on refraction, reduced topographic reliability and poor quality 
aberrometry scan acquisition all occurring as corneal shape becomes more 
irregular. Mukherjee et al reported TransPRK/CXL outcomes in 22 eyes of 14 
patients based on spherocylindrical parameters only, aiming to fully correct 
the subjective refractive cylinder up to a maximum ablation depth of 50 µm. 
Where the topographic and subjective cylinder did not correlate, a lower 
proportion of cylinder was corrected. If the cylindrical correction did not 
require the maximal permitted 50 µm ablation, then the remaining available 
ablation depth was used to correct as much spherical error as possible. 
Mitomycin-C was not used. At 12-months, mean LogMAR CDVA improved 
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from 0.31 ± 0.2 to 0.11 ± 0.13 (p < .05) and spherical equivalent improved 
from -2.74 ± 4.1 D to -0.3 ± 3.2 D (p = 0.002). However, these results belie 
large and unfortunate hypermetropic shifts, with a mean spherical equivalent 
prediction error (achieved – expected spherical equivalent) of 1.3 D  (range -
4.75 to +10 D).  4 eyes (18 %) developed some haze, although all gained 
vision compared with pre-operative values. We chose not to use mitomycin C 
in this present study on the expectation that keratocyte apoptosis may be 
achieved by CXL itself. However, the 24% of eyes developing haze within the 
first 3 months suggests this CXL-mediated stromal keratocyte depopulation is 
insufficient to prevent clinical significant haze. 
 
The largest study based on topography-guided ablations is a series with 
minimum 2 year postoperative follow-up (Kanellopoulos 2009) comparing 
prospective outcomes of 198 eyes treated with topography guided PRK 
followed immediately by CXL (simultaneous combined treatment) with an 
earlier retrospective series of 127 eyes treated with topography guided PRK a 
minimum of 6 months after CXL (sequential combined treatment). 
Simultaneous combined treatment produced greater improvement across a 
range of measures: LogMAR CDVA improved from 0.39 ± 0.3 D to 0.11 ± 0.2 
D, with a reduction in spherical equivalent of -3.2 ± 1.4 D and mean 
keratometry of -3.5 ± 1.3 D. This compares with the sequential group’s CDVA 
improvement from 0.41 ± 0.3 D to 0.16 ± 0.2 D, spherical equivalent reduction 
of -2.5 ± 1.2 D and mean keratometry reduction of -2.75 ± 1.3 D. Haze scores 
were also significantly better for simultaneous combined treatment. 20 second 
intraoperative applications of mitomycin C were used throughout, and the 
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maximum ablation depth was limited to 50µm. The essential problem for this 
comparison is that the time interval between CXL and PRK for sequential 
treatment was not specified, and may have been considerably shorter than 
the 2 year period in which refractive results typically continue to improve after 
CXL alone.(Caporossi et al. 2010)  
No reports of ocular wavefront-guided transPRK and CXL in keratoconus exist 
in the literature. In this study I have demonstrated that ocular wavefront-
guided treatments targeting irregular astigmatism ablate significantly less 
tissue compared with treatments based on anterior corneal surface 
aberrotmetry alone. The implication is that the posterior corneal surface 
partially offsets anterior corneal surface irregularities. This is analogous to the 
negatively powered posterior corneal surface reducing whole corneal power 
by partially correcting the positively powered anterior corneal surface. Less 
tissue ablation has theoretical advantages in terms of maintained corneal 
biomechanics and reduced haze formation post-ablation.  
 
In conclusion, these interim results show great promise for combined 
simultaneous transPRK and CXL to provide rapid visual rehabilitation in 
patients with progressive keratoconus. Simultaneous combined treatments 
have clear advantages for patient comfort (the epithelium is only removed 
once) as well as promising faster visual recovery without the need to wait for 
corneal shape improvement. As compared with sequential transPRK and 
CXL, simultaneous treatment also avoids the risk of destabilizing the cornea 
by ablating previously cross-linked tissue which is concentrated in the anterior 
stroma. (Lombardo, Serrao, et al. 2014) Further study is required to determine 
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whether increased haze scores for sequential combined treatment observed 
by Kanellopoulos are still evident where PRK is performed later in the post 
CXL wound healing cycle, a minimum of 2 years after treatment.  
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8 Conclusions – Past, present and future 
 
The last few years have seen new and exciting developments in the 
management of keratoconus, both stabilizing and reversing corneal shape 
changes, with interventions for visual rehabilitation originally developed in the 
field of refractive surgery finding new applications in ectatic corneas. The 
evidence favouring the safe and efficacious use of (standard) epithelium-off 
CXL is robust, backed by over a decade of clinical data, crucially underpinning 
existing and emerging combined-treatment algorithms. The substantial 
interest in CXL (Figure 8.1) is likely to continue, with a drive (both clinical and 
pragmatic) for safer and quicker office-based treatments.  
 
Figure 8.1 PubMed listings for collagen cross-linking 
 
 
 
 
Supporting on-going development will be improvements in our understanding 
of corneal biomechanics, the mechanisms of CXL and the tissue changes it 
induces. X-ray scattering, dynamic deformational Scheimpflug imaging and 
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Brillouin microscopy are three examples from where this new knowledge will 
likely arise. Someone, one-day, may be even rebut the misnomer claims for 
CXL and prove once and for all that collagen cross-linking does, in fact, 
generate collagen cross-links. 
 
More pragmatically perhaps, significant improvements in CXL are also likely 
to be industry driven. Even if Avedro Inc.’s ultimate goal is to develop CXL 
into a bespoke “no laser” refractive procedure for the correction of low myopic 
astigmatism, their involvement should be no less welcomed within the world of 
keratoconus. Keratoconus is not comparable to age-related macular 
degeneration in terms of societal burden of disease and cannot, of itself, 
attract the same level of industry-funded research. Outcomes describing 
‘Photorefractive CXL’ have already been published, applying topography-
guided high-irradiance CXL in a bow-tie pattern in order to achieve corneal 
astigmatic changes.(Kanellopoulos et al. 2014) The aim here is to achieve 
guided corneal flattening which could be along the steep axis in physiological 
astigmatism (Seven et al. 2014) or over the cone in ectasia. A further 
ingredient in such a photorefractive CXL algorithm for keratoconus would be 
combining spatially-derived Brillouin maps with corneal topography and 
refraction to definitively lock-in a new emmetropic shape.  
 
 
 
In the shorter term, it is anticipated that results from clinical studies reporting 
outcomes compared to the gold-standard ‘Dresden’ protocol will continue to 
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guide clinicians as to best practice. A number of randomised controlled trials 
(RCT) are on-going which will significantly add to the evidence base, but 
RCTs are not the only answer. Despite a recent statement by the Cornea 
Clinical Committee of the American Society of Cataract and Refractive 
Surgery that, ‘robust evidence will only be forthcoming from well designed, 
multicenter, prospective, sham-controlled RCTs,’ (Ziaei et al. 2015) there are 
very good reasons to oppose this path in favour of patient registries. With so 
many different protocol permutations in current use (riboflavin formulation 
/instillation, epithelium status, UV device/irradiance/power/exposure, oxygen 
supplementation etc.) RCTs cannot be expected to appropriately reflect, let 
alone keep up-to-date with real-world practice. Nor can their results be 
assumed to apply to keratoconus subpopulations who, for example, may have 
different risk profiles for disease progression both before and after treatment. 
Registry data, on the other hand, would perfectly complement the use of 
different treatment parameters and patient groups. An electronic registry, with 
in-built temporal trend analysis, also has the potential to improve patient care 
by making the process of disease monitoring easier and more robust (visual 
acuity, astigmatism, keratometry, pachymetry and specular microscopy are all 
continuous variables). Furthermore, on a national level, by virtue of numbers, 
a web-based CXL registry represents a much less expensive way to answer 
the same question driving RCTs: which protocol is best for my patient? 
 
To date, the conventional approach remains to intervene with CXL only for 
patients with documented disease progression. Factors predictive at 
diagnosis of an increased risk of disease progression in keratoconus include 
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young age, steep keratometry, high astigmatism, reduced CDVA and non-
Caucasian ethnicity.(Tuft et al. 1994; Gordon et al. 2006) As experience is 
accrued on the safety and efficacy of this treatment, the era of prophylactic 
treatment in all newly diagnosed young keratoconics is likely to emerge. No 
patient is born with keratoconus; a diagnosis during the adolescence or early 
adulthood could be considered progression de facto. Assuming the treatment 
works, the inevitable question is why wait?  
 
And the future? As CXL becomes more widespread (FDA approval is not 
granted yet), and focus shifts from treating the prevalence to the incidence, it 
is a given that the need for interventions for advanced disease will become 
less common. One university-based corneal department in Norway has 
reported the frequency of keratoplasty halving over the past decade since 
their introduction of CXL. (Sandvik et al. 2015) The provision of CXL within the 
UK’s National Health Service remains wholly inadequate (Papamichael & 
Harman 2013) but I predict that our own keratoplasty trends (both numbers 
and indications) will markedly change over the next decade. The same trend 
is likely to be seen in ICRS implantation: Already a niche service, the pool of 
keratoconic corneas in need of such gross shape correction can be expected 
to decline. 
 
146 years ago, the Swiss ophthalmologist Johann Horner presented a thesis 
entitled ‘On the treatment of keratoconus’, to the University of Zurich.  Besides 
the first reference in the literature giving the condition its current name, Horner 
also described the accepted interventions of the day: Pharmacological miosis 
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and silver nitrate cautery to flatten the cornea by scarring. (Horner 1869) 
Fittingly, another Swiss ophthalmologist, Theo Seiler, through his original 
work on corneal cross-linking has since revolutionised the management of this 
disease  - paradigm shifts in medicine are uncommon, but it is no 
exaggeration in the case of keratoconus over the past few years. Thick case 
note files documenting the progression of keratoconus towards corneal 
transplantation and blindness will be a welcome historical anecdote among 
ophthalmologists by the time I retire. 
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10 Appendix B – study protocols 
10.1 Chapter 1 – meta-analysis 
MEDLINE (1950-2015) and the Cochrane Central Register of Controlled Trials 
was searched using the following search terms: keratoconus; corneal cross-
linking; cross-linkage; intracorneal ring segment; topographic photorefractive 
keratectomy; phakic intraocular lens. For the meta-analysis, two investigators 
(Alex Shortt & I) independently assessed the search results for randomised 
controlled trials (RCTs) of corneal cross-linking in keratoconus. The authors of 
2 RCTs (O’Brart et al. 2011; Wittig-Silva et al. 2014) were contacted for 
clarification of trial methodology and provision of additional unpublished 
data. A risk of bias assessment was performed on studies and only studies 
with a low risk of selection, performance, detection and attrition bias were 
included.  Data extraction was done independently by DG and AS. Data 
synthesis was performed using a meta-analysis software package, Review 
Manager (RevMan, The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, 2008). The effect of the intervention was 
expressed as odds ratios and confidence intervals were 
calculated.  The Mantel-Haenszel fixed-effect method of meta-analysis was 
used.  
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10.2 Chapter 2 – Epithelium-off two-photon microscopy 
imaging 
10.2.1 Two-photon microscope set-up  
A Ti:Sapphire laser (Chameleon Vision II, Coherent, CA, USA) equipped with 
a prism based Group Velocity Dispersion (GVD) compensation unit was used 
as the excitation laser source. The laser has a tuning range from ~680 nm up 
to 1080 nm, operating with a 140 femtosecond pulse duration and 80 MHz 
pulse repetition rate. The excitation laser beam was guided to a Leica 
DM6000CS upright microscope via an Electro-Optical-Modulator (EOM) to 
control laser output and coupled into the Leica SP8 Spectral Scan-head 
(Leica Microsystems, GmBH) where it passes through two galvoscanners, 
allowing scanning in the x-y plane, before being focused into the sample by a 
Leica 25X /0.95 NA water immersion objective (coverslip corrected) that 
facilitated a working depth of up to 2 mm. Theoretical (full-width half-
maximum) resolutions were calculated at 0.34 μm laterally and 1.4 μm axially. 
Employing the two-photon fluorescence principle, I used excitation light of 
wavelength 890 nm to correspond with the highest absorption wavelength of 
riboflavin (i.e. 445 x 2 = 890 nm, Figure 3.3). The emitted fluorescence 
passed through an 800 nm short pass dichroic filter (Chroma Technology 
Corp., Vermont, USA), which was then spectrally separated by a Leica 
Acousto-Optic-Beam Splitter (AOBS®) before passing to the Leica HyD® 
detectors.  
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10.2.2 Sample preparation 
Freshly enucleated porcine eyes (First Link Ltd., Wolverhampton, UK), stored 
within a sealed bottle of phosphate buffered saline (0.85% NaCl, 0.01M 
NaPhos, pH 7.2-7.4), were transported on ice to arrive within 24 hours of 
death. Rabbit globes, more closely matching human corneal epithelial 
thickness were additionally used to confirm findings in epithelium-on 
experiments. Each globe was secured within a custom-made perspex cylinder 
to ensure stability on the microscope stage (Figure 3.4A). A custom reservoir 
chamber for riboflavin (a coverslip glued onto two rubber O-rings) was placed 
coverslip down and filled with ~400 µl of riboflavin solution. The epithelium 
was either left intact or debrided using a hockey stick scraper (e.janach srl, 
Como, Italy), the cornea of the intact globe was apposed to the O-ring and 
immersed in riboflavin and a timer was started (time = 0 minutes). Relying on 
surface tension to keep the O-ring/coverslip and cornea apposed, the 
assembly was then inverted, creating a bubble-free, sealed lake of riboflavin 
over the cornea and beneath the coverslip ready for imaging (Figure 3.4B). 
The assembly was then positioned within a custom-built recessed stage to 
house the cylinder-supported globes beneath the objective. The first TPF z-
stack was started at time = 2.5 minutes. 
 
10.2.3 Imaging protocol and concentration calibration 
All TPF experiments were performed with the room lights at a minimum. The 
microscope stage and objective were enclosed in opaque Perspex casing to 
reduce incident light being detected. TPF excitation light of 890 nm 
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wavelength was chosen to correspond with the highest riboflavin absorption 
peak (445 nm) as determined by spectrophotometry. The average laser 
output power at 890 nm was 33 mW at the objective with minimal fluctuation 
in average power being observed during the course of any given day’s 
experiment. Emitted riboflavin fluorescence was collected between 525 nm 
and 650 nm, to avoid overlap with the absorption spectrum of riboflavin. I 
confirmed the absence of any reabsorption of this emitted light by 
demonstrating no change in measured TPF signals with excitation depth in 
homogeneous riboflavin solutions within a well slide (Figure 3.5).  
 
Serial z-stacks at 10 µm intervals were started within the pre-corneal riboflavin 
reservoir at approximately 30 µm above the corneal surface to provide a 
reference TPF signal level for this 0.1% w/v solution. This level provided a 
signal-to-concentration calibration for each eye. Z-stacks were acquired 
through the depth of the cornea (scan rate: 600 Hz, 512 x 512 pixels, image 
size: 445 µm x 445 µm, line average: 2, pinhole wide open). An iterative 
approach to developing this protocol was used, balancing the need for 
sufficient axial resolution with 10 µm stacks and a fast total acquisition time 
(approximately 130 seconds) to limit the possibility to riboflavin migration 
during each whole corneal scan. Each run was repeated every 2.5 minutes, 
up to 20 minutes, and then every 5 minutes, up to 60 minutes.  
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10.3 Chapter 3 – Epithelium-on two-photon microscopy 
imaging 
 
10.3.1 Sample preparation 
Adult pigmented rabbit heads transported on ice in a phosphate buffered 
saline (PBS) bath were received within 5 hours post-mortem (First Link Ltd., 
Wolverhampton, UK). Intact globes were enucleated and examined under a 
low-magnification light microscope to rule out obvious epithelial trauma or 
scars. The globes were warmed to room temperature in balanced salt solution 
before different commercially-available riboflavin solutions (Table 4.1) were 
applied to the corneas of intact globes according to the manufacturers’ 
protocols (Protocols tested, section 4.2.3).  
 
10.3.2 NC-1059 solution preparation 
NC-1059 is a synthetic non-selective ion channel-forming peptide. A 200 µM 
NC-1059 peptide solution (amino acid sequence KKKK-
AARVGLGITTVLVTTIGLGVRAA; LifeTein LLC, New Jersey, USA) was 
prepared by dissolving it in either 0.25 % or 0.1 % w/v riboflavin 5’-
monophosphate solution (Ricrolin +, Table 4.1) 
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Table 10.1 Commercially prepared riboflavin solutions 
Formulation Manufacturer Composition 
Vibex Rapid Avedro, Inc., MA, USA 0.1% wt/vol riboflavin 5’-monophosphate, saline, HPMC 
Ribocross TE 
 
IROS Srl, Napoli, Italy 0.125% wt/vol riboflavin 5’-monophosphate,     
D-alpha-tocopheryl poly(ethylene glycol) 1000 succinate 
Medio-Cross TE  
 
Peschke Meditrade GmbH, Germany 0.25% wt/vol riboflavin 5’-monophosphate, HPMC, benzalkonium 
chloride 0.01% 
Ricrolin + 0.1% 
 
Sooft Italia S.p.A. Montegiorgio, Italy 0.1% wt/vol riboflavin 5’-monophosphate, sodium edetate, 
trometamol, sodium dihydrogen phosphate dihydrate, sodium 
phosphate dibasic dehydrate 
Ricrolin + 0.25% 
 
Sooft Italia S.p.A. Montegiorgio, Italy 0.25% wt/vol riboflavin 5’-monophosphate, sodium edetate, 
trometamol, sodium dihydrogen phosphate dihydrate, sodium 
phosphate dibasic dehydrate 
ParaCel  
 
Avedro, Inc., MA, USA 0.25% wt/vol riboflavin 5’-monophosphate, HPMC, sodium edetate, 
trometamol, benzalkonium chloride, saline 
VibeX Xtra  Avedro, Inc., MA, USA 0.25% wt/vol riboflavin 5’-monophosphate, saline  
All the above solutions (except Vibex Rapid) are designed for transepithelial use. HPMC, hydroxypropyl methylcellulose 
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10.3.3 Protocols tested 
Positive controls were prepared using a 9 mm vacuum well secured to 
epithelial-debrided corneas of whole globes filled with 0.1 % w/v riboflavin in 
HPMC and saline (Vibex Rapid) for 30 minutes (n = 5). Unsoaked globes (i.e. 
no riboflavin) served as negative controls (n = 5). 
 
10.3.3.1 Non-iontophoresis protocols 
1. Medio-Cross TE 
A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of Medio-Cross TE solution for 30 minutes. Riboflavin was not rinsed from 
the cornea (n = 5). 
 
2. Ribocross TE  
A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of Ribocross TE solution for 30 minutes. Riboflavin was not rinsed from the 
cornea (n = 5). 
 
3. ParaCel and VibeX Xtra   
ParaCel drops were applied at a rate of 1 drop every 90 seconds for 4 
minutes. The cornea was then rinsed with VibeX Xtra completely coating the 
cornea. Additional VibeX Xtra was applied at a rate of 1 drop every 90 
seconds for 6 minutes (total riboflavin soak time 10 minutes). Riboflavin was 
not rinsed from the cornea (n = 5). 
 
4. 200 µM NC-1059 peptide in 0.1 % w/v Ricrolin + 
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A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of 200 µM NC-1059 peptide in 0.1 % w/v Ricrolin + solution for 30 minutes. 
Riboflavin was rinsed from the cornea with PBS for 1 minute (n = 3). 
 
5. 200 µM NC-1059 peptide in 0.25 % w/v Ricrolin + 
A 9 mm vacuum well secured on the cornea was filled with approximately 0.5 
ml of 200 µM NC-1059 peptide in 0.1 % w/v Ricrolin + solution for 30 minutes. 
Riboflavin was rinsed from the cornea with PBS for 1 minute (n = 3). 
 
10.3.3.2 Iontophoresis protocol 
The iontophoresis system comprised 2 electrodes: a negatively-charged metal 
grid housed within the corneal applicator and a positively-charged 20G needle 
inserted through the sclera into the vitreous (Figure 4.3A). The corneal 
applicator was vacuum-attached to the cornea. The reservoir was filled with 
differing riboflavin formulations to above the level of the metal grid before 
beginning the iontophoresis treatment. Protocols varied either by 
iontophoresis dosage, soak time or riboflavin formulation (n = 4, Table 4.2). 
After the iontophoretic procedure, the applicator was removed and the 
corneas were rinsed with PBS to both remove any riboflavin on the corneal 
surface and to try to reduce riboflavin concentration within the epithelium.  
 
 
 
Table 10.2 iontophoresis protocols 
Protocol Solution Current Soak I Current Soak Rinse 
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Negative 
control 
None None - - - - 
Positive 
Control 
Vibex Rapid None 30 min - - - 
A MedioCross 1mA 5 min 5 min 0.5 mA 5 5 min 5 min * 
B MedioCross 1mA 5 min 15 min - - 1 min 
C Ricrolin+ 1mA 5 min 5 min 0.5 mA 5 5 min 5 min * 
D Ricrolin+ 1mA 10 - - - 5 min 
E MedioCross 1mA 5 min - - - 1 min 
F Ricrolin + 1mA 5 min - - - 1 min 
G Vibex Rapid 1mA 5 min - - - 1 min 
H Vibex Rapid 1mA 5 min 5 min 0.5 mA 5 5 min 5 min 
Min, minute;  * St. Thomas’/Cardiff Iontophoresis protocol (unpublished) 
 
10.3.4 Section preparation 
At the end of the riboflavin soak, the globes were immediately immersed in 
liquid nitrogen for 5 minutes and stored overnight at -25 degrees Celsius. A 
broad incision across the posterior globe was made just before immersion to 
prevent the cornea from splitting open on freezing. For each globe, three 
35 µm corneal cross-sections were cut on a cryostat 1 mm apart (Figure 4.5). 
With the frozen section on the blade platform (maintained at -21°C), a knife 
was used to cut the cornea free and the remaining tissue was brushed away. 
The cornea itself was meticulously brushed to ensure no ice remained 
attached that might allow riboflavin to leak out once thawed (transparent 
images of processed sections during the development of the methodology 
confirmed the epithelium itself was not removed by this brushing; see Figure 
4.4 below). Colour photographs were taken of the sagittally-exposed globe 
and free corneal section. 
 
The corneal section was then mounted on a slide and covered with 
 226 
fluorescence-free immersion oil (Immersol 518 F, Carl Zeiss Ltd.) to prevent 
any leakage of riboflavin out of the tissue. No dye leakage was observed over 
several minutes during protocol development using immersion oil. This 
compared with prompt dye leakage when either water-based optimal cutting 
temperature (OCT) compound or water itself was used as an immersion 
medium. A coverslip was placed on top prior to imaging under the microscope 
objective (Figure 4.3B). The time taken from the tissue thawing onto the slide 
to image acquisition on the microscope was approximately 1 minute, and I 
refer to this earliest imaging time point as t = 0 minutes. To investigate 
riboflavin migration within the thawed slide-mounted tissue, serial images 
were captured every minute for selected samples. For all other 
measurements, data was acquired as soon as possible following tissue 
thawing, i.e. after approximately 1 minute. 
 
10.3.5 Two-photon microscope set-up and imaging protocol 
The two-photon microscope set-up is based on that described in chapter 2. A 
Ti:Sapphire laser, operating at a wavelength of 890 nm with a 140 
femtosecond pulse duration and 80 MHz pulse repetition rate,  was used as 
the excitation laser source. The excitation laser beam was guided to a Leica 
DM6000CS upright microscope where it passes through two galvoscanners, 
allowing scanning in the x-y plane, before being focused into the sample by a 
Leica 10 X /0.3 NA water immersion objective. Theoretical (full-width half-
maximum) axial and lateral resolutions were calculated at 16 µm and 1.1 µm 
respectively. TPF excitation light of 890 nm wavelength was chosen to 
correspond with the highest riboflavin absorption peak (445 nm) as 
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determined by spectrophotometry. Emitted riboflavin fluorescence was 
collected between 525 nm and 650 nm to avoid overlap with the absorption 
spectrum of riboflavin. 553 µm x 553 µm (512 x 512 pixel) images were 
captured at a scan rate of 600Hz (line average 16) with the pinhole wide 
open. 
 
10.3.6 Image analysis 
Grey scale images (Figure 4.6A) were exported and analysed using Java-
based imaging software (ImageJ, 1.48v, http:// imagej.nih.gov.ij; provided in 
the public domain by the National Institutes of Health, Bethesda, MD, USA). 
For each image, three separate rectangular regions of interest each 40 pixels 
wide in the x-direction were manually selected.  The intensity profiles along 
the z-direction for each region of interest were then exported to a .txt file 
(Excel for Mac, 2011; Microsoft Corp, Redmond, WA, USA) (Figure 4.6B). 
The epithelial/stromal junction was then identified in each trace by the abrupt 
change in signal and confirmed with reference to the corresponding image 
region of interest. This information was then used to align all three plots along 
the z-axis and a mean intensity plot was then generated representing the 
average TPF signal for that image as a function of depth (z). TPF signals 
were converted to riboflavin concentration by normalizing to the TPF signal 
achieved in a well-slide reservoir of 0.1 % riboflavin solution during the same 
experimental session. Mean (SD) concentrations were calculated from 5 
globes tested for each protocol. Unpaired Student t-tests were used to 
compare riboflavin concentrations achieved at a depth of 300 µm. A p value 
less than 0.05 was considered significant. Analyses were performed in Excel 
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for Mac, 2011; Microsoft Corp, Redmond, WA, USA).  
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10.4 Chapter 4 – Accelerated CXL 
10.4.1 Ethics and data handling 
This study design was reviewed by the Research Governance Committee and 
approved as an audit project by the Clinical Audit Working Group at 
Moorfields Eye Hospital NHS Foundation Trust. Patients were identified from 
a prospective electronic database of all patients aged above 15 years of age 
attending the Early Keratoconus Clinic. The database contains keratometric 
and refractive data entered prospectively in clinic and at the time of surgery. I 
extracted data from a consecutive series beginning with the first accelerated 
treatment in September 2012 through to April 2013. Eyes with 12-months’ 
keratometric follow-up data were included in this study. 
 
10.4.2 Outcomes measures 
The primary outcome measure was the failure rate of CXL treatment, defined 
by an increase in maximum anterior keratometry (Kmax) on corneal 
tomography of >1.5 D at 12 months. Secondary outcome measures included 
anterior keratometry of the steep (K2 front) and flat (K1 front) axes in the 
central 3mm zone, posterior keratometry of the steep axis (K2 back), 
uncorrected distance visual acuity (UCVA), spectacle-corrected distance 
visual acuity (CDVA), subjective refraction, corneal thickness at the thinnest 
point and endothelial cell density. Visual acuities were initially measured in 
Snellen, before the using LogMAR charts in the clinic from September 2013.  
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10.4.3 Monitoring for disease progression 
Serial corneal tomography (Pentacam HR, Oculus GmbH, Germany) and 
subjective refractions were used to confirm pre-operative keratoconus 
progression. Progression was defined by one or more of the following: >1.5 D 
increase in Kmax or anterior K2 (K2 front); >0.5 D increase in posterior K2 (K2 
back); >1 D increase in refractive astigmatism; >1 line loss of CDVA or >13 
µm decrease in pachymetry. These criteria were based on published (Szalai 
et al. 2012) limits of agreement for repeated measurement using the 
Pentacam in patients with keratoconus, where changes >1.5 D have a >95% 
probability of not being simply attributable to measurement error. Exclusion 
criteria included pregnancy or breastfeeding, active ocular surface disease or 
a minimum stromal thickness less than 375 µm. 
 
10.4.4 Specular microscopy 
Corneal endothelial cell densities were measured using the Topcon SP-2000P 
noncontact specular microscopy and analyzed with IMAGEnet 2000 
computerized analysis system (v2.5x; Topcon, Tokyo, Japan). If a clear image 
could not be acquired centrally, the patient was asked to look just to side of 
the fixation light. Only whole cells with a continuous border (manually refined) 
on a frame with 75 or more cells, were accepted for planimetric analysis.  
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10.4.5 Surgical procedure 
Following topical instillation of proxymetacaine 0.5%, tetracaine 1% and 
povidone-iodine 5%, the eyelashes were taped and a lid speculum inserted. 
The corneal epithelium was manually debrided to approximately 9mm. 
Dextran-free riboflavin 5’-monophosphate in saline and hydroxypropyl 
methylcellulose (VibeX Rapid, Avedro, Mass. USA) was applied every 2 
minutes for either 20 minutes (if minimum pachymetry ≥ 400 µm) or 10 
minutes (if minimum pachymetry < 400 µm). Continuous UVA exposure 
(KXL®, Avedro, Mass. USA) at 30 mW/cm2 for 4 minutes was then applied 
(total energy 7.2 mJ/cm2). 
 
At the end of the procedure, preservative-free dexamethasone 0.1% and 
chloramphenicol 0.5% were instilled and a bandage contact lens applied. 
Post-operatively, patients were prescribed a tapered course of preservative-
free topical dexamethasone 0.1%, moxifloxacin and hyaluronic acid 0.1% for 
1 week, along with topical diclofenac 0.1%, cyclopentolate 1% twice a day 
and 50 mg oral diclofenac three times a day for 3 days. Patients were 
additionally provided with 3 minims of proxymetacaine 0.5% for use in the 
early post-operative period. The bandage contact lens was removed at 1 
week after which all therapy was discontinued except topical hyaluronic acid 
0.1% and fluorometholone 0.1% four times a day for 1 month.  
 
10.4.6 Statistical analysis 
For purposes of statistical analysis, I have converted Snellen visual acuities to 
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logMAR equivalents (−log decimal acuity). I present data as means ± 
standard deviation. I use Paired Student t-tests to compare baseline and 12-
month post-operative data, accepting a p value ≤ 0.05 as significant. Analyses 
were performed in Excel for Mac (2011, Microsoft Corp.). 
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10.5 Chapter 5 – Gross shape correction 
10.5.1 Study design 
Retrospective consecutive case series. 
 
10.5.2 Inclusion criteria 
The medical records were reviewed for all keratoconic patients receiving 
KeraRing implantation by 3 surgeons at Moorfields Eye Hospital between 
2010 and 2013 inclusive. All patients met all 4 of the following inclusion 
criteria before surgery: 
5. Contact lens intolerance  
6. Corrected distance visual acuity (CDVA) ≤ 6/9  
7. Corneal thickness at the 6 mm channel site ≥ 450 µm. 
8. Controlled ocular surface inflammation 
 
10.5.3 Surgical procedure 
 
Surgical plans based on Scheimpflug tomography and subjective refraction 
were obtained from the manufacturer (Mediphacos Ltd,   Belo Horizonte, 
Brazil). Following topical instillation of proxymetacaine 0.5%, tetracaine 1% 
and povidone-iodine 5%, a 360-degree femtosecond laser channel of internal 
diameter 5mm and external diameter 5.9mm was created at a depth between 
350 – 400 µm as dictated in the surgical plan (see example in Figure 6.1 
below). Into this channel, either 1 or 2 ring segments were implanted. No 
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sutures were used. At the end of the procedure, preservative-free 
dexamethasone 0.1% and chloramphenicol 0.5% were instilled.   
 
10.5.4 Post-operative care 
Post-operatively, patients were prescribed preservative-free topical 
dexamethasone 0.1% and chloramphenicol 0.5% four times a day for 1 week.  
Serial tomography and subjective refractions were performed to monitor for 
post-implantation ectasia progression. The first topography scan after 3 
months post-surgery was used as an updated baseline with which to compare 
for ectasia progression. 
 
10.5.5 Outcome measures 
The main outcome measure was CDVA. Secondary outcomes measures 
included UDVA, manifest refraction, corneal coma, contact lens tolerance and 
complications. Snellen visual acuity was converted to LogMAR equivalent for 
statistical analysis. Mean ± standard deviation are presented. 
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10.6 Chapter 6 – Fine shape correction 
 
10.6.1 Design  
Prospective interventional series.  
10.6.2 Primary outcome 
LogMAR CDVA at 12 months 
10.6.3 Secondary outcomes 
LogMAR UCVA  
Manifest refraction 
Pentacam indices 
Rate of infective keratitis 
10.6.4 Subject selection 
Inclusion criteria 
 Patients with progressive stage I - III keratoconus  
 CDVA < 0.00 logMAR  
Exclusion criteria 
 Patients under the age of 18 years 
 Active ocular surface disease 
 Minimum corneal thickness <390 µm (leaving 325 µm residual stromal 
thickness after transPTK) 
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10.6.5 Study interventions 
TransPRK programming  
Three consistent scotopic ocular wavefront scans (Ocular Wavefront 
Analyzer, SCHWIND eye-tech-solutions GmbH, Germany) were acquired 
within 0.5 D spherical equivalent refraction of each other. Corneal topography 
(Schwind Sirius) was also recorded to allow a comparison of planned 
wavefront and topography-guided treatments. Patients were required to 
remove gas permeable contact lenses for 2 weeks and soft contact lenses for 
1 week prior to scanning. Pharmacological pupil dilation with tropicamide 1% 
was used where pupil diameter was less than 5.5 mm. The scan with the 
lowest sphere and highest coma was exported for treatment programming. Iris 
scans were taken for static cyclotorsion control during the treatment. Ablation 
depth was minimised during treatment programming by removing all sphero-
cylindrical constraints. I aimed to preserve a minimum corneal stromal 
thickness prior to CXL of 325 µm. To ensure effective CXL was not 
compromised by a smaller diameter zone of epithelial removal, epithelial 
transPTK and stromal PRK was delivered separately where the programmed 
laser ablation zone for transPRK was predicted to be less than 8mm in 
diameter.  
 
 
 
 
 
TransPRK/CXL surgery 
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Treatments were performed by either by myself or Bruce Allan. Following 
topical instillation of proxymetacaine 0.5%, tetracaine 1% and povidone-iodine 
5%, a lid speculum inserted. After the laser treatment was complete, dextran-
free 0.1 % w/v riboflavin 5’-monophosphate solution in saline and 
hydroxypropyl methylcellulose (VibeX Rapid, Avedro, MA, USA) was applied 
every 2 minutes for a total of 10 minutes before UVA exposure (KXL®, 
Avedro, MA, USA) at 30 mW/cm2 for 4 minutes (pulsed every 1.5 seconds) 
was then applied (total energy 7.2 mJ/cm2). Mitomycin C was not used. 
 
At the end of the procedure, preservative-free dexamethasone 0.1% and 
chloramphenicol 0.5% were instilled and a bandage contact lens applied. 
Post-operatively, patients were prescribed a tapered course of preservative-
free topical dexamethasone 0.1%, moxifloxacin and hyaluronic acid 0.1% for 
1 week, along with topical diclofenac 0.1%, cyclopentolate 1% twice a day 
and 50 mg oral diclofenac 3 times a day for 3 days. Patients were additionally 
provided with 3 minims of proxymetacaine 0.5% for use in the early post-
operative period. The bandage contact lens was removed at 1 week after 
which all therapy was discontinued except topical hyaluronic acid 0.1% and 
fluorometholone 0.1% 4 times a day for 1 month.  
 
 
 
 
